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ABSTRACT 
Cancer is the second leading cause of death worldwide and among them, lung 
and breast cancers have mortality rates of 1.4 million and 400,000 deaths each year 
respectively. This is due to the current chemotherapies that are still far from ideal and 
hence, alternative treatments founded in a ‘back-to-nature’ approach might yield 
improved treatment avenues. The genus Phyllanthus is a rainy season weed that has 
been exploited for various medicinal usages due to the presence of abundant polyphenol 
compounds in the plant that can be broadly grouped into ellagitannins, gallotannins, 
flavonoids, and phenolic acids. Therefore, the aim of the current study was to evaluate 
the antimetastatic potential of four Phyllanthus species (P. niruri, P. urinaria, P. 
watsonii, and P. amarus) on lung (A549) and breast (MCF-7) carcinoma cell lines.  
Phyllanthus exhibited antiproliferative activity by causing selective toxicity on 
A549 and MCF-7 cells with IC50 values ranging from 50-470g/ml, without the 
involvement of cell cycle arrest. At these IC50 concentrations, Phyllanthus successfully 
halted the endothelial-mesenchymal transition process by increasing cell aggregation 
and cell-cell adhesion. Phyllanthus also reduced the invasion of A549 and MCF-7 cells 
through the extracellular matrix layer by 40% and 10%, respectively. It was also 
observed that Phyllanthus inhibited almost 60% cells adhesion to the matrix layer while 
suppressing up to 80% migration of these cells through an 8µm pore size polycarbonate 
membrane. This ability of Phyllanthus to inhibit A549 and MCF-7 cells’ invasion, 
migration, and adhesion were even enhanced at increasing treatment concentrations and 
were associated with their capacity to repress the expressions of matrix 
metalloproteinases 2, 7, and 9 in cancer cells that function to hydrolyze the basement 
membrane during cell metastasis. In addition, Phyllanthus induced apoptosis in A549 
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and MCF-7 cells in conjunction to its antimetastatic action with the activation of 
caspases-3 and -7 as well as DNA fragmentation. Among the four Phyllanthus species, 
P. urinaria inhibited cancer cells growth and metastasis most effectively, closely 
followed by P. watsonii. 
Following this, we screened the ten major cellular signaling pathways and 
recognized that Phyllanthus exerted its antimetastatic and apoptosis-inducing activities 
by inhibiting ERK1/2 and hypoxia pathways, attributed to the repression of signaling 
transduction components such as G proteins, G protein receptors, and serine/threonine-
protein kinases. ERK1/2 pathway inhibition by Phyllanthus subsequently led to 
downregulated expression of cytoskeletal proteins for cell invasion and mobility, 
protein synthesis and transcriptional proteins for cell growth, as well as antiapoptotic 
protein for cell survival. Meanwhile, inhibition of the hypoxia pathway repressed 
expression of angiogenic proteins that are essential for cell angiogenesis and migration 
as well as various glucose uptake and glycolytic enzymes for cell growth and 
metabolism. Phyllanthus also suppressed drug detoxification enzymes and tumor 
defense mechanism proteins including gluthathione transferase, gluthathione synthetase, 
metallothionein, and annexins.  
In summary, Phyllanthus could be a valuable candidate as a therapeutic agent 
for metastatic cancers since it does not only stop spreading of cancer cells, but it also 
inhibits cell growth and induces apoptosis. 
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ABSTRAK 
Kanser adalah pembunuh kedua di seluruh dunia dan di antaranya, kanser peparu 
(1.4 juta) dan payudara (400,000) merangkumi jumlah kematian yang tertinggi pada 
setiap tahun. Hal ini kerana kemoterapi pada masa kini masih tidak memuaskan 
disebabkan oleh ‘multidrug resistance’ fenomena, pelbagai kesan sampingan yang 
dialami oleh pesakit-pesakit kanser, serta kemampuan tumor malignan untuk merebak. 
Oleh kerana itu, rawatan alternatif yang bertemakan 'back-to-nature' mungkin boleh 
menjadi penawar kanser yang lebih efektif. Genus Phyllanthus adalah merupakan 
sejenis rumpai yang tumbuh semasa musim hujan dan tumbuhan ini telah digunakan 
untuk merawat pelbagai jenis penyakit disebabkan ia mengandungi polifenol-polifenol 
yang boleh dikelompokkan kepada ellagitannins, gallotannins, flavonoids dan phenolic 
acids. Oleh itu, objektif kajian ini adalah untuk menilai potensi empat Phyllanthus 
species (P. niruri, P. urinaria, P. watsonii, dan P. amarus) untuk mengelak perebakan 
kanser sel peparu (A549) dan payudara (MCF-7).  
Phyllanthus telah menunjukkan bahawa ia menghindari pertumbuhan sel-sel 
A549 dan MCF-7 secara spesifik dengan nilai IC50 berkisar antara 50-470µg/ml, tanpa 
pembantutan kitaran sel. Pada nilai-nilai IC50 tersebut, Phyllanthus berjaya untuk 
menghentikan proses perubahan endothelial-mesenchymal melalui perangsangan 
agregasi serta adhesi sel-sel. Selain itu, ia juga berupaya untuk mengencatkan 40% dan 
10% invasi sel-sel A549 dan MCF-7 masing-masing melalui lapisan matriks 
ekstraselluler. Phyllanthus juga terbukti berkebolehan untuk mengencatkan 60% adhesi 
sel-sel ke lapisan matriks tersebut sementara membantutkan 80% migrasi sel-sel A549 
dan MCF-7 melalui membran polikarbonat yang mempunyai liang-liang bersaiz 8µm. 
Kebolehan Phyllanthus untuk mengelak invasi, migrasi, dan adhesi juga meningkat 
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apabila dos yang diuji dinaikkan dan hal ini mungkin disebabkan oleh kebolehan 
Phyllanthus untuk mencegah ekspresi matriks metalloproteinase 2, 7 serta 9 yang 
bertangungjawab untuk memusnahkan membran semasa metastasis. Selain itu, 
Phyllanthus juga mampu untuk menginduksikan apoptosis dengan pengaktifan 
caspases-3 dan -7 berserta fragmentasi DNA. Di antara empat spesies Phyllanthus yang 
diuji dalam kajian ini, P. urinaria menunjukkan aktiviti yang paling efektif untuk 
menghalang pertumbuhan dan metastasis sel kanser, diikuti oleh P. watsonii. 
Berikutannya, transduksi isyarat-isyarat di dalam sel yang digunakan oleh 
Phyllanthus untuk mengelakkan perebakan sel-sel kanser dikaji dan pemerhatian 
menunjukkan bahawa Phyllanthus menyebabkan aktiviti ‘antimetastatic’ melalui 
perencatan transduksi isyarat ERK1/2 dan hipoksia. Kejayaan Phyllanthus untuk 
menghalang transduksi isyarat tersebut kemungkinan besar disebabkan oleh 
kemampuannya untuk menghindari ekspresi pelbagai komponen transduksi isyarat 
seperti G proteins, G protein receptors serta serine/threonine-protein kinases. 
Penghambatan transduksi isyarat ERK1/2 menyebabkan pencegahan ekspresi protein-
protein cytoskeletal untuk invasi dan mobiliti, transkripsi serta sintesis protein untuk 
pertumbuhan sel-sel, dan antiapoptosis protein untuk meneruskan kehidupan sel-sel. 
Sementara itu, penghambatan transduksi isyarat hipoksia menyebabkan pencegahan 
ekspresi protein angiogenik untuk pertumbuhan kapilari-kapilari darah dan migrasi sel-
sel serta pelbagai enzim glikolitik untuk pertumbuhan dan metabolism sel-sel. 
Tambahan pula, Phyllanthus berjaya menghambatkan enzim mendetoksifikasi ubat serta 
protein untuk mekanisme pertahanan tumor seperti gluthathione transferase, 
gluthathione synthetase, metallothionein dan annexins.  
Semua penemuan di atas membuktikan bahawa Phyllanthus adalah calon yang 
baik untuk mengubati penyakit kanser metastasis kerana ia bukan sahaja mengelakkan 
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perebakan sel-sel kanser, tetapi ia juga menghentikan pertumbuhan sel-sel serta 
menginduksikan apoptosis. 
  
viii 
 
DEDICATION 
I would like to dedicate this Thesis with much love and 
gratitude to 
My own determination and persistence 
My late grandfather, YOW MUN YEW 
My grandmother, CHAM AH MOY 
My father, LEE AH FAH  
My mother, YOW LAI YIN 
MY sisters 
My family members 
And all my friends 
Without your patient, continuous support and 
encouragements, this project would not have possibly been a 
success. 
LEE SAU HAR 
  
ix 
 
ACKNOWLEDGEMENTS 
I would like to thank a number of people for their useful comments and advice 
given in preparing this thesis. Firstly, I would like to thank my honorable supervisor, 
Prof Dr Shamala Devi Sekaran for her supervision. She has been providing me valuable 
advices, guidance as well as continuous support for this project. Otherwise, I personally 
think that I will not be able to accomplish the whole project within a short term. 
Secondly, I would like to express my appreciation to the helps and great efforts 
from all my seniors, labmates and friends who had been with me through many ups and 
downs. They include Dr Wang Seok Mui, Ms Thamil Vaani, Mr Tang Yin Quan, Mr Le 
Cheng Foh, Ms Anusyah Rathakrishnan, Mr Tan Wee Chee, Ms Adeline Yeo, Dr 
Deepa, and Ms Audrey Hooi. My special thanks also to Dr Mohammed Abdelfatah for 
his great assistance throughout the project as well as his kindness during my thesis 
preparation.  
Thanks are also addressed to Blood Bank of University Malaya Medical Centre 
(UMMC) for their flow cytometry facility, staffs of Medical Biotechnology Laboratory 
(MBL) for their proteomics facility, as well as all the staffs of the Department of 
Medical Microbiology (MMB) for their great cooperation and a conducive environment 
to work at. I would also like to acknowledge National Science Fellowship (NSF) for 
their scholarship and University Malaya for their funds in this project. 
Finally yet importantly, I would like to express my gratitude for my supportive 
family members especially my parents who have been giving me tremendous moral 
support as well as their care for my health while I was indulged in this study. 
  
x 
 
TABLE OF CONTENTS 
 
ABSTRACT ............................................................................................................... iii 
ABSTRAK ................................................................................................................... v 
DEDICATION ......................................................................................................... viii 
ACKNOWLEDGEMENTS ...................................................................................... ix 
TABLE OF CONTENTS ........................................................................................... x 
LIST OF FIGURES ................................................................................................. xvi 
LIST OF TABLES .................................................................................................... xx 
LIST OF SYMBOLS AND ABBREVIATIONS................................................... xxi 
LIST OF APPENDICES ....................................................................................... xxiv 
CHAPTER 1: INTRODUCTION ..................................................................... 1 
1.1 CANCER ................................................................................................. 1 
1.1.1 LUNG CANCER ............................................................................... 2 
1.1.2 BREAST CANCER .......................................................................... 6 
1.1.3 TNM STAGING ................................................................................ 8 
1.2 MULTISTEP CARCINOGENESIS ...................................................... 10 
1.3 HALLMARKS OF CANCER ............................................................... 14 
1.3.1 INFINITE REPLICATIVE POTENTIAL ...................................... 15 
1.3.2 EVASION OF CELL DEATH ........................................................ 17 
1.3.2.1 APOPTOSIS ................................................................................... 19 
1.3.2.2 NECROSIS ..................................................................................... 24 
1.3.3 TISSUE METASTASIS AND SUSTAINED ANGIOGENESIS ... 25 
1.3.3.1 EPITHELIAL-TO-MESENCHYMAL TRANSITION .................. 28 
1.3.3.2 INVASION ..................................................................................... 29 
1.3.3.3 MOTILITY ..................................................................................... 30 
1.3.3.4 ATTACHMENT AND LOCALIZATION ..................................... 32 
1.3.3.5 PROTEOLYTIC ENZYME – MATRIX 
METALLOPROTEINASES ..................................................... 33 
  
xi 
 
1.3.4 SELF-SUFFICIENCY IN GROWTH SIGNALS AND 
INSENSITIVITY TO ANTIGROWTH SIGNALS ........................ 36 
1.3.4.1 TUMOR SUPPRESSOR, P53 ........................................................ 38 
1.3.4.2 MAP KINASES .............................................................................. 40 
1.3.4.3 HYPOXIA INDUCIBLE FACTOR (HIF) ..................................... 43 
1.3.4.4 B CELL LYMPHOMA-2 GENE ENCODED PROTEIN (BCL-
2) ................................................................................................ 45 
1.3.4.5 CASPASES CASCADE ................................................................. 46 
1.3.4.6 C-MYC ........................................................................................... 48 
1.3.4.7 ACTIVATED PROTEIN-1 (AP-1) ................................................ 49 
1.3.4.8 E2F .................................................................................................. 50 
1.3.4.9 NFκB ............................................................................................... 51 
1.4 CANCER TREATMENTS ................................................................... 52 
1.4.1 PLANT-DERIVED CHEMOTHERAPEUTICS ............................ 54 
1.4.2 PHYLLANTHUS .............................................................................. 56 
1.4.2.1 ANTIBACTERIAL ACTIVITY ..................................................... 58 
1.4.2.2 ANTIOXIDANT ACTIVITY ......................................................... 58 
1.4.2.3 ANTIVIRAL ACTIVITY ............................................................... 59 
1.4.2.4 ANTIAMNESIC ACTIVITY ......................................................... 59 
1.4.2.5 DIURETIC ACTIVITY .................................................................. 60 
1.4.2.6 ANTIINFLAMMATORY ACTIVITY........................................... 60 
1.4.2.7 ANTICANCER ACTIVITY ........................................................... 60 
1.4.2.8 OTHER THERAPEUTIC AND PHARMACOLOGICAL 
ACTIVITIES ............................................................................. 61 
1.5 JUSTIFICATION AND OBJECTIVES OF STUDY ........................... 61 
CHAPTER 2: METHODOLOGY .................................................................. 64 
2.1 TEST COMPOUNDS ........................................................................... 64 
  
xii 
 
2.1.1 PHYLLANTHUS PLANT EXTRACTS .......................................... 64 
2.1.2 STANDARD DRUGS ..................................................................... 65 
2.2 CELL CULTURE .................................................................................. 66 
2.2.1 CELL LINES ................................................................................... 66 
2.2.2 CELL MAINTENANCE ................................................................. 67 
2.2.3 CELL COUNTING ......................................................................... 68 
2.2.4 CELL CRYOPRESERVATION ..................................................... 68 
2.3 ANTIPROLIFERATIVE EFFECTS OF PHYLLANTHUS ................... 69 
2.3.1 MORPHOLOGICAL ANALYSIS .................................................. 69 
2.3.2 CYTOTOXICITY ANALYSIS ...................................................... 69 
2.3.3 CELL CYCLE ANALYSIS – PROPIDIUM IODIDE 
STAINING ...................................................................................... 71 
2.4 ANTIMETASTASIS EFFECTS OF PHYLLANTHUS ......................... 72 
2.4.1 CELL INVASION ASSAY ............................................................. 72 
2.4.2 CELL MIGRATION ASSAY ......................................................... 74 
2.4.3 SCRATCH MOTILITY ASSAY .................................................... 74 
2.4.4 CELL ATTACHMENT ASSAY .................................................... 75 
2.4.5 CELL-MATRIX ADHESION ASSAY .......................................... 75 
2.4.6 ZYMOGRAPHY ASSAY ............................................................... 76 
2.5 MECHANISM OF CELL DEATH INDUCED BY 
PHYLLANTHUS ............................................................................... 77 
2.5.1 APOPTOSIS .................................................................................... 77 
2.5.1.1 CASPASE-GLO 3/7 ASSAY ......................................................... 77 
2.5.1.2 TUNEL ASSAY ............................................................................. 78 
2.5.1.3 DNA FRAGMENTATION ASSAY .............................................. 79 
2.5.2 NECROSIS ...................................................................................... 79 
2.6 EFFECTS OF PHYLLANTHUS ON CELL’S ANGIOGENIC 
ABILITY .......................................................................................... 80 
2.6.1 PRODUCTION OF VASOACTIVE AGENT, INOS ..................... 81 
  
xiii 
 
2.6.2 PRODUCTION OF VASCULAR ENDOTHELIAL GROWTH 
FACTOR (VEGF) ........................................................................... 82 
2.7 EFFECTS OF PHYLLANTHUS ON CELL’S ENDOTHELIAL TO 
MESENCYHMAL TRANSITION (EMT) ...................................... 82 
2.7.1 HANGING DROP AGGREGATION ASSAY .............................. 83 
2.7.2 CELL-CELL ADHESION ASSAY ................................................ 83 
2.8 EFFECTS OF PHYLLANTHUS ON CELLULAR SIGNALLING 
TRANSDUCTION PATHWAYS .................................................... 84 
2.8.1 SIGNALING PATHWAY ANALYSIS USING CANCER 10-
PATHWAY REPORTER ARRAY ................................................ 85 
2.8.2 PREPARATION OF CYTOPLASMIC PROTEIN LYSATE ........ 86 
2.8.3 WESTERN BLOT ASSAY ............................................................. 88 
2.8.4 TWO-DIMENSIONAL (2D) GEL ELECTROPHORESIS 
ASSAY ........................................................................................... 90 
2.8.5 PROTEIN IDENTIFICATION BY MATRIX-ASSISTED 
LASER DESORPTION IONISATION-TIME OF FLIGHT 
MASS SPECTROMETRY ............................................................. 92 
2.9 DATA ANALYSIS ............................................................................... 93 
CHAPTER 3: RESULTS ................................................................................. 94 
3.1 POLYPHENOLS IDENTIFICATION IN PHYLLANTHUS SPP. ..... 94 
3.2 ANTIPROLIFERATIVE EFFECTS OF TEST COMPOUNDS .......... 97 
3.2.1 MORPHOLOGICAL ANALYSIS OF PHYLLANTHUS-
TREATED CELLS ......................................................................... 97 
3.2.2 CYTOTOXIC EFFECTS OF PHYLLANTHUS CRUDE 
EXTRACTS, FRACTIONS, AND STANDARD DRUGS ............ 99 
3.2.3 PHYLLANTHUS DID NOT MODULATE CELL CYCLE .......... 108 
3.3 ANTIMETASTASIS EFFECTS OF PHYLLANTHUS ....................... 111 
3.3.1 EFFECTS OF PHYLLANTHUS EXTRACTS ON CELL 
INVASION ................................................................................... 111 
  
xiv 
 
3.3.2 EFFECTS OF PHYLLANTHUS EXTRACTS ON CELL 
MOTILITY ................................................................................... 113 
3.3.3 EFFECT OF PHYLLANTHUS EXTRACTS ON CELL 
ATTACHMENT ........................................................................... 123 
3.3.4 EFFECTS OF PHYLLANTHUS ON CELL-MATRIX 
ADHESION .................................................................................. 128 
3.3.5 EFFECTS OF PHYLLANTHUS ON MATRIX 
METALLOPROTEINASES (MMPs) EXPRESSION ................. 130 
3.4 MECHANISM OF CELL DEATH INDUCED BY 
PHYLLANTHUS ............................................................................. 135 
3.4.1 EFFECTS OF PHYLLANTHUS EXTRACTS ON CASPASE-3 
AND -7 ACTIVITIES ................................................................... 135 
3.4.2 EFFECTS OF PHYLLANTHUS EXTRACTS ON CELLULAR 
MEMBRANE INTEGRITY ......................................................... 137 
3.4.3 EFFECTS OF PHYLLANTHUS EXTRACTS ON NUCLEAR 
FRAGMENTATION .................................................................... 139 
3.5 EFFECTS OF PHYLLANTHUS ON CELL’S ANGIOGENIC 
ABILITY ........................................................................................ 145 
3.6 EFFECTS OF PHYLLANTHUS ON CELL’S ENDOTHELIAL TO 
MESENCHYMAL TRANSITION (EMT) .................................... 151 
3.6.1 EFFECTS OF PHYLLANTHUS ON CELL AGGREGATION .... 151 
3.6.2 EFFECTS OF PHYLLANTHUS ON CELL-CELL ADHESION .. 160 
3.7 SIGNALING PATHWAYS ANALYSIS ........................................... 162 
3.7.1 DETERMINATION OF SIGNALING PATHWAYS 
AFFECTED BY PHYLLANTHUS ................................................ 162 
3.7.2 WESTERN BLOTTING OF SIGNALING PATHWAYS 
AFFECTED BY PHYLLANTHUS ................................................ 167 
3.7.3 DIFFERENTIALLY EXPRESSED PROTEINS IN 
PHYLLANTHUS-TREATED CELLS ........................................... 174 
CHAPTER 4: DISCUSSION ........................................................................ 187 
  
xv 
 
4.1 CONCLUSION ................................................................................... 207 
4.2 FUTURE WORK ................................................................................ 210 
REFERENCES ....................................................................................................... 211 
APPENDICES ........................................................................................................ 234 
APPENDIX 1: PREPARATION OF CULTURE MEDIA, REAGENTS, AND 
CHEMICALS ................................................................................. 234 
APPENDIX 2: EXAMPLE OF MASCOT SEARCH RESULT ......................... 242 
APPENDIX 3: IDENTIFIED PROTEINS OF A549 AND MCF-7 
DOWNREGULATED (-) IN THE PRESENCE OF 
PHYLLANTHUS EXTRACTS ....................................................... 243 
APPENDIX 4: ADDITIONAL OUTPUTS OF THE PHD PROJECT ............... 256 
 
 
  
xvi 
 
LIST OF FIGURES 
Figure 1.1: Number of new cases and deaths worldwide for the 15 most common 
cancers, 2000, cited from (Parkin et al. 2001) ........................................ 3 
Figure 1.2: Acquired capabilities of cancer, cited from (Hanahan & Weinberg 
2000) ..................................................................................................... 14 
Figure 1.3: Cell cycle process, cited from (Kong et al. 2003) ................................... 16 
Figure 1.4: Regulation of apoptosis via intrinsic and extrinsic cell death 
pathways, cited from (Oliver & Vallette 2005) .................................... 22 
Figure 1.5: The metastatic cascade, cited from (Chaffer & Weinberg 2011) ............ 28 
Figure 1.6: Matrix metalloproteinases (MMPs) domain structures and functions, 
cited from (Bourboulia & Stetler-Stevenson 2010) .............................. 35 
Figure 1.7: Schematic representation of MAP kinase cascade and their nuclear 
targets, cited from (Plotnikov et al. 2011) ............................................ 41 
Figure 1.8: Schematic diagram of caspase activation, cited from (Donepudi & 
Grutter 2002) ........................................................................................ 48 
Figure 2.1: Histogram for cell population distribution based on cell DNA content .. 72 
Figure 2.2: Assembly of western blot “Sandwich Stack” .......................................... 90 
Figure 3.1: Morphological changes of treated A549 and MCF-7 cells. ..................... 98 
Figure 3.2: Growth inhibition effect of P. niruri on A549 and MCF-7. .................. 102 
Figure 3.3: Growth inhibition effect of P. urinaria on A549 and MCF-7. .............. 102 
Figure 3.4: Growth inhibition effect of P. watsonii on A549 and MCF-7. .............. 103 
Figure 3.5: Growth inhibition effect of P. amarus on A549 and MCF-7. ............... 103 
Figure 3.6: Growth inhibition effect of P. niruri on NL20 and 184B5. ................... 104 
Figure 3.7: Growth inhibition effect of P. urinaria on NL20 and 184B5. ............... 104 
Figure 3.8: Growth inhibition effect of P. watsonii on NL20 and 184B5. .............. 105 
Figure 3.9: Growth inhibition effect of P. amarus on NL20 and 184B5. ................ 105 
Figure 3.10: Growth inhibition effect of standard drugs on A549 and MCF-7. ...... 106 
Figure 3.11: Growth inhibition effect of standard drugs on NL20 and 184B5. ....... 106 
Figure 3.12: Cell cycle phase distribution of A549 in response to Phyllanthus 
extracts. ............................................................................................... 109 
Figure 3.13: Cell cycle phase distribution of MCF-7 in response to Phyllanthus 
extracts. ............................................................................................... 110 
  
xvii 
 
Figure 3.14: Invasion inhibition percentage induced by aqueous and methanolic 
extracts of Phyllanthus on (A) A549 and (B) MCF-7 cells treated at 
varying concentrations. ....................................................................... 112 
Figure 3.15: Migration inhibition percentage of aqueous and methanolic extracts 
of Phyllanthus on (A) A549 and (B) MCF-7 cells treated at varying 
concentrations. .................................................................................... 115 
Figure 3.16: Wound closure activity of A549 in response to P. niruri and P. 
urinaria. .............................................................................................. 116 
Figure 3.17: Wound closure activity of A549 in response to P. watsonii and P. 
amarus. ............................................................................................... 117 
Figure 3.18: Wound closure activity of MCF-7 in response to P. niruri. ................ 118 
Figure 3.19: Wound closure activity of MCF-7 in response to P. urinaria. ............ 119 
Figure 3.20: Wound closure activity of MCF-7 in response to P. watsonii. ............ 120 
Figure 3.21: Wound closure activity of MCF-7 in response to P. amarus. ............. 121 
Figure 3.22: Quantitative assessment of migration inhibition rate of aqueous and 
methanolic extracts of Phyllanthus on (A) A549 and (B) MCF-7 
cells. .................................................................................................... 122 
Figure 3.23: Cell attachment status of A549 in response to P. niruri and P. 
urinaria. .............................................................................................. 124 
Figure 3.24: Cell attachment status of A549 in response to P. watsonii and P. 
amarus. ............................................................................................... 125 
Figure 3.25: Cell attachment status of MCF-7 in response to P. niruri and P. 
urinaria. .............................................................................................. 126 
Figure 3.26: Cell attachment status of MCF-7 in response to P. watsonii and P. 
amarus. ............................................................................................... 127 
Figure 3.27: Cell-matrix adhesion percentage of (A) A549 and (B) MCF-7 cells 
treated with Phyllanthus extracts at varying concentrations. ............. 129 
Figure 3.28: Matrix metalloproteinases 2, 7, and 9 (MMP2, MMP7, and MMP9) 
expression levels in A549 cells in response to Phyllanthus extracts. . 131 
Figure 3.29: Quantitative assessment of (A) MMP2, (B) MMP7, and (C) MMP9 
expressions in A549 cells in response to aqueous and methanolic 
Phyllanthus extracts. ........................................................................... 132 
Figure 3.30: Matrix metalloproteinases 2 and 9 (MMP2 and MMP9) expression 
levels in MCF-7 in response to Phyllanthus extracts. ........................ 133 
  
xviii 
 
Figure 3.31: Quantitative assessment of (A) MMP2 and (B) MMP9 expressions 
in MCF-7 cells in response to aqueous and methanolic Phyllanthus 
extracts. ............................................................................................... 134 
Figure 3.32: Caspase-3 and -7 levels released from A549 and MCF-7 cells 
treated with aqueous and methanolic Phyllanthus extracts. ............... 136 
Figure 3.33: Lactate dehydrogenase (LDH) released from A549 and MCF-7 cells 
treated with aqueous and methanolic Phyllanthus extracts. ............... 138 
Figure 3.34: Agarose gel electrophoretic analysis of DNA fragmentation in (A) 
A549 and (B) MCF-7 cells in response to Phyllanthus extracts and 
standard drugs. .................................................................................... 140 
Figure 3.35: TUNEL-positive A549 in response to aqueous Phyllanthus extracts. . 141 
Figure 3.36: TUNEL-positive A549 in response to methanolic Phyllanthus 
extracts. ............................................................................................... 142 
Figure 3.37: TUNEL-positive MCF-7 in response to aqueous Phyllanthus 
extracts. ............................................................................................... 143 
Figure 3.38: TUNEL-positive MCF-7 in response to methanolic Phyllanthus 
extracts. ............................................................................................... 144 
Figure 3.39: Expression levels of (A) iNOS and (B) VEGF in untreated and 
Phyllanthus-treated A549 cells. .......................................................... 147 
Figure 3.40: Western blotting of VEGF expression in A549 in response to 
Phyllanthus extracts. ........................................................................... 148 
Figure 3.41: Expression levels of (a) iNOS and (b) VEGF in untreated and 
Phyllanthus-treated MCF-7 cells. ....................................................... 149 
Figure 3.42: Western blotting of VEGF expression in MCF-7 in response to 
Phyllanthus extracts. ........................................................................... 150 
Figure 3.43: Cell aggregation status of A549 in response to P. niruri. .................... 152 
Figure 3.44: Cell aggregation status of A549 in response to P. urinaria. ................ 153 
Figure 3.45: Cell aggregation status of A549 in response to P. watsonii. ............... 154 
Figure 3.46: Cell aggregation status of A549 in response to P. amarus. ................. 155 
Figure 3.47: Cell aggregation status of MCF-7 in response to P. niruri. ................. 156 
Figure 3.48: Cell aggregation status of MCF-7 in response to P. urinaria. ............. 157 
Figure 3.49: Cell aggregation status of MCF-7 in response to P. watsonii. ............ 158 
Figure 3.50: Cell aggregation status of MCF-7 in response to P. amarus. .............. 159 
  
xix 
 
Figure 3.51: Cell-cell adhesion percentage of (A) A549 and (B) MCF-7 cells 
treated with Phyllanthus extracts at varying concentrations. ............. 161 
Figure 3.52: Expression level of ten cellular signalling pathways in A549 as 
determined by cignal finder cancer 10-pathway reporter array. ......... 165 
Figure 3.53: Expression level of ten cellular signalling pathways in MCF-7 as 
determined by cignal finder cancer 10-pathway reporter array. ......... 166 
Figure 3.54: Pathways cascade activation. ............................................................... 169 
Figure 3.55: Western blotting of pathways activated in A549 in response to 
Phyllanthus extracts. ........................................................................... 170 
Figure 3.56: Percentage of individual protein expressions in untreated and 
Phyllanthus-treated A549 analyzed using Image J software. ............. 171 
Figure 3.57: Western blotting of pathways activated in MCF-7 in response to 
Phyllanthus extracts. ........................................................................... 172 
Figure 3.58: Percentage of individual protein expressions in untreated and 
Phyllanthus-treated MCF-7 analyzed using Image J software. .......... 173 
Figure 3.59: 2D-PAGE gels for A549 treated with aqueous Phyllanthus extracts. . 176 
Figure 3.60: 2D-PAGE gels for A549 treated with methanolic Phyllanthus 
extracts. ............................................................................................... 177 
Figure 3.61: Clusters of Orthologous Groups (COGs) classification of identified 
proteins in A549 cells. ........................................................................ 178 
Figure 3.62: 2D-PAGE gels for MCF-7 treated with aqueous Phyllanthus 
extracts. ............................................................................................... 181 
Figure 3.63: 2D-PAGE gels for MCF-7 treated with methanolic Phyllanthus 
extracts. ............................................................................................... 182 
Figure 3.64: Clusters of Orthologous Groups (COGs) classification of identified 
proteins in MCF-7 cells. ..................................................................... 183 
Figure 4.1: Antiproliferative and antimetastatic mechanisms of Phyllanthus in 
A549 and MCF-7 cancer cells ............................................................ 194 
 
  
xx 
 
LIST OF TABLES 
Table 1.1: Projected demographic effects on cancer burden: Incidence ...................... 4 
Table 1.2: Histological subtypes of NSCLC and SCLC and their clinical features ..... 5 
Table 1.3: General classification of carcinogenic agents ........................................... 11 
Table 1.4: The caspase family and their functions ..................................................... 47 
Table 2.1: Preparation of standard curve for protein quantification .......................... 88 
Table 3.1: Polyphenol Compounds Detected in Aqueous Extracts of Phyllanthus 
species ................................................................................................... 95 
Table 3.2: Polyphenol Compounds Detected in Methanolic Extracts of 
Phyllanthus species ............................................................................... 96 
Table 3.3: Cytotoxic effect (IC50) of Phyllanthus extracts, fractions, and standard 
drugs. .................................................................................................. 107 
Table 3.4: Classification of identified proteins of A549 downregulated (-) in the 
presence of aqueous Phyllanthus extracts .......................................... 179 
Table 3.5: Classification of identified proteins of A549 downregulated (-) in the 
presence of methanolic Phyllanthus extracts ...................................... 180 
Table 3.6: Classification of identified proteins of MCF-7 downregulated (-) in 
the presence of aqueous Phyllanthus extracts .................................... 184 
Table 3.7: Classification of identified proteins of MCF-7 downregulated (-) in 
the presence of methanolic Phyllanthus extracts ................................ 185 
  
xxi 
 
LIST OF SYMBOLS AND ABBREVIATIONS 
Abbreviations Description 
DNA Deoxyribonucleic acid 
RNA Ribonucleic acid 
SCLC Small cell lung cancer 
NSCLC Non small cell lung cancer 
BRCA Breast cancer type 1 susceptibility protein 
P53 Tumor protein 53 
ER Estrogen receptor 
Bcl-2 B-cell lymphoma 2 
PI3K/AKT Phosphoinositide 3-kinase/protein kinase B 
pTEN Phosphatase and tensin homolog 
mm Millimeter 
ECM Extracellular matrix 
Cdk Cyclin-dependent kinases 
pRB Retinoblastoma protein 
MMP Matrix metalloproteinase 
ATP Adenosine triphosphate 
TNFR Tumor necrosis factor receptor 
AIF Apoptosis inducing factor 
TRAIL TNF-related apoptosis-inducing ligand 
EMT Endothelial-mesenchymal transition 
E-cadherin Epithelial cadherin 
N-cadherin Neuronal cadherin 
SDF-1 Stromal cell-derived factor-1 
VEGF Vascular endothelial growth factor 
AP-1 Activator protein 1 
NF-κB Nuclear factor-kappa B 
MAPK Mitogen-activated protein kinase 
TIMP Tissue inhibitor of metalloproteinase 
Ets-1 E26 transformation-specific sequence-1 
PEA3 Poly-oma enhancer activator 
SNP Single-nucleotide polymorphism 
u-PA Urinary plasminogen activator 
Hdm2 Human double minute 2 
ERK Extracellular signal-regulated kinase 
JNK c-Jun N-terminal kinases 
MAPKAPK MAP Kinase Activated Protein Kinase 
SAPK Stress-activated protein kinase 
ATF Activating transcription factor 
  
xxii 
 
HIF Hypoxia inducible factor 
PHD Prolyl hydroxylase 
HRE Hypoxia responsive element 
mRNA Messenger ribonucleic acid 
IκB NF-kappa B inhibitor 
mg Mmilligram 
ml Milliliter 
kg Kilogram 
HCV Hepatitis C virus 
NS1 Non-structural protein 1 
µm Micrometer 
PBS Phosphate buffered saline 
DMSO Dimethyl sulfoxide 
HPLC High performance liquid chromatography 
MS-MS Tandem mass spectrometry 
µl Microliter 
EDTA Ethylenediaminetetraacetic acid 
FBS Fetal bovine serum 
rpm Revolutions per minute 
MTS/PMS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium]/phenazine methosulfate 
PI Propidium iodide 
RNase Ribonuclease 
IC50 Half maximal inhibitory concentration 
BSA Bovine serum albumin 
SDS Sodium dodecyl sulfate 
V Volt 
cm2 Centimeter squared 
HCl Hydrochloric acid 
M Molar 
LDH Lactate dehydrogenase 
nm Nanometer 
iNOS Inducible nitric oxide synthase 
GADPH Glyceraldehyde-3-phosphate dehydrogenase 
VEGF Vascular endothelial growth factor 
HUVEC Human umbilical vein endothelial cells 
°C Degree celcius 
kDa Kilodalton 
cm Centimeter 
IPG Immobilized pH gradient 
mA Miliampere 
TBST Tris-buffered saline with tween 20 
  
xxiii 
 
DAB 3,3′-Diaminobenzidine 
Elk1 E twenty-six (ETS)-like transcription factor 1 
RSK Ribosomal s6 kinase 
NL Nonlinear 
DTT Dithiothreitol 
IAA Iodoacetamide 
ACN Acetonitrile 
UV Ultraviolet 
µg Microgram 
TGFβ Transforming growth factor beta 
GFP Green fluorescent protein 
HIV Human immunodeficiency virus 
ADP Adenosine diphosphate 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
2DE Two dimensional gel electrophoresis 
hnRNP Heterogeneous nuclear ribonucleoprotein 
tRNA Transfer ribonucleic acid 
CaM Cell Adhesion Molecules 
Hsp Heat shock protein 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
NO Nitric oxide 
DHAP Dihydroxyacetone phosphate 
H2O2 Hydrogen peroxide 
SCID Severe combined immunodeficiency 
Thr Threonine 
Tyr Tyrosine 
Glu Glutamate 
 
  
xxiv 
 
LIST OF APPENDICES 
Appendix 1: Preparation of Culture Media, Reagents, and Chemicals ……...….. 234 
Appendix 2: Example of MASCOT Search Result …………………...…………. 242 
Appendix 3: Identified Proteins of A549 and MCF-7 Downregulated (-) in 
   the Presence of Phyllanthus Extracts ……………………………. 243 
Appendix 4: Additional Outputs of the PhD Project ………………...………….. 256 
  
1 
 
CHAPTER 1: INTRODUCTION 
1.1 CANCER 
Cancer is a complex group of heterogeneous diseases due to accumulation of 
gene mutations that inhibit the activity of regulatory genes that usually restrain cell 
proliferation while at the same time enhancing the activity of proteins that stimulate it 
(Williams & Stoeber 2007). This disease is in fact an exceedingly old disease although 
it is often mistaken as a disease of the developed world. This is because cancer has been 
discovered even in the Egyptian mommies and hence it is sensible to consider that 
cancer has constantly been a part of the pluricellular life (Sasco 2008). 
The absolute number of cancer cases has increased tremendously with an 
accelerating trend in most of the countries worldwide (Sasco 2008). It is currently the 
second leading cause of death after cardiovascular diseases with more than 11 million 
deaths every year. By 2020, the number of new cancer cases could increase up to 16 
million each year. Globally, mortality from cancer is predicted to be continuously 
increasing with an estimated 9 million and 11.4 million people dying from cancer in 
2015 and 2030 respectively (Sardari et al. 2009). This estimation of cancer incidences 
and mortality is in accordance with the world population evolution whereby there is a 
projected gradual decline in fertility with an increase in life expectancy. This implies 
that there will be a continually decreasing population of children with a concurrent 
increase in elderly population. The predicted 80 million increase of people each year 
will produce 7.5 billion human population by year 2020, and is expected to increase to 
8.9 billion by 2050 of which the elderly group constitutes 16% (Parkin et al. 2001). 
Hence, age is becoming a powerful determinant of cancer risk as cancer is one of the 
common causes of disability and death in the elderly population, since more than 50% 
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of malignant neoplasms occurs in people aged above 70. This could be associated to 
several hypotheses such as the development of malignant neoplasm (carcinogenesis) is 
said to occur over several years and therefore, is more likely to manifest in older 
individuals; a higher prevalence of cancer in older people reflecting their prolonged 
exposure to environmental carcinogens and the progressive changes in the internal 
milieu of the individuals as they age, hence providing a favorable condition for the 
initiation of new neoplasms or development of the existing latent malignant cells 
(Anisimov 2009).  
Different individuals irrespective of their age and gender are exposed to varying 
risk of numerous cancer diseases. Some of the cancer diseases such as acute 
lymphoblastic leukemia and acute myeloid leukemia are more likely to manifest in 
children (Dorak et al. 2007) while lung, colorectal, and bladder cancers are more 
common in men (Parkin et al. 2001). This information is made available through 
collection of statistics on cancer incidences and deaths that are commonly used to 
monitor the trends as well as for the epidemiologic studies for the etiology, prevention, 
and control of cancer diseases (German et al. 2011). Different types of cancers 
worldwide present varying profiles in terms of their incidences and mortality as shown 
in Figure 1.1. Meanwhile, the projected number of cases and deaths worldwide at 
different future times are shown in Table 1.1. 
1.1.1 LUNG CANCER 
Among cancer diseases, lung cancer is by far the most common cause of cancer-
related mortality in the world. Despite the advances in diagnostic imaging and 
therapeutic improvements over the decade, lung cancer has a poor prognosis with a 5-
year patient survival rate. This disease is more frequent in men, comprising 75% of the 
world total (Parkin et al. 2001, Beadsmoore & Screaton 2003). Lung cancer occurrence 
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patterns are greatly affected by past exposure to tobacco smoking, depending on several 
factors including number of cigarettes smoked per day, degree of inhalation, and the age 
at initiation. A family history of lung cancer may also increase the risk in individuals 
due to genetic polymorphisms in carcinogen-metabolizing enzymes such as glutathione-
S-transferase-1 (GSTM1) deletion homozygote which enhances susceptibility to 
tobacco smoke. Other factors increasing risk of lung cancer are occupational exposures 
to asbestos, metals, radon, and ionizing radiations (Parkin et al. 2001). 
 
Figure 1.1: Number of new cases and deaths worldwide for the 15 most common 
cancers, 2000, cited from (Parkin et al. 2001) 
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Table 1.1: Projected demographic effects on cancer burden: Incidence 
  Number (thousands) 
  2000 2010 2020 2050 
Stomach cancer Incidence 880 1110 1440 2440 
 Mortality 650 810 1060 1900 
Colorectal cancer Incidence 940 1140 1390 2080 
 Mortality 490 590 740 1160 
Lung cancer Incidence 1230 1540 2030 3160 
 Mortality 1110 1360 1740 2860 
Female breast cancer Incidence 1050 1250 1480 1970 
 Mortality 370 450 540 770 
Cervical cancer Incidence 470 600 740 1130 
 Mortality 230 300 390 620 
Prostate cancer Incidence 540 660 820 1250 
 Mortality 200 250 320 580 
Adapted from (Parkin et al. 2001) 
The most important distinction among lung cancers is that between a non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), due to their differences in 
biological and clinical characteristics. SCLC is a clinically aggressive tumor that 
accounts for 20% of all lung cancers, with patients presenting with extensive disease 
and hence is rarely amenable to surgery with curative objective. Meanwhile, NSCLC 
can be further subdivided into three histologic subtypes, namely adenocarcinoma, 
squamous cell carcinoma, and large cell carcinoma (Chang et al. 2004, Mollah et al. 
2009, Saeed & Anderson 2011). The major clinicopathologic features for each type of 
lung cancer are listed in Table 1.2. 
Prognosis for lung cancer patients is dependent on the anatomical staging and 
histological classification of the tumor as well as clinical factors. SCLC is a rapidly 
growing tumor that commonly spreads to the extra thoracic region at the time of 
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Table 1.2: Histological subtypes of NSCLC and SCLC and their clinical features 
Tumor Location Features Comments 
Adenocarcinoma 
(45%) 
Peripheral (75% 
cases) 
Lymph node metastases are common; 
Differentiation from secondary tumors may be 
difficult 
Bronchoalveolar carcinoma is a subtype: grows 
along alveolar septae, often synchronous, 
multifocal lesions 
Squamous cell 
(30%) 
Located centrally near 
hilum or major 
bronchi (70% cases) 
Prominent endobronchial component; Propensity 
for local invasion 
Most likely to produce malignant cells on 
sputum cytology; Usually associated with a 
history of heavy smoking 
Undifferentiated 
large cell (5-10%) 
Peripherally located Poorly differentiated tumors often cavitate Poor prognosis: early spread to distant sites 
(e.g. brain and mediastinum are common) 
Small cell (oat 
cell) (20%) 
Central (80% cases) Chest X-ray – classically large central tumor with 
bulky mediastinal lymphadenopathy; Can express 
neuroendocrine neurotransmitters, hormones or 
paracrine regulators; Adrenocorticotropic 
hormone (ACTH) and antidiuretic hormone 
(ADH) commonly overproduced; Most frequently 
associated with preneoplastic syndromes 
Clinically aggressive tumors with high rates of 
cell proliferation and tendency to early 
dissemination; Usually associated with a 
history of heavy smoking; Majority of patients 
present with extensive disease: median survival 
8-12 months 
Cited from (Saeed & Anderson 2011)
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diagnosis. This type of tumor has dismal prognosis and even the minority SCLC 
patients who have prolonged survival are at a high risk to develop a second malignancy. 
Meanwhile, squamous carcinoma has the most optimistic prognosis compared to other 
NSCLCs, mostly attributed to its localization to the chest. This is followed by 
adenocarcinoma, which can be grouped into bronchoalveolar and adenosquamous 
carcinomas. Generally, large cell carcinoma has a poor prognosis (Beadsmoore & 
Screaton 2003, Zhang et al. 2009). 
1.1.2 BREAST CANCER 
According to the cancer statistics, breast cancer is the second most common 
cancer in the world with 999,000 new cases and 375,000 deaths each year (Parkin et al. 
2001). It is the leading cause of morbidity and mortality in women, not only in 
developed countries but increasingly also in developing countries. Several studies have 
shown that the number of cases in North America and North Europe is considerably 
higher than in Asia, the Far East, African, and South America (Jo et al. 2005, Kanaan et 
al. 2009). The high incidence of breast cancer could be due to various important factors, 
including differences in the endogenous reproductive and hormonal factors, particularly 
high levels of free estradiol. Hence, the risk to develop breast cancer increases with 
early menarche, late age at first birth, low parity, as well as late menopause. Besides 
that, the risk also increases proportionally with the aging process, but it slows down 
when a woman reaches approximately 50 years that mostly represents the onset of 
menopause characterized by a change in hormonal environment involving a decrease in 
estrogen levels. Lifestyle and environmental factors such as diet also play a role in 
increasing the risk, as a large weight gain after the age of 18 years has been shown to be 
a strong independent risk factor. Alcohol consumption has also been shown to amplify 
the risk (Parkin et al. 2001). On top of that, genetic predisposition may confer 
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susceptibility of an individual to breast cancer, especially among the relatives of young 
breast cancer cases. Several genes presenting susceptibility to breast cancer include 
BRCA1 on chromosome 17q, BRCA2 on chromosome 13q, germline mutations in 
TP53 gene as well as polymorphism of genes involved in estrogen metabolism such as 
cytochrome P450c17α, 17β hydroxysteroid dehydrogenase 1 gene, and the estrogen 
receptor gene (Parkin et al. 2001, Kanaan et al. 2009). 
One of the complexities of breast cancer is due to the presence of distinct classes 
of tumors that have distinct proliferative responses towards hormonal signals as well as 
other environmental cues. Among the breast cancer patients, approximately 70% of 
them express estrogen receptor (ER) and hence, are responsive to the estrogen-
dependent progression of the disease (Al-Dhaheri et al. 2006, Jump et al. 2008). ER is 
classified in the nuclear receptor superfamily of ligand-dependent transcription factors 
and is activated via binding of estrogen that leads to the initiation of breast cancer cells’ 
proliferation (Al-Dhaheri et al. 2006). 
Breast cancer is curable if it is detected at an early stage. Since estrogen plays a 
major role in breast cancer development and growth in the estrogen responsive breast 
cancers, they can be controlled with adjuvant therapies that act either directly such as 
non-steroidal antiestrogen tamoxifen, or indirectly such as aromatase inhibitors. Effects 
of tamoxifen depend greatly on the specific promoter, cell, and ER subtypes (Al-
Dhaheri et al. 2006). Recent improvement in therapy and diagnosis greatly increases the 
survival chances of women with estrogen-dependent breast cancer. Unfortunately, 
breast cancer cells can eventually survive and develop a resistance to the drug despite 
the fact that the tumors initially did respond to the chemotherapy (Yang et al. 2006). 
Contrarily, the treatment options available for estrogen-independent tumors are not as 
satisfactory, therefore, having a poorer prognosis. The only available treatment options 
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for estrogen-independent breast cancer mainly involve surgery, general chemotherapy, 
and radiation therapy (Kanaan et al. 2009). 
1.1.3 TNM STAGING 
In cancer medicine, the main concern for patients and physicians involved 
prognostication of recovery or survival from the disease. In order to do so, the endpoints 
were often correlated with the anatomical extent of the tumor. Hence, the surgeons from 
the early days proposed the staging concept that is done by retrospective analysis of a 
large number of patients’ scale with a certain tumor and its demographic, clinical, 
anatomical, radiological, and pathological characteristics (van Meerbeeck 2001). The 
TNM classification was first proposed by Denoix in 1946 as an anatomical basis to 
unify staging. The T component of the classification expresses the extent of the primary 
tumor in terms of size and local invasion. Meanwhile, the N component denotes the 
involvement of regional lymph nodes and the M component informs the presence or 
absence of metastases. Various combinations of T, N, and M define different clinical or 
surgical-pathological stages (IA-IV) characterized by different survival characteristics 
(van Meerbeeck 2001, Beadsmoore & Screaton 2003, Saeed & Anderson 2011). An 
ideal cancer staging is critically important to provide an accurate and reproducible 
description of the extent of the disease that could be readily communicated to other 
people. Besides that, it allows the selection of an optimal therapeutic approach, whether 
it is surgical or non-surgical, curative or non-curative. The pathological stage also gives 
the most precise information for estimation of the prognosis as well as calculation of the 
result of a treatment (van Meerbeeck 2001, Gross et al. 2011). 
For lung cancer, there is a precise classification developed for NSCLC while a 
relatively broader classification was used for SCLC. The latest version of the 
International system to stage lung cancer was adopted by the American Joint Committee 
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for Cancerstaging (AJCC) and Union Internationale Contre le Cancer (UICC) in 1997 
(van Meerbeeck 2001). The various procedures used to diagnose and stage lung cancer 
can be divided into invasive (transbronchial needle biopsy, transthoracic needle biopsy, 
mediastinoscopy, and open lung biopsy) or non-invasive (sputum cytology, chest 
computed tomography, positron emission tomography, and magnetic resonance 
imaging) (Saeed & Anderson 2011). The most critical lung cancer stage is stage 4 or 
T4, whereby any size of the lung tumor that has invaded into the mediastinum, heart, 
great vessels, tracheas, esophagus, vertebral body, and/or carina, the tumor presents 
with malignant pleural and/or pericardial effusion, as well as the presence of satellite 
tumor nodules within an ipsilateral primary tumor (van Meerbeeck 2001, Saeed & 
Anderson 2011). 
Similarly, the TNM classification was created to allow recognition of breast 
cancer stages by indicating the extent of local, regional, and general extension of the 
disease at the time of primary treatment. However, the previous classification failed to 
relate the size of the primary tumor, degree of axillary involvement, and the indicators 
for endocrine responsiveness (Veronesi et al. 2006). Therefore, the new TNM staging 
systems of breast cancer introduced at the beginning of last century (Guth et al. 2007) 
has considered skin invasion as a morphologic parameter. This is because patients with 
the classical picture of breast cancer are often characterized as having visible tumors of 
considerable size that often cause entire breast deformation, as well as distant 
metastases. In the current TNM classification, all breast carcinomas with skin 
involvement are grouped together under T4 category, which relates to tumor of any size 
with direct extension to chest wall or skin (Guth et al. 2007). 
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1.2 MULTISTEP CARCINOGENESIS 
Cancer cells grow out of our normal body cells through carcinogenesis, the 
process in which cancer is generated because of somatic mutations accumulation in a 
single cell over a period that causes a gradual phenotypic change from a normal to a 
preneoplastic cell, which moves on to become neoplastic (Russo 2007). Carcinogenesis 
is often considered as an active phenomenon induced in a living organism through 
various chemical or physical agents that can be categorized into four rather distinct 
groups: chemical, radiation, biological, and genetic. Both biological and genetic 
carcinogenesis are mostly due to the informational macromolecules (DNA or RNA) 
carried by the carcinogens. Radiation carcinogenesis is attributed to the direct or 
indirect action of high-energy photons or particles, while chemical carcinogenesis 
usually causes a permanent chemical change in the DNA structure. Table 1.3 shows 
some representative examples of carcinogens for individual categories with their 
respective range of molecular masses (Pitot & Dragan 1991).  
Nevertheless, passive or spontaneous carcinogenesis may also occur in 
organisms without any active introduction of carcinogenic agents, although there is not 
a distinction between the two types of carcinogenesis (Pitot & Dragan 1991). This is 
because DNA damage is a common phenomenon that occurs daily in a living cell due to 
the replication machinery that does not have true 100% efficiency. Substantially, our 
body has certain complex mechanisms to detect and repair this DNA damage, or trigger 
its own suicide program if the DNA damage is too severe. However, occasionally the 
cell’s repair mechanism fails to correct the DNA damage and does not trigger the cell's 
suicide apparatus, hence giving rise to a constant low level of spontaneous mutation 
(Minamoto et al. 1999).  
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Extensive experimental observations in carcinogenesis have showed that this 
process can be divided into three distinct steps which require different lengths of time to 
accomplish, namely initiation (days), promotion (several years), and progression (1-5 
years) (Klaunig et al. 2011). 
Table 1.3: General classification of carcinogenic agents  
Class Examples Relative molecular 
mass (Da) 
I. Chemical Polycyclic hydrocarbons, aromatic 
amines and halides, diet, hormones, 
metals, and polymer surfaces 
5 x 101 – 5x 104 
II. Radiation Ionizing (X and γ ray, particle radiation) 
and ultraviolet radiation 
<<< 1-1+ 
III. Biological Viruses (papova, herpes, retro, and 
hepadna viruses) 
3 x 106 – 170 x 106 
(viral genomes) 
IV. Genetic Transgenic by enhancer-promoter-
oncogene constructs; selective breeding 
~ 106 - 108 
Cited from (Pitot & Dragan 1991) 
Initiation is the first step of the process involving an irreversible change in the 
initiated cells as a result of mutation in a critical gene (Avila et al. 2004). Some of the 
most harmful cancer-causing mutations are mutations in the genes that regulate DNA 
repair and apoptosis, which enhance cancer survival rate (Minamoto et al. 1999). These 
genetic damages can be divided into two categories: (1) a dominant mutation involving 
mainly proto-oncogenes, which normally results in a gain of function and (2) a recessive 
mutation involving tumor suppressor genes, growth suppressor genes, recessive 
oncogenes, or antioncogenes that normally cause a loss of function. Tumor suppressor 
genes are genes whose normal function is to inhibit the cell cycle. Cancer will develop 
once both copies of this gene have lost their function resulting in the release of the cell 
cycle from inhibition (Avila et al. 2004, Sullivan & Lu 2007, Anisimov 2009). The 
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efficiency of initiation step is often associated with the cellular replicative DNA 
synthesis and cell division process (Pitot & Dragan 1991). At this stage, the initiated 
population does not or produces minimal observable changes in their appearance and 
they will not develop into a tumor without additional stimulus (Vincent & Gatenby 
2008). Nevertheless, they are already at an advantage as compared to normal cells, 
permitting them to evolve towards fitter and more tumorigenic phenotypes. These 
mutant cells will increase slowly in number and line the basement membrane for an 
indefinite length of time (Vincent & Gatenby 2008). 
This is followed by the promotion step that is constantly modulated by various 
environmental factors, depending on the frequency of the promoting agent 
administration, age, composition and amount of diet. The major distinct characteristic of 
promotion that distinguishes it from other stages of carcinogenesis is its operational 
reversibility. The prior initiation event usually will not be tumorigenic without the 
pressure by secondary environmental agitations such as wounding, inflammation, 
hypoxia, and acidosis, which produce a harsh condition that increases the selection 
pressure for the growth of the passively initiated cells (Pitot & Dragan 1991, Hennings 
et al. 1993). One example would be the limitation of nutrients for the population of 
initiated cells during promotion stage, hence resulting in their growth reaching a plateau 
state. Therefore, they begin to evolve by adapting to the tissue growth constraints that 
allows them to switch to anaerobic metabolism, hence promoting a phenotypic change 
that becomes increasingly insensitive to the proliferation constraints as well as with 
heritable changes in oncogenes and tumor suppressor genes (Vincent & Gatenby 2008, 
Klaunig et al. 2011). 
Although the mutated cells continue to grow after initiation and promotion stage, 
intact basement membrane causes them to remain malnourished as the nutrients and 
oxygen must diffuse over a long distance to the deeply buried blood vessels resulting in 
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severe hypoxia of the cells (Vincent & Gatenby 2008). At the same time, the lactic acid 
accumulated from the aerobic and anaerobic glycolysis is not eliminated, causing an 
acidic extracellular environment (Helmlinger et al. 2002). This therefore enhances the 
fitness of the mutated cells that have been adapted to their own acid-induced toxicity 
that normally kills a large number of normal cells. Due to the rapid death of these 
normal cells, the mutated cells are accessible to a larger amount of nutrients. As the 
tumor increases in size, it has the ability to breech the basement membrane that confers 
to its invasiveness (Vincent & Gatenby 2008). This progression stage is irreversible 
mostly due to the unstable alterations of the cell’s genome and its evolution, leading to 
the final stage of carcinogenesis with six essential alterations in cell physiology. They 
collectively describe the malignant growth, including evasion of cell death, infinite 
replicative potential, sustained angiogenesis, self-sufficiency in growth signals, 
insensitivity to antigrowth signals, as well as tissue invasion and metastasis (Pitot & 
Dragan 1991, Russo 2007). 
A complete carcinogenic process will give rise to two types of neoplasms or 
tumors depending on their characteristics. Tumors that only proliferate and enlarge at 
their site of origin are benign tumors. This type of tumor lacks the ability to spread to 
other parts of the body and is usually not harmful to their host. Besides that, cells in the 
benign tumor are well-differentiated resembling the normal cells, encapsulated with a 
membrane, and grow at a slower rate. They rarely cause death of their surrounding 
tissue. They only cause a medical problem when its sheer bulk interferes with the 
normal bodily functions or when they secrete abundant biological substances such as 
hormones. Unlike benign tumors, malignant tumors that are better known as cancer are 
dangerous when they metastasize, start growing and dividing elsewhere in the body 
after they had overcome the strict growth factors and adhesive requirements. These cells 
are less differentiated with continuously changing properties, not membrane-bound, as 
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well as growing rapidly resulting in the destruction of the neighboring tissue (Darnell et 
al. 1986, Lee et al. 2011a). 
1.3 HALLMARKS OF CANCER 
Observations from human cancers and animal models suggest that the 
development of tumor occurs through a process similar to Darwinian’s theory of 
evolution, where each succession of genetic changes contributes a particular type of 
growth advantage that leads to the progressive conversion of normal human cells into 
cancer cells (Hanahan & Weinberg 2000). Figure 1.2 depicts the six essential changes in 
cell physiology which collectively dictate tumor growth; infinite replicative potential, 
evasion of cell death, sustained angiogenesis, tissue invasion and metastasis, self-
sufficiency in growth signals, and insensitivity to antigrowth signals (Hanahan & 
Weinberg 2000, Pietras & Ostman 2010). 
 
Figure 1.2: Acquired capabilities of cancer, cited from (Hanahan & Weinberg 2000) 
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1.3.1 INFINITE REPLICATIVE POTENTIAL 
Normal cells are confined to a finite replicative potential, as their growth will be 
halted once they have undergone a certain number of doublings, a process known as 
senescence. The counting device that determines the number of cell divisions is the 
telomere (ends of chromosome) which is made up of several thousand repeats of short 
6bp sequence element (Hanahan & Weinberg 2000). In the absence of telomerase that 
functions to replicate the 3’ ends of chromosomal DNA during each S phase, the 
telomere is shortened after each cell division and once the telomere length has ended, 
the cell no longer has the ability replicate and will eventually die (Hanahan & Weinberg 
2000, Anisimov 2009). 
However, senescence does not seem to occur in cancer cells, hence suggesting 
that the evolving premalignant cell populations have breached the mortality barrier 
during the course of multistep tumor progression. One of the crucial processes in order 
for a cancer cell to become immortal is to constantly reactivate the telomerase activity 
that adds hexanucleotide repeats onto the ends of telomeric DNA to maintain the 
telomere length above a critical threshold (Hanahan & Weinberg 2000, Rha et al. 2000). 
Alternatively, cancer cells might activate a mechanism known as ALT which maintains 
telomeres length via recombination-based-interchromosomal exchanges of sequence 
information (Hanahan & Weinberg 2000). This in turn allows the unlimited 
multiplication of the descendant cells through a continuous series of events known as 
cell cycle. 
Cell cycle is defined as a cell division process by which the two replicas of 
genome are partitioned into the daughter cell. This division process can be divided into 
five phases (Raven et al. 2004) as shown in Figure 1.3. G1, S, and G2 are grouped 
together as interphase, forming the portion of the cell cycle between cell divisions. G1 is 
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the primary growth phase that comprises the major portion of the cell’s life span. S is 
the phase in which the cell synthesizes a replica of the genome. G2 is the second growth 
phase, in which preparations are made for genomic separation (Weinberg 2007). 
Meanwhile, M (for Mitosis) is the essential phase of the cell cycle for separation of the 
two daughter genomes (Raven et al. 2004). Each subsequent phase is activated only if 
the previous stage has been properly progressed and completed where the cells that have 
temporarily or reversibly stopped dividing will usually enter a quiescent state known as 
G0 phase (Pecorino 2005). 
 
Figure 1.3: Cell cycle process, cited from (Kong et al. 2003) 
Normally, the cell cycle is tightly regulated to prevent uncontrolled cell 
proliferation that may lead to various diseases. For instance, progress into mitosis will 
be halted during DNA replication, and sister-chromatid separation is delayed until all 
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kinetochores are attached to the spindle (Vogelstein & Kinzler 2002, Schönthal 2004). 
There are also three main checkpoints to assess the internal state of cell and integrate 
external signals, which are the G1/S, G2/M, and Spindle Checkpoint. The G1/S 
checkpoint is the primary point at which the cell decides whether to divide, mainly 
governed by the Cyclin D/Cdk-4/6. The activated complex will increase 
phosphorylation of Rb protein that in turn releases bound transcription factors such as 
E2F-1 that subsequently activates genes transcription whose products are necessary for 
cells entry into S phase (Moon et al. 2000, Chou & Huang 2002). Meanwhile, G2/M 
checkpoint, which is controlled by the Cyclin A/Cdk-2, assesses the success of DNA 
replication and can stall the cycle if DNA has not been accurately replicated. The last 
spindle checkpoint ensures that all of the chromosomes are attached to the spindle in 
preparation for anaphase. This process depends on the presence of Cyclin B/A/Cdk-2 
(Raven et al. 2004, Schönthal 2004). 
At the same time, inhibitory proteins, Cdk inhibitors (CKIs) also help to regulate 
Cdks activity throughout the cell cycle process. CKIs identified in mammalian cells can 
be broadly grouped into two categories. The first group consists of p21WAF1, p27KIP1, 
and p57KIP2 that work by binding and inhibiting all the G1 cyclin/Cdk complexes. 
Among this group, p21CIP1/WAF1 is the key regulator of cell cycle arrest as it stops G1/S 
transition in cell cycle by blocking complex formation between cyclins A to D1, D2, 
and E with Cdk2. On the other hand, the second group of CKIs that includes p15INK4B, 
p16INK4A, p18INK4C, and p19INK4D specifically inhibits Cyclin D/Cdk4 or Cyclin D/Cdk6 
(Moon et al. 2000, Watson et al. 2008). 
1.3.2 EVASION OF CELL DEATH 
Besides bypassing the proliferation constraints imposed in a normal cell, cancer 
cell also has the ability to evade death. Accumulation of evidence from past researches 
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showed that the programmed cell death machinery is present in almost all the cell types 
of the body in a latent form. This program will unfold in a precisely choreographed 
order once it is stimulated by a variety of signals. The cell death mechanism is 
essentially divided into two groups of components: sensors and effectors. Sensors 
function to monitor both the extracellular and intracellular environment for any 
normality or abnormality conditions that may influence the survival of a cell. The 
information received will then be interpreted via regulation of the effectors of the cell 
death machinery (Hanahan & Weinberg 2000). 
The resistance of cell death acquired by cancer cells is mostly attributed to the 
survival signals supplied by the stromal component because of several genetic 
alterations in cellular death pathway components (Sledge & Miller 2003, Pietras & 
Ostman 2010). For instance, when bcl-2 was co-expressed with a myc oncogene, the 
bcl-2 gene was found to be able to promote formation of B cell lymphomas via inducing 
lymphocyte survival by stimulating myc-stimulated proliferation. Besides that, p53 
tumor suppressor protein (DNA damage sensor) which is a crucial member of the 
apoptotic signaling pathway was frequently inactivated, thus leading to a rapidly 
growing tumor with minimal number of dead cells (Hanahan & Weinberg 2000, Sledge 
& Miller 2003). Additionally, the survival signaling circuit such as PI3 kinase-
AKT/PKB could be activated by a number of extracellular signals such as IGF-1/2 or 
IL3, intracellular signals originating from Ras, as well as loss of pTEN tumor 
suppressor that usually stops AKT survival signal. Stimulation of such survival 
pathways in turn mitigates cell death program in a substantial number of human tumors 
(Hanahan & Weinberg 2000). 
The two fundamental modes of cell death in nucleated eukaryotic cells are 
apoptosis, which is also known as programmed cell death, and necrosis. Apoptosis is a 
Greek word that means dropping or falling of leaves from a tree. This term was coined 
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in 1972 by John Kerr, Andrew Wyllie and Sir Alistair Currie to explain the morphologic 
events during apoptosis, involving a controlled cell removal phenomenon which seemed 
to play a complementary but opposite role to mitosis in the regulation of animal cell 
population (Kerr et al. 1972). Meanwhile, necrosis is derived from the word “oncos” 
that means swelling, in accordance with cell swelling which is a characteristic feature 
occurring during necrosis (Proskuryakov et al. 2003). Apoptosis is a genetically 
regulated process of cell death that is ATP-dependent and it requires time to take place 
after the initial insult. In contrary, necrosis is an ATP-independent process and it occurs 
rapidly after the initial insult. Hence, the intracellular ATP concentration is an important 
factor in the selection of the pathway of cell death. Both of these modes have distinct 
morphological and biochemical features (Kiechle & Zhang 2002, Woo et al. 2008). 
1.3.2.1 APOPTOSIS 
Apoptosis, a highly organized physiological process, plays an important role to 
eliminate superfluous, aged, and damaged cells without inducing local inflammatory 
response that would likely damage adjacent cells. During apoptosis, the undesired cells 
will undergo several biochemical changes to prepare themselves to be phagocytized by 
macrophages. Ingestion of the cellular components by the macrophages therefore avoids 
the leakage of noxious proteolytic enzymes or reactive oxygen metabolites which 
otherwise would harm surrounding cells (Vinatier et al. 1996, Yang et al. 2006, Manu & 
Kuttan 2008). Apoptosis is also important during embryonic development and adult 
tissue homeostasis to remove unwanted and potentially harmful cells such as self-
reactive lymphocytes that may cause autoimmune diseases during development of 
reproductive organs and for remodeling of vascular pattern (Vinatier et al. 1996). In 
addition, apoptosis also plays a crucial role as a protective mechanism against certain 
pathological conditions such as cancer (Del Bello et al. 2004, Choi et al. 2006). 
Induction of apoptosis is a highly desirable mode as a therapeutic strategy in cancer 
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control. Currently, most of the chemopreventive agents exert their anticancer activities 
by inducing apoptosis in order to suppress tumor promotion and progression (Chen et 
al. 2004, Kim et al. 2005). 
Several remarkable stereotyped morphologies are the outstanding features of 
apoptosis. They include plasma membrane blebbing, loss of cell volume, loss of 
positional organization of organelles in the cytoplasm, breakdown of nuclear DNA with 
subsequent nucleosomal fragmentation, followed by cleavage of nucleus and cytoplasm 
by calpains into multiple membrane-enclosed bodies known as apoptotic bodies 
containing chromatin fragments (Taraphdar et al. 2001, Yang et al. 2006, Manu & 
Kuttan 2008, Lee et al. 2011a). A highly complex biochemical process involving 
various events that trigger the activation of the cellular machinery of apoptosis often 
accompanies these morphological characteristics (Taraphdar et al. 2001, Yang et al. 
2006). Nevertheless, activation of catabolic caspases seem to be the one that is directly 
accountable for the various molecular and structural modifications during apoptosis. 
Upon activation of effector caspases, the phosphatidylserine (PS) which 
normally resides at the inner leaflet of the plasma membrane is translocated to the outer 
leaflet. Since the apoptotic cell debris will eventually be phagocytized by macrophages 
or surrounding cells, this translocation is necessary to facilitate their recognition by the 
macrophages (Kiechle & Zhang 2002). The first structural or regulatory cellular protein 
targeted by effector caspases includes poly ADP-ribose polymerase (PARP), a DNA 
repair enzyme which is cleaved from its full length of 116kDa into an inactive 85kDa 
form. At the same time, the effector caspases activate the inactive caspase-activate 
deoxyribonuclease by removing its inhibitor. Without the presence of PARP, the 
nuclear DNA will be cleaved at inter-nucleosomal sites resulting in the production of 
DNA fragments with 180-200 bp. These DNA fragments show a typical “DNA ladder” 
configuration when they were analyzed using agarose gel electrophoresis (Vinatier et al. 
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1996, Kiechle & Zhang 2002). Meanwhile, fragmentation of cells to multiple 
membrane-bound apoptotic bodies is due to the cleavage of cytoskeletal elements and 
membrane proteins by calpains, a calcium-binding and thiol-containing enzyme 
(Taraphdar et al. 2001). 
The activation of apoptosis can be divided into three phases, which are initiation, 
execution, and degradation. Apoptosis can be initiated by a variety of environmental 
and physiological stimuli, such as growth factor deprivation, ionizing radiation, 
chemotherapeutic drugs, ultraviolet radiation, as well as activation of cell death 
receptor. Activation of this programmed cell death will then trigger the signalling for 
apoptosis which may occurs via several independent pathways, depending whether the 
initial assault is triggered from outside of the cell [death receptor or extrinsic pathway] 
or within the cell [mitochondrial or intrinsic pathway] (Manu & Kuttan 2008). 
Nevertheless, apoptosis has several common “cytoplasmic regulator” irrespective of the 
biochemical pathways being initiated (Kiechle & Zhang 2002, Lee et al. 2011a). Figure 
1.4 illustrates the regulation of the integrated apoptosis via both the intrinsic and 
extrinsic cell death pathways. 
Activation of death receptor or extrinsic pathway involves the binding of a 
ligand to a death receptor resided on the cell’s surface whereby apoptotic signals will be 
transmitted upon their ligation. This death receptors are grouped under the tumor 
necrosis factor receptor (TNFR) gene superfamily, which includes Fas(CD95), tumor 
necrosis factor receptor type 1 (TNF-R1), and TRAIL-receptor (Chen et al. 2004, Hung 
et al. 2010). Activation of these receptors by their respective ligands will stimulate the 
oligomerization of their intracellular death domain resulting in the recruitment of signal 
transducing molecules, namely TNFR 1-associated death domain protein (TRADD) and 
Fas-associated death domain (FADD). Consequently, they will activate the procaspases-
8 and -10 to form a death-inducing signalling complex (DISC), which in turn leads to 
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the activation of the caspases. The activated caspases-8 and -10 will then cleave and 
activate other downstream procaspases, triggering the caspase cascade that eventually 
lead to the apoptotic cell death (Kiechle & Zhang 2002, Hung et al. 2010). 
 
Figure 1.4: Regulation of apoptosis via intrinsic and extrinsic cell death 
pathways, cited from (Oliver & Vallette 2005) 
Nonetheless, activated caspase 8 may also induce apoptosis by cleaving Bid 
(Kiechle & Zhang 2002), the only molecule which forms a link between death receptor 
pathway and mitochondrial pathway. Cleavage of the cytoplasmic Bid (p21) forms a 
truncated form, tBid (p15) which then associates with another Bax-related protein such 
as Bak to induce the release of cytochrome c. It in turn activates the initiator 
procaspase-9 into caspase-9 that subsequently proteolytically initiates the caspases 
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cascade which includes downstream effector caspases such as caspases-3 and -7, 
leading to the death of cell (Kuo et al. 2006). 
Comparing with the extrinsic pathway, amplification of the death signals 
induced by a variety of stimuli via the mitochondrial or intrinsic pathway occurs most 
frequently in majority of the cell lines to induce apoptosis. With regard to this pathway, 
mitochondria act as the central control point for apoptosis by releasing apoptogenic or 
death-promoting proteins which are normally confined to the intermembrane space of 
mitochondria, including cytochrome c, Smac/DIABLO, apoptosis-inducing factor 
(AIF), and endonuclease G (Kiechle & Zhang 2002, Wu et al. 2009). These 
mitochondrial proteins are normally released as a response to an increase in the inner 
mitochondrial transmembrane potential due to opening of the permeability transition 
pore (PTP) during permeability transition (PT) process. As a consequence of the 
megachannel pores opening, there is an osmotic swelling of the matrix owing to its 
hypertonic condition. Since the inner membrane is made up of numerous cristae 
contributing to a large surface area, its expansion upon matrix swelling breaks the outer 
mitochondrial membrane. This in turn triggers the release and irreversible dilution of 
the intermembrane content into the cytoplasm (Desagher & Martinou 2000, Huang et al. 
2009). 
Apoptosis is said to be time-consuming due to the delay between the change in 
the inner mitochondrial membrane potential and the release of cytochrome c which 
usually takes approximately 5 minutes upon the initiation of the process (Kiechle & 
Zhang 2002). Once cytochrome c is released into the cytoplasm, it interacts with 
apoptotic protease-activating factor-1 (Apaf-1). This complex in turn undergoes self-
oligomerization in the presence of dATP or ATP through the CED-4-like domains. 
Subsequently, this complex further binds with two procaspase-9 molecules, forming a 
complex known as apoptosome to begin caspase-9 auto-activation via “proximity-
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induced action”. This activated caspase-9 will then activate other downstream effector 
caspases, including caspases-3 and -7, which cleave a variety of cellular proteins and 
cause cell death (Del Bello et al. 2004, Lv et al. 2008). As for the remaining 
apoptogenic proteins, Smac/DIABLO acts mainly as a caspase activator by interacting 
with the inhibitors of apoptosis proteins (IAPs) to interfere with their ability to inhibit 
the caspase enzymes (Kiechle & Zhang 2002). Meanwhile, AIF and endonuclease G 
works in concert to directly cause chromatin condensation and DNA fragmentation to 
induce apoptotic morphological changes (Wu et al. 2009). 
1.3.2.2 NECROSIS 
Theoretically, it is desirable for most chemotherapeutic agents to induce 
apoptosis as the main mode of cell death in the cancer cells. In practical terms however, 
it may not always occur this way for some of the drugs. Some of the chemotherapeutic 
drugs such as cladribine, cisplatin, and doxorubicin have the ability to activate both the 
apoptotic and necrotic cell death pathways (Tang et al. 2010, Lee et al. 2011a). 
Moreover, both apoptosis and necrosis share some common pathways and hence, have 
the possibility to occur concurrently (Proskuryakov et al. 2003, Woo et al. 2008).  
Necrosis has a different set of defined morphological characteristics as 
compared to apoptosis. This includes an early phase mitochondrial and organelle 
swelling, cytoplasmic swelling, mottled chromatin condensation, loss of membrane 
asymmetry, loss of plasma membrane integrity, followed by leakage of intracellular 
cytoplasmic constituents and rapid cell lysis which eventually result in an induction of 
inflammation (Suin et al. 2008). Unlike apoptosis that could be induced by a variety of 
stimuli, necrosis is usually induced by severe external damage resulting in accidental 
cell death via unregulated processes of membranes, cytoplasmic structures, and nucleus 
destruction. Therefore, necrosis is often thought as a form of passive cell death 
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(Proskuryakov et al. 2003). Nevertheless, some of the TNF receptor family such as 
TNF, FAS, and TRAIL are able to initiate both the apoptotic and necrotic cell deaths. 
An example would be the induction of the necrosis-like cell death via Fas-FasL system 
in the presence of caspase inhibitors that evokes the mitochondria swelling. Binding of 
TRAIL ligand to death receptors (DR4 and DR5) can also induces caspase-independent 
necrosis (Proskuryakov et al. 2003, Ohno et al. 2008). Another protein which also 
specifically triggers necrotic cell death is BNIP3, a member of the Bcl-2 family 
(Proskuryakov et al. 2003). 
Necrotic membrane damage can be divided into four events: (1) activation of 
phospholipases (such as phospholipase A2) which degrade the phospholipids into free 
fatty acids (such as arachidonic acid) and lysophospholipids, (2) surfactant effect of 
these products and other amphipathic lipid species, (3) disruption of the membrane-
associated cytoskeletal scaffold, as well as (4) direct attack by reactive oxygen species 
(ROS), free radicals, and lipid peroxides (Raffray & Cohen 1997). Meanwhile, DNA 
degradation during necrosis usually occurs randomly whereby caspase-independent 
DNase I and II are probably involved, resulting in a ‘smear’ formation on agarose gels 
(Proskuryakov et al. 2003, Lee et al., 2011). Other possible explanations could be due to 
the pH-associated chromatin changes that aid non-enzymatic disintegration of high 
order structures. This is because intracellular acidification or acidosis has been known 
as a common change in cells undergoing necrosis due to oxidative phosphorylation 
inhibition, lactic acid and inorganic phosphate build-up, as well as end-stage release of 
acidic groups by degradative enzymes (Raffray & Cohen, 1997). 
1.3.3 TISSUE METASTASIS AND SUSTAINED ANGIOGENESIS 
Tissue invasion and metastasis eventually occur as tumor cells progress into a 
malignant state, as the primary tumor masses develop the capability to invade adjacent 
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tissues as well as basement membrane and hence travel to distant locations via 
lymphatic or blood vessels to form new colonies. In order to do so, they need to acquire 
a migratory phenotype as well as extensively remodelling the surrounding extracellular 
matrix and blood vessels (Hanahan & Weinberg 2000, Sledge & Miller 2003, Pietras & 
Ostman 2010).  
The major alteration in cell-to-environment interactions in cancer involves E-
cadherin whose function is lost mainly as a result of mutational inactivation of E-
cadherin or β-catenin genes, transcriptional repression, or proteolysis of extracellular 
cadherin domain (Hanahan & Weinberg 2000, Pietras & Ostman 2010). Another 
parameter for invasive and metastatic cells is their ability to secrete extracellular 
proteases such as the matrix metalloproteinases (MMPs) which degrade the basement 
membrane and surrounding stroma. Expression of these protease genes is normally 
upregulated while the expression of the protease inhibitor genes is downregulated. On 
top of that, inactive zymogen forms of these proteases will be stimulated and converted 
into active enzymes. In addition to MMPs, some tumors may also produce other 
proteases such as membrane-associated urokinase-type plasminogen activator (uPA) 
which binds to the urokinase receptor (uPAR) expressed on the cancer cells (Hanahan & 
Weinberg 2000, Sledge & Miller 2003). 
The proteases expression is also crucial during vascular remodelling. Normal 
cell function and survival depends very much on the adequate supply of oxygen and 
nutrients by the vasculature. This necessity obligates almost all cells in a tissue to grow 
within 100µm of a capillary blood vessel (Hanahan & Weinberg 2000, Sledge & Miller 
2003). Hence, the developing neoplasias must acquire the ability to stimulate 
angiogenesis in order for them to grow into a larger tumor size (Sledge & Miller 2003).  
Tumors that are well-vascularized have the capability to expand locally and metastasize 
but avascular tumors grow only within a diameter of 2-3 mm (Song et al. 2008). A 
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common strategy to alter the angiogenic switch involves a modification of gene 
transcription to increase the expression of vascular endothelial growth factor (VEGF), 
which is the most potent angiogenic peptide (Hanahan & Weinberg 2000, Sledge & 
Miller 2003). Other examples of angiogenic peptide is basic fibroblast growth factor 
(bFGF1/2) and inducible nitric oxide synthase (iNOS). Alternatively, the expression of 
endogenous inhibitors such as thrombospondin-1 or β-interferon can be downregulated 
to induce angiogenesis. Suppression of plasmin (a pro-angiogenic component of the 
blood clotting system) that has the ability to cleave itself to form angiostatin, an 
angiogenesis inhibitor, also increases angiogenesis. The bioavailability of these 
angiogenic inducers and inhibitors can be regulated by a variety of proteases stored in 
the extracellular matrix (ECM) (Hanahan & Weinberg 2000). 
Malignant tumors are often fatal due to the ability of the cancer cells to invade 
other tissues and spread to other organs. For the majority of the cancer patients, 
metastasis to the regional lymph node or distant organs has occurred by the time of 
diagnosis of the primary tumor, hence it is responsible for 90% of cancer-associated 
mortality (Folgueras et al. 2004, Yang et al. 2008, Chaffer & Weinberg 2011). 
Metastasis of a cancer cell from its primary tumor must accomplish the following steps 
in the correct sequence for a successful dissemination (Figure 1.5): reduced adhesion 
ability via epithelial-mesenchymal transition (EMT), damaging intercellular interaction 
and detachment from their matrix, secretion of proteolytic enzymes for matrix 
degradation, invasion of surrounding tissues and blood vessels, translocation via 
circulatory or lymphatic stream to microvessels of distant tissues, extravasation, 
survival, and adaptation to the microenvironment of distant tissues, and finally 
recruitment of blood vessels for nourishment to establish a secondary tumor (Nelson et 
al. 2003, Yang et al. 2008, Bourboulia & Stetler-Stevenson 2010, Chaffer & Weinberg 
2011). Throughout this entire interrelated sequential events, a metastasizing cell may 
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face the possibility of being eliminated from the process if there is failure in any of the 
steps (Xie & Huang 2003, van Zijl et al. 2011). 
 
Figure 1.5: The metastatic cascade, cited from (Chaffer & Weinberg 2011) 
1.3.3.1 EPITHELIAL-TO-MESENCHYMAL TRANSITION 
The population of cells within a malignant tumor is hierarchically structured, 
with self-renewing cancer stem cells, progenitor cancer cells, and fully differentiated 
end-stage cancer cells. Cancer stem cells have superior tumor-initiating potential as 
compared to other cancer cells within a tumor. Features such as motility, invasiveness, 
and self-renewal that are essential in a malignant tumor could be owing to the inherent 
capabilities of the cancer stem cells subpopulation within a larger population of 
neoplastic cells (Chaffer & Weinberg 2011). However, epithelial-to-mesenchymal 
transition (EMT) has been shown to possess the potential to induce those non-cancer 
stem cells into cancer stem cell-like state by conferring polarized, epithelial cells with 
traits that enable them to detach from primary tumors and metastasize. An example 
would be a heightened resistance to apoptosis, a critical criterion of carcinoma cells to 
survive the harsh environments throughout their journey from their primary tumor to 
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dissemination locations for initiation of new cancer cells colonies (Chaffer & Weinberg 
2011). Besides that, EMT is characterized by epithelial loss with a concurrent gain of 
mesenchymal gene expression program. During this process, there would be a reduction 
or loss of epithelial E-cadherin, whose function is to bind its extracellular domain to an 
E-cadherin molecule of the neighbouring epithelial cells to stabilize cell-to-cell contact 
(Spaderna et al. 2006, Jang et al. 2011). Meanwhile, successive up-regulation of 
mesenchymal markers such as vimentin and neuronal-cadherin (N-cadherin) cause the 
rearrangement of cytoskeleton as well as formation of lamellopodia and filopodia. This 
cadherin switch (E-cadherin to N-cadherin) leads to a more efficient movement of 
EMT-transformed cells after detaching from their epithelial cell clusters that allows 
them to move like a single mesencymal-like cells (Palmer et al. 2011, van Zijl et al. 
2011). 
1.3.3.2 INVASION 
Although not all tumor cells have the ability to detach from its primary tumor 
and disseminate into blood or lymphatic circulation, this is a pre-requisite for 
metastasis. Therefore, EMT provides these cells with an upper hand for invasion with 
cytopathological changes which no longer constraint them to contact inhibition so that 
they are capable to cross barriers that are non-permissive for normal cells (Hsiao et al. 
2007, Palmer et al. 2011). Tumor cells that are located closely to a blood vessel have the 
brightest chances to disseminate since they can easily access the on-site growing vessels 
with immature vascular structure and high interstitial pressure (Xie & Huang 2003). 
Cancer cells that grow far apart from the blood vessels will have to go through a 
complex maneuver of invasion (Hsiao et al. 2007).  
Invasion of cancer cells may occur either by moving collectively as epithelial 
sheets or detached clusters, or as single cells in the form of mesenchymal or amoeboid 
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cell types (Painter et al. 2010, van Zijl et al. 2011). Invasion of tumor cells usually 
incorporates cell attachment to the basement membrane with succeeding proteolytic 
degradation of the barrier to allow migration through the extracellular matrix (Hsiao et 
al. 2007). This is achieved via production of a specific type of protease, namely matrix 
metalloproteinase (MMP) by cancer and stroma cells into the peritumoral environment 
to degrade the extracellular matrix. On top of that, they also synthesize different 
cytokines that form a positive feedback loop to enhance the MMP expression. The 
concentration of these MMP proteins is often associated with more advanced tumor 
stage and depth that involve lymph node and distant metastases (Lukaszewicz-Zajac et 
al. 2011). 
1.3.3.3 MOTILITY 
Although epithelial cells are generally stationary, tightly interconnected sheets 
of cells, they can also be mobilized depending on their developmental differentiation, 
environmental stimuli and surrounding tissue architecture. This is because cell motility 
is another fundamental process occurring while an embryo develops, repairing of 
wound, and during inflammatory responses (Ho et al. 2010, Palmer et al. 2011). The 
migration of adherent cells is described as the movement of cells from one location to 
another and it involves five processes, namely polarization, protrusion, adhesion, cell 
body translocation and finally rear retraction. In order to do so, integration of numerous 
molecular mechanisms is crucial so that a tumour cell can direct the configuration of 
new adhesions while disengaging existing adhesions and concomitantly applying force 
to move the cell body (Palmer et al. 2011).  
The role of motility in the evolution of a metastatic phenotype is supported by 
evidence of the primary tumor re-seeding itself in the context of circulating tumor cells 
(Palmer et al. 2011). Many cancer patients with advanced primary carcinomas contain 
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circulating cancer cells in their blood that are believed to be in transit to their future 
sites of metastasis (Chaffer & Weinberg 2011). Although blood circulatory system is 
considered as the main mode for metastasis, the lymphatic system can also claim a role 
during metastatic spread, as lymph capillaries are only thin-walled single layers of 
endothelial cells that lack inter-endothelial tight junctions and basement membrane. 
Therefore, it provides an easier means of access for the metastasizing cancer cells (van 
Zijl et al. 2011). Different routes of dissemination may pose different fates for the 
migrating cell. In contrary to pulmonary dissemination, portal vein dissemination would 
provide the cells a greater chance of survival since the circulation is much slower and its 
microvessels lack extracellular matrix, offering a less shear-force stress condition and 
easier extravasation (Xie & Huang 2003). 
Nonetheless, various factors in both the disseminating tumor cells and host may 
cause the death of the circulating cells. First, the tumor cells might die quickly while 
circulating because of non-specific factors such as hemodynamic turbulent forces. 
Besides that, the presence of T-lymphocyte cells, natural killer cells, endothelial cells 
and macrophages activity may destroy the blood-borne tumor emboli. In addition, 
intravascular death of disseminating tumor cells could also be due to oxygen-derived 
free radicals such as superoxide anion (Xie & Huang 2003). Therefore, highly 
metastatic cells must acquire the ability to survive the challenges of the blood stream in 
terms of physical constraints and host immune system. Enhanced homotypic tumor cell 
aggregation such as platelet-cancer cell association and formation of tumor embolus 
could be the survival factor for the disseminating tumor cells (Xie & Huang 2003, 
Laubli & Borsig 2010, Chaffer & Weinberg 2011, van Zijl et al. 2011). 
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1.3.3.4 ATTACHMENT AND LOCALIZATION 
Circulating tumor cells that have survived transport must arrest as a function of 
hemodynamic properties vasculature and identify endothelium of various tissues 
(Stafford et al. 2008). Although mechanical forces are important for tumor cells’ 
delivery to secondary sites, not all of these circulating cells present in the vessels of 
various organs would give rise to metastatic disease. Stephen Paget has hypothesized in 
1889 a “seed-to-soil” theory explaining a disseminating cancer cell as a seed that grows 
only if it had found an appropriate organ or soil at a secondary site (Kauffman et al. 
2003, Palmer et al. 2011). A successful engraftment and growth at a clinically relevant 
metastatic site is dependent on the receptive microenvironment that is normally 
optimized to create a “landing dock” before the arrival of the cancer cells. This process 
is known as the pre-metastatic niche formation that explains the tendency of solid 
tumors to home preferentially at distinct organs (Peinado et al. 2011). For example, lung 
and brain are the preferred metastatic sites for melanoma while bone is the preferred 
metastatic site for prostate carcinomas. This pre-metastatic niche usually attracts the 
disseminating tumor cells by releasing factors such as SDF-1, S1000A8, and S100A9 
(Chaffer & Weinberg 2011, Peinado et al. 2011). Otherwise, tumor cells can release 
factors such as VEGF-A, PIGF, and PSAP that educate specific distant sites to prepare 
before their arrival (Chaffer & Weinberg 2011). 
Cells that have completed all metastatic steps will eventually extravasate 
through the endothelial walls into the organs’ parenchyma and proliferate to colonize 
ectopic tissue. Tumor cells have developed various ways for extravasation: (1) inducing 
endothelial cell’s death or retraction, (2) generating reactive oxygen species resulting in 
an irreversible damage to the endothelial cells, (3) inducing angiogenesis or vascular 
remodeling, and (4) stimulating proliferation of arrested tumor cells intravascularly to 
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grow into large metastases without undergoing extravasation that eventually erupts 
through the basement membrane (Stafford et al. 2008, Shibue & Weinberg 2011). 
Once the tumor cell has extravasated, tumor-host interactions within the target 
organs’ parenchyma became the major contributing factor for a successful colonization 
of the metastatic cell (Shibue & Weinberg 2011). This includes the ability of tumor cell 
to trigger mitogenic stimulation from growth factors and cytokines (Chaffer & 
Weinberg 2011), vascularization and immune surveillance (Shibue & Weinberg 2011). 
The surviving metastatic cells can exist in one of the three alternative forms: (1) as 
solitary viable cancer cells in a quiescent, non-proliferative dormant state, (2) actively 
growing macrometastatic lesions allowing net increases in cell number, and (3) 
remaining as a small lesion due to a balance between proliferation and apoptosis 
(Chaffer & Weinberg 2011, Shibue & Weinberg 2011). 
1.3.3.5 PROTEOLYTIC ENZYME – MATRIX METALLOPROTEINASES 
Basement membrane degradation has been found to be a crucial process during 
metastasis for migration and invasion of cancer cells. This process is normally 
associated with overexpression and activation of proteolytic enzymes that provide an 
access for cancer cells into the vascular or lymphatic system, constituting a getaway 
route for distribution. More than 500 genes that encode for proteases or protease-like 
proteins were discovered in human genome (Folgueras et al. 2004). However, the main 
proteolytic enzymes involved in tumor invasion include the members of matrix 
metalloproteinase (MMP) family that have the potential to cleave almost all components 
in the extracellular matrix and basement membrane (Folgueras et al. 2004, Ho et al. 
2010, Kim et al. 2010).  
MMPs are grouped in a family of zinc-dependent endopeptidases that degrades a 
variety of proteins such as fibrillar and non-fibrillar collagens, fibronectin, laminin, as 
  
34 
 
well as glycoproteins in the extracellular matrix and basement membrane by cleaving 
their internal peptide bonds (Bourboulia & Stetler-Stevenson 2010, Lukaszewicz-Zajac 
et al. 2011). The human MMPs family comprises of 26 endopeptidases that can be 
subdivided depending on their cellular localization, either secreted or membrane bound, 
as well as based on their sequence homology and substrate specificity (Figure 1.6). 
Similar to other proteolytic enzymes, MMPs are synthesized as inactive 
enzymes or zymogens which require additional activation steps to form a functional 
MMP form. Most of the MMPs are activated outside the cell, requiring participation of 
other proteases such as serine proteinases, furin, plasmin, and others (Verma & Hansch 
2007, Lukaszewicz-Zajac et al. 2011). An example would be urokinase-type 
plasminogen activator (u-PA), a serine proteinase that converts plasminogen into 
plasmin that in turn cleaves and activates MMPs (Hsiao et al. 2007). 
Among the various MMPs, MMP2 and MMP9 are greatly associated with tumor 
invasion and metastasis, and can be attributed to their capability to degrade the type-IV 
collagen, the main component in basement membrane. Both these MMPs work via 
different mechanisms, as MMP2 promotes cleavage of extracellular matrix proteins 
while MMP9 alters vascular endothelium permeability (Hsiao et al. 2007, Yang et al. 
2008, Lukaszewicz-Zajac et al. 2011). Other roles of MMPs include regulation of tumor 
growth by favoring release of cell proliferation factors such as insulin-like growth 
factors, as well as targeting and activating growth factors whose precursors are attached 
to cell surface or sequestered in the peritumor extracellular matrix (Folgueras et al. 
2004). 
Under normal conditions, MMPs activities are maintained at low levels and are 
tightly monitored at several steps, namely transcriptional (through AP-1 or NF-κB via 
mitogen activated protein kinase (MAPK) or PI3K/Akt pathways), post-transcriptional, 
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Figure 1.6: Matrix metalloproteinases (MMPs) domain structures and functions, cited 
from (Bourboulia & Stetler-Stevenson 2010) 
  
36 
 
post-translational, and through the involvement of their endogenous inhibitors (TIMPs). 
Tissue inhibitors of metalloproteinases (TIMPs) can be found in most tissues and body 
fluids. Each TIMP molecule consists of one structural and one functional domain, 
known as the N- and C-terminals. The N-terminal region acts as the main inhibitor of all 
MMPs by interacting with the enzyme’s catalytic domain. Meanwhile, the C-terminal 
region contains at least two binding sites for enzyme as well as for interaction with pro-
forms of MMP2 and MMP9 to stabilize the complex (Lukaszewicz-Zajac et al. 2011). 
Four known human forms of TIMPs have the capability to inhibit almost all MMPs 
since they do not seem to differentiate much between various MMPs (Folgueras et al. 
2004, Snoek-van Beurden & Von den Hoff 2005). TIMPs inhibit MMPs activity mainly 
by forming a MMP/TIMP complex in a 1:1 stoichiometric pattern (Snoek-van Beurden 
& Von den Hoff 2005, Lukaszewicz-Zajac et al. 2011). Regulation of the MMPs 
promoters and inhibitors affect the balance of matrix degradation or synthesis that 
subsequently determines the invasive potential of cancer cells (Curran & Murray 2000, 
Snoek-van Beurden & Von den Hoff 2005, Lee et al. 2010, Lukaszewicz-Zajac et al. 
2011). 
1.3.4 SELF-SUFFICIENCY IN GROWTH SIGNALS AND INSENSITIVITY TO 
ANTIGROWTH SIGNALS 
Cell proliferation is strictly regulated during growth, differentiation and 
subsequent life of the normal cells as they only move from a quiescent state into an 
active proliferative state when the mitogenic growth signals (GS) are present (Hanahan 
& Weinberg 2000, Sledge & Miller 2003). Nevertheless, cancer cells have escaped the 
normal growth control through mutations that lead to an overexpression of differentially 
regulated growth factors, hormones, and cytokines such as hepatocyte growth factor 
(HGF), fibroblast growth factor (FGF), stromal derived factor (SDF)-1α and 
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interleukin-6 (IL6) (Sledge & Miller 2003, Pietras & Ostman 2010). Besides that, many 
of the oncogenes in cancer cells act by mimicking normal growth signaling. They 
produce various growth factors that they themselves are responsive towards, hence 
removing their dependence for growth stimulation from their normal tissue 
microenvironment (Hanahan & Weinberg 2000). Overexpression of receptors is another 
key factor that enables the cancer cells to be hyperresponsive towards ambient levels of 
growth factors that otherwise would not stimulate cell proliferation. Besides that, cancer 
cells also have the capability to selectively express their favourable extracellular matrix 
receptors (integrins) which transmit progrowth signals (Hanahan & Weinberg 2000, 
Sledge & Miller 2003).  
On the other hand, many and perhaps most of the anti-proliferative signals are 
channeled through retinoblastoma protein (pRb) and its two relatives, p107 and p130. 
pRb normally blocks proliferation by altering the function of E2F transcription factors  
that govern genes expression critical for G1 progression into S phase. Disruption of this 
pRb pathway in cancer cells will lift its control on E2Fs and thus allowing cell 
proliferation, rendering the cells become insensitive to anti-growth factors (Hanahan & 
Weinberg 2000). 
Therefore, activation of the signaling machineries by different growth signals or 
stimuli could either cause an induction or inhibition effect in different cell types and 
even within the same cell. This is because the protein components for the cell death 
program were already expressed in the cells and are maintained in association with their 
respective inhibitors (Vinatier et al. 1996, Kiechle & Zhang 2002). Similarly, each of 
the metastatic processes are dependent on various factors, broadly grouped into two 
categories known as metastasis promoters and metastasis suppressors (Shevde & Welch 
2003). The balance and complex interplay of both the metastasis promoters and 
suppressors in each step will determine whether a tumor cell can establish a successful 
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distant metastasis (Iiizumi et al. 2008). Hence, analysis of a large network of upstream 
complex signaling pathways that control cell death and metastasis remains to be proven 
as a routine tool for clinicopathological assessment (Williams & Stoeber 2007).  
1.3.4.1 TUMOR SUPPRESSOR, P53 
The p53 is a well-known tumor suppressor protein that is also known as the 
“guardian of the genome”. It protects cells against numerous physiological stresses via 
relay of signals through the p53 signaling network into the nucleus (Dey et al. 2010). 
The p53 gene is mapped on the short arm of human chromosome 17, encoding for a 
53kDa protein that consists of 393 amino acids (Shu et al. 2007, Machado-Silva et al. 
2010). The p53 signaling pathway is made up of p53 gene with its downstream genes 
which responds to various intrinsic and extrinsic stimuli to control cell survival, DNA 
damage repair, chromosome segregation, metabolic adaptation, cell senescence, aging 
and cell death (Shu et al. 2007, Hock & Vousden 2010, Solozobova & Blattner 2010). 
P53 protein functions are controlled by its post-translational modifications that affect its 
stability and transcriptional activity. Hock and Vousden depicts the outcomes of p53 
protein after several modifications such as neddylation, sumoylation, and ubiquitination 
(Hock & Vousden 2010). Other modification processes include acetylation, 
methylation, and phosphorylation (Brooks & Gu 2011). 
Since the presence of p53 has a negative effect in cell proliferation, their levels 
are usually kept low in a normal healthy cell by rapid degradation through ubiquitin-
proteasome pathway. One of the key regulators would be human double minute 2 
(Hdm2), the predominant and crucial E3 ubiquitin ligase which mediates p53 
ubiquitination via a RING domain by ubiquitinating p53 at six key lysine residues 
(K370, K372, K373, K381, K382, and K386) present at the C terminal of the protein. 
Working in a negative feedback loop, p53 drives the transcription of Hdm2 that 
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stimulates its degradation to maintain its low level at times of normal homeostasis 
(Hock & Vousden 2010, Solozobova & Blattner 2010, Brooks & Gu 2011). 
In response to DNA damage, ribosomal stress, hypoxia, or oncogene activation, 
p53 level will be stabilized to allow its accumulation through various mechanisms 
(Ryan 2011). Firstly, Hdm2 has the ability to target itself for degradation via 
autoubiquitination after inactivation of its own E3 ligase activity (Hock & Vousden 
2010). Besides that, phosphorylation of p53, enzymatic process of p53 acetylation at 
ubiquitination sites, as well as binding of tumor suppressor p14ARF to Hdm2 also 
prevents Hdm2-p53 interactions (Brooks & Gu 2011).  
Once p53 proteins are activated, they bind to their p53 responsive element to 
initiate one of the three transcriptional programs, including cell cycle arrest, DNA 
repair, or cell death. One of the primary target genes is the cyclin-dependent kinase 
inhibitor, p21WAF1/CIP1 which interacts and inhibits with cyclin-dependent kinases, 
resulting in phosphorylation of retinoblastoma protein (pRb) that leads to cell cycle 
arrest (Shu et al. 2007, Ryan 2011). The p53 has also been implicated in DNA repair by 
initiating repair mechanisms such as nucleotide excision repair (NER), base excision 
repair (BER), non-homologous end-joining (NHEJ) and homologous recombination 
(HR) (Shu et al. 2007). However, if the damage is beyond repair, the cell will be 
subjected to programmed cell death whereby p53 may activates both the intrinsic and 
extrinsic cell death pathways (Ryan 2011). 
Nevertheless, the loss of p53 function is implicated in carcinogenesis and hence 
rendering tumor cells resistant to chemotherapy and radiotherapy. Contrary to other 
tumor suppressors that contain large deletion or frameshift mutations, p53 is normally 
altered via missense mutations in the conserved DNA binding core domain of the 
protein (Machado-Silva et al. 2010, Schilling et al. 2010). This results in the inability of 
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the p53 proteins to produce a proper response in the presence of any physiological 
stresses, leading to uncontrolled cancer cell growth and survival. 
1.3.4.2 MAP KINASES 
Protein phosphorylation is a crucial mechanism utilized by a large number of 
proteins that are mainly enzymes, receptors, transporters, docking and scaffolding 
proteins to control their activity that regulate a variety of biological processes from cell 
growth and differentiation to apoptosis and disease. The human genome may encode as 
many as 2000 protein kinases to phosphorylate amino acid residues serine, threonine 
and tyrosine present in proteins of various tissues, cells, and organelles (Farooq & Zhou 
2004). The MAPK family consists of highly conserved proline-directed, protein-
serine/threonine kinases that transduce extracellular signals or physical stresses such as 
osmotic shock, ischemic injury, radiation, growth factors, cytokines, and 
neurotransmitters via different receptor types for intracellular cell regulation. The wide 
range of cellular processes modulated by MAPK cascades include cell proliferation, 
differentiation, survival, division, movement, immune responses, development, and cell 
death (Farooq & Zhou 2004, Zohrabian et al. 2009, Porta et al. 2011). Transmission of 
the extracellular signals into their intracellular targets is mainly mediated through a 
network of interacting proteins, in a cascade module known as “the central three-tiered 
core” since it consists of three sequentially activating enzyme cascades of 
phosphorylation-dephosphorylation reaction. It begins with an active MAPK kinase 
kinase (MAPKKK such as Raf and mos) that activates MAPK kinase (MAPKK such as 
Mek and MKK) and subsequently activates a particular MAPK (such as ERK, JNK, 
p38, or p42). In this case, the terminal activated MAPK functions as an effector of a 
unique pathway that regulates the gene expression and protein activity to carry out a 
precise physiological response (Mutalik & Venkatesh 2006, Porta et al. 2011). 
Depending on the terminal MAPK activated, MAP kinases are divided into three major 
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subfamilies as shown in Figure 1.7, namely extracellular signal-regulated kinases (ERK-
1/2), c-Jun N-terminal kinases (JNK-1/2/3) and p38 proteins (p38-α/β/γ/δ). Upon 
activation, various membrane-associated and cytoplasmic proteins are phosphorylated 
and translocated to the nucleus to activate specific transcription factors resulting in 
immediate gene transcription of important cellular proteins and cytokines (Farooq & 
Zhou 2004, Porta et al. 2011). 
 
Figure 1.7: Schematic representation of MAP kinase cascade and their nuclear targets, 
cited from (Plotnikov et al. 2011) 
The first MAPK pathway elucidated was extracellular signal-regulated kinases 
(ERK-1/2) cascade since ERK-1/2 proteins are ubiquitously expressed. ERK-1/2 
phosphorylation cascade is normally initiated due to activation of GTPase Ras at the 
plasma membrane by insulin or other growth factors, leading to activation of the 
MAPKKK tier of the cascade (mainly Raf-1 and B-raf). The signal is then transmitted 
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to MEK1 and MEK2 (MAPKKs) via phosphorylation of two serine residues in their 
activation loop. Subsequently, ERK1 and ERK2 receive the signal and are activated via 
phosphorylation of the regulatory Thr and Tyr residues in the Thr-Glu-Tyr domain 
(Plotnikov et al. 2011). The final destination of the signal would be the MAPKAPK 
components (such as RSKs, MNKs, and MSKs) or other substrates localized either in 
cytoplasm, nucleus, or cellular organelles such as cytoskeletal (Porta et al. 2011). 
Mutations of signalling components upstream or within the cascade of this pathway 
have been observed in many cancer types (Plotnikov et al. 2011). Constitutive activation 
of this pathway leads to increased expression of transcriptional products such as cyclin 
D1 that resulted in cell cycle progression. In addition, genes that inhibit proliferation are 
suppressed, while genes involved in angiogenesis, migration, invasion, and metastasis 
are upregulated (Zohrabian et al. 2009). 
c-Jun N-terminal kinases (JNK) was initially also named as stress-activated 
protein kinase (SAPKs) cascade since it is a mediator of intra- or extra-cellular stresses 
including UV irradiation, growth factor deprivation, and DNA damaging agents. It was 
found out later on that JNK pathway can also be activated in response to other stress-
independent stimuli and growth factors such as cytokines (Plotnikov et al. 2011, Porta et 
al. 2011). Those stress and other stimuli transduce their signal via GTPases such as 
Cdc42 and Rac1, which subsequently activate “the central three-tiered core” (Plotnikov 
et al. 2011). JNK pathway is identified as the regulator for transcription factor c-Jun 
since activated JNKs phosphorylate and activate the N-terminus of c-Jun protein, hence 
stabilizing and increasing the activity of c-Jun as a transcription factor (Krens et al. 
2006). Most of the JNK targets are nuclear hormone receptors and nuclear 
transcriptional regulators, including ATF2, NF-AT4, and p53, which in turn mediate 
cellular processes such as apoptosis, innate immune response after activation of various 
Toll-like receptor family proteins, neuronal activity, and insulin signalling. 
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Dysregulation of JNK has also been implicated in several cancer types (Plotnikov et al. 
2011, Porta et al. 2011). 
The p38 cascade is another SAPK pathway that can be stimulated by 
environmental stress and inflammatory cytokines. Upon activation of the receptors, the 
signals are transmitted to four isoforms of p38, each having specific functions that are 
determined by the specificity of the upstream activators as well as the identities and 
functions of the downstream substrates (Plotnikov et al. 2011, Porta et al. 2011). 
Alternatively, p38 can also be autophosphorylated in a MAPKK-independent manner, 
induced either by; (1) stimulated interaction with adaptor proteins Tab1, (2) 
phosphorylation of Tyr323 by ZAP-70, or (3) interaction with lipidic phosphatidyl 
inositol analogues (Plotnikov et al. 2011). Dysregulation of this cascade is usually 
noticed in pathological conditions such as inflammation, autoimmune diseases, 
neurodegenerative diseases, diabetes, as well as cancer due to cancer-associated 
inflammation or dysregulation of cell cycle (Krens et al. 2006, Plotnikov et al. 2011). 
1.3.4.3 HYPOXIA INDUCIBLE FACTOR (HIF) 
Hypoxia, defined as a state of reduced oxygen level below normal values, 
usually exists within solid tumors due to the disordered perfusion and unregulated 
growth (Joung et al. 2008, Kaluz et al. 2008, Manolescu et al. 2009). Although mild-
hypoxia is considered pro-survival, prolonged hypoxia will lead to cell death. If the 
tumor cells survive the hypoxic insult, they may develop drug therapy resistance, DNA 
over-amplification, enhanced malignancy and metastatic potential (Ho et al. 2006, 
Sermeus et al. 2008).  
The hypoxic condition normally activates hypoxia inducible factor (HIF) 
pathway which regulates post-translational modifications of the hypoxia inducible 
factor 1 (HIF-1) through two mechanisms, whereby the first controls the abundance of 
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HIF-1α and the second controls its transcriptional activity (Kaluz et al. 2008). HIF-1 is a 
heterodimeric transcription factor made up of two subunits, HIF-1α (120kDa) that is 
continuously produced and degraded in cells while HIF-1β (91-94kDa) presents in the 
cell irrespective of oxygen tension changes and therefore is important for hypoxia-
induced transcriptional changes mediated by HIF-1 heterodimer (Lee et al. 2006, Kaluz 
et al. 2008, Klaunig et al. 2011). Oxygen dependent degradation of HIF-1 is regulated 
by prolyl hydroxylases (PHDs) in the presence of iron and 2-oxoglutarate and oxygen, 
whereby HIF-1 is hydroxylated either via capturing by von Hippel-Lindau (pVHL) 
through prolyl hydroxylation or preventing transactivator recruitment through 
asparaginyl hydroxylation (Maxwell 2005, Sermeus et al. 2008). 
Elevated HIF-1 expression has been implicated in various human tumors with 
poor outcome, such as head and neck cancer, colorectal, nasopharyngeal carcinoma, 
breast, osteosarcoma, pancreatic and others. The signaling pathway is activated in 
response to reactive oxygen species (ROS) and other cellular oxidants level (Klaunig et 
al. 2011). This leads to stabilization of HIF-1α, which is an essential step so that it can 
assemble with HIF-1β to form a functional HIF-1 complex on the hypoxia responsive 
element (HRE) in the regulatory regions of its target genes to recruit different proteins 
that participates in the adaptation to hypoxic environment (Ruas & Poellinger 2005, Lee 
et al. 2006). Some of the adaptations induced by HIF-1 include: (1) stimulating protein 
synthesis to promote metabolic changes into anaerobic glycolysis in hypoxic tissues 
(Sermeus et al. 2008, Manolescu et al. 2009), (2) inducing neovascularization via 
transcriptional activation of a number of growth factors such as VEGF to ensure an 
adequate supply of oxygen (Manolescu et al. 2009, Ndubuizu et al. 2010), (3) increasing 
expression of transferrin receptor and transferring genes to replenish iron deficiency 
(Lee et al. 2006), and (4) increasing expression of drug export pumps such as MDR1 
(Sermeus et al. 2008). 
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1.3.4.4 B CELL LYMPHOMA-2 GENE ENCODED PROTEIN (BCL-2) 
Bcl-2 (B cell lymphoma-2 gene encoded protein) was first discovered in human 
B-cell lymphomas as a gene translocated from its normal position on chromosome 18 to 
chromosome 14 (Vinatier et al. 1996). It has been established to be a proto-oncogene 
since the translocation causes it to become an oncogene that helps to prolong cell 
survival by inhibiting apoptosis (Manu & Kuttan 2008). The various Bcl-2 proteins 
constitute a protein family consisting at least 22 members that have similar α-helical 
sequences, known as Bcl-2 homology (BH) domains (Martin & Vuori 2004). Bcl-2 
family proteins play a pivotal role as the main regulators of apoptosis as well as for 
induction of caspase activation. Its family members can be grouped into two categories, 
whether they are proapoptotic or antiapoptotic molecules. They may contain up to four 
conserved Bcl-2 homology domains, from BH1 to BH4. Most of the antiapoptotic 
members of Bcl-2 family that includes Bcl-2, Bcl-XL, Mcl-1, and Bcl-w possess 
sequence conservation in all four domains. On the other hand, the proapoptotic 
members of Bcl-2 family can be subdivided into two groups. The first group shares 
sequence homology from BH1 to BH3 domains but not in BH4, and it consists of Bax, 
Bak, and Bok. Whereas, the second group shares only sequence homology in BH3 
domain and they are Bid, Bim, Bad, Bik, Bmf, Hrk, Noxa, Puma, BNIP3 and Spike 
(Komarasamy 2011).  
The crucial function of Bcl-2 family members is their involvement in the direct 
control of mitochondrial membrane permeability that regulates the release of apoptosis-
inducing factors from the intermembrane space into the cytoplasm (Jin et al. 2006). Bcl-
2 is the key regulator among the family members that control cell homeostasis. It 
usually forms a partner with Bax (its death promoting partner) protein to constitute a 
“pre-set rheostat” within a cell, where the ratio of Bcl-2 to Bax often decides whether a 
cell receiving a death stimulus to accept or ignore it (Vinatier et al. 1996). If the 
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antiapoptotic Bcl-2 protein is in excess in the cell, it heterodimerizes with Bax and 
hence averts the conformational changes of Bax. Under these circumstances, the cell is 
able to survive (Hao et al. 2007). Another member of the Bcl-2 family that has a similar 
role is Bcl-X that is divided into two types, Bcl-XL and Bcl-XS after differential 
splicing. Both of these proteins form another competing pair, whereby excess amount of 
Bcl-XS will result in cell death (Vinatier et al. 1996). 
1.3.4.5 CASPASES CASCADE 
The shift of the balance between Bcl-2 family proteins will in turn induce 
activation of cysteine-containing, aspartate-specific proteases known as caspases that 
form the central component of the apoptotic mechanism (Choi et al. 2006, Graf et al. 
2007). Caspases are usually synthesized as pro-enzymes or zymogens that consist of an 
N-terminal pro-domain, linked with a small linker sequence to a 20kDa (p20) subunit 
followed by a 10kDa (p10) subunit (Graf et al. 2007, Zhu et al. 2007). Catalytically 
active caspase is normally released upon cleavage of the prodomain. To date, fourteen 
human caspases have been identified, with twelve caspases (caspases 1-10, 12, and 14) 
of human origin while caspase 11 is of bovine origin and caspase 13 is of murine origin. 
These human caspases can be subdivided into three groups, based on their prodomain 
structure, substrate specificity and functions (Oliver & Vallette 2005, Graf et al. 2007) 
as shown in Table 1.4. 
The first group of the caspase family is involved in the maturation of cytokines, 
but their involvement in the apoptosis is not straightforward. Meanwhile, the other 
caspases who are participating in the induction and execution of cell death are grouped 
into initiator and effector caspases. The initiator caspases are made up of long 
prodomains with recognizable homotypic protein-protein interaction motifs, such as 
caspase recruitment domain (CARD) or a death effector domain (DED). These caspases 
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transduce various signals into proteolytic activity. In contrast to the initiator caspases, 
the effector caspases do not contain a large prodomain and lack intrinsic enzymatic 
activity. These procaspases are activated after proteolytic cleavage by initiator caspases 
into large and small subunits (Oliver & Vallette 2005, Graf et al. 2007). Figure 1.8 
shows a schematic representation of the events leading to caspases activation. 
Table 1.4: The caspase family and their functions 
Group Function Caspase Optimal tetrapeptide 
sequence 
Group I Inflammation Caspase 1 WEHD 
  Caspase 4 (W/L)EHD 
  Caspase 5 (W/L)EHD 
  Caspase 12 Not known 
  Caspase 14 WEHD 
Group II Effector Caspase 3 DEVD 
  Caspase 7 DEVD 
  Caspase 6 VEHD 
Group III Initiator Caspase 2 DEHD 
  Caspase 8 LETD 
  Caspase 9 LEHD 
  Caspase 10 LEXD 
  Caspase 12 Not known 
Adapted from (Oliver & Vallette 2005, Graf et al. 2007) 
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Figure 1.8: Schematic diagram of caspase activation, cited from (Donepudi & Grutter 
2002) 
1.3.4.6 C-MYC 
The c-myc protein is a transcription factor made up of 439 amino acids, which 
regulates 15% of genes in genomes from flies to humans. Regulation of the transcription 
is done through several mechanisms, such as recruitment of histone acetylases, 
chromatin modulating proteins, basal transcriptional factors, and DNA 
methyltransferase (Dang et al. 2006, Wang et al. 2012). It usually heterodimerizes with 
its partner protein Max, forming a c-myc/Max complex which binds to a consensus 
enhancer box (E-box) DNA element to act as a transcription factor that regulates 
various aspects of cell behavior such as cell proliferation, cell cycling, apoptosis, 
adhesion, and tumorigenesis (Sanders & Gruppuso 2005, Cho et al. 2010).  
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Since c-myc has a role in cellular proliferation and growth, its expression is 
normally higher in proliferating cells and is downregulated during differentiation. This 
change in expression level is regulated at multiple stages, such as transcription 
initiation, elongation, mRNA stability, and protein stability (Sanders & Gruppuso 
2005). However, genetic alterations of myc genes were discovered in abundant human 
malignancies and have been considered as one of the most frequently activated 
oncogenes involved in the initiation of several cancer types (Luscher 2001, Cho et al. 
2010). Some of the consequences of myc proteins overexpression include: (1) 
promoting cell cycle progression, (2) increasing protein synthesis, (3) allowing 
neoplastic transformation of susceptible cell lines, (4) increasing glucose uptake and 
glycolysis, (5) up-regulating transferrin receptor (TFRC1), (6) enhancing nucleotide 
synthesis and metabolism, and (7) regulating stability or translational efficiency of 
target mRNAs (Luscher 2001, Dang et al. 2006). 
1.3.4.7 ACTIVATED PROTEIN-1 (AP-1) 
Activated protein-1 (AP-1) is a redox-sensitive basic leucine zipper (bZIP) 
transcription factor, hence regulating genes expression involved in cell differentiation, 
proliferation, migration, transformation, oxidative response, inflammation, apoptosis 
and immune response (Jang & Surh 2005, Vesely et al. 2009). It is a sequence-specific 
transcription factor consisting of either homodimers or heterodimers proteins of jun (c-
jun, junB, junD), fos (c-fos, fosB, fra-1, fra-2), Jun dimerization partners (JDP1, JDP2), 
Maf (musculoaponeurotic fibrosarcoma), and the closely related activating factors 
subfamilies (ATF2, LRF1/ATF3, B-AT) (Jang & Surh 2005, Klaunig et al. 2011).  
Activation of AP-1 is regulated by cis-elements in the promoters of AP-1-
encoding genes and mediated mainly via the MAP kinase cascades (Vaiopoulos et al. 
2010). One of the obvious effects of AP-1 activation involves an elevated cell 
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proliferation since both c-fos and c-jun are positive regulators of cell proliferation. This 
is due to the binding of AP-1 at its binding site in cyclin D1 promoter, hence activating 
cyclin-dependent kinase that promotes progression of cell division cycle. Alternatively, 
expression of cyclin-dependent kinase inhibitor, p21WAF that inhibits cell cycle is 
suppressed (Klaunig et al. 2011). In addition, overexpression of AP-1 also results in an 
increase of matrix metalloproteinase (MMP) expression, therefore enhancing the 
cellular invasion since they share a consensus AP-1 binding site at position-66 to -72 in 
their promoters (Ozanne et al. 2000). JunB, although it is another member of the jun 
family proteins, has a distinct function from c-jun due to its negative regulation of c-
jun-induced cell proliferation activity by transcribing the cell cycle inhibitor, 
p16INK4A. Similarly, junD is also shown to inhibit intestinal epithelial cell 
proliferation via activation of p21 promoter and reducing tumor angiogenesis by 
protecting cells from oxidative stress. Therefore, AP-1 activation is greatly depending 
on the relative abundance and composition of AP-1 dimers, as well as cell types, 
stimuli, and cellular environment (Klaunig et al. 2011). 
1.3.4.8 E2F 
E2F proteins are implicated in cell cycle control, DNA licensing and synthesis, 
mitosis, DNA repair, and apoptosis due to the presence of E2F responsive site in the 
promoters of the genes. E2F expression is regulated via multiple mechanisms, mainly 
through the pocket protein interaction involved in the E2F cell cycle activity. The 
pocket protein family consists predominantly of retinoblastoma protein (pRb), as well as 
p107 and p130, all having the capability to regulate cell cycle progression via arresting 
cells in G1 phase when their expression are upregulated. This is possible as 
hypophosphorylated pocket proteins (p130) will bind themselves to E2F proteins (E2F4 
and E2F5) rendering them inactive (Stevaux & Dyson 2002, Stevens & La Thangue 
2004). An increased oncogenic capacity measured by unscheduled proliferation could 
  
51 
 
be due to; (1) higher E2F protein levels in tumor cell, as well as (2) higher extent of 
phosphorylated pRb proteins with E2F colocalization which suggest overexpression of 
E2F that corresponds to the free and active form (Tsantoulis & Gorgoulis 2005). 
1.3.4.9 NFκB 
NFκB is an ubiquitously expressed nuclear transcription factor that is generally 
known as an antiapoptotic factor (Manu & Kuttan 2008, Klaunig et al. 2011). NFκB is a 
dimeric transcription factor made up of homodimerization or heterodimerization of 
different proteins in the Rel family, including p50 (NFκB1), p52 (NFκB2), c-Rel, v-Rel, 
Rel-A (p65), and Rel-B (Klaunig et al. 2011). In majority of the cells, it consists of a 
heterodimer of p65 and p50 or p52 subunits that are the most frequent components of an 
active NFκB molecule. This is because the p65-containing complexes have the ability to 
bind to the consensus DNA sequences at p65/c-Rel with high affinity, resulting in 
transcriptional activation (Kiechle & Zhang 2002, Manu & Kuttan 2008). At normal 
conditions, these dimers are sequestered in the cytoplasm in an inactive form via 
binding to its inhibitory counterpart IκB proteins such as IκBa, IκBb, and IκBe (Kundu 
& Surh 2004, Klaunig et al. 2011).  
NFκB can be activated by intracellular mediators in response to various external 
stimuli, including cytokines, oxidative stress, oncogenes, and DNA damage. For 
example, cytokines binding to their receptors will lead to interaction with TNF receptor-
associated factors, hence activating the NFκB-inducing kinase through activation of 
Tat-associated kinase-1. Subsequently, activated NFκB-inducing kinase phosphorylates 
and activates IκB kinase which in turn phosphorylates two critical serine residues 
(Ser32 and Ser36) in the inhibitory NFκB binding protein IκB, leading to their 
degradation. Thus, the active NFκB will be released and translocated into the nucleus 
for binding on the κB-regulatory elements, modulating the expression of a number of 
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genes that sustain cell survival (Kiechle & Zhang 2002, Romano et al. 2004, Klaunig et 
al. 2011). NFκB activation has been implicated in various malignant cancers such as 
breast, colorectal, pancreatic adenocarcinoma, and T-cell leukemia due to its critical 
roles in: (1) growth factor mediated cell proliferation, (2) tumor cell invasion, (3) 
angiogenesis, (4) tumor cell metastasis, and most importantly (5) promoting cell 
survival by inducing antiapoptotic gene expression (Kiechle & Zhang 2002, Manu & 
Kuttan 2008, Klaunig et al. 2011). 
1.4 CANCER TREATMENTS 
Cancers that are left untreated ultimately results in serious illness and most 
often, death. Therefore, adopting appropriate conventional treatments such as surgery, 
radiation therapy and chemotherapy drugs can help to control most of these cancers 
(Jemal et al. 2008). Most of the time, these conventional therapies are used in 
compliment to each other as none of those therapies can be used as a standalone therapy 
for cancer due to their limitations (Avila et al. 2004). 
Surgery has been the basis of treatment for patients with solid cancers. It was 
considered as having the central role when it concerns cancer management since it is 
often the most effective therapy to achieve cure. Surgery has a role in different aspects 
of cancer treatment (King & Primrose 2003). More than half of the people diagnosed 
with cancer will have some type of surgery or operation at some point as it can be used 
to remove tumours confined to a small space. Biopsy is a type of surgery, and is 
preferable for diagnosis of malignancy because more information can be gained from a 
core biopsy as compared to fine-needle aspiration cytology, hence allowing a more 
reliable diagnosis of invasive disease (Reed 2009). Besides that, surgery may also 
benefit cancer patients with gastrointestinal and pancreatic tumours that cause 
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obstruction of the gastrointestinal tract and the biliary tree, which can only be 
overcomed by performing a bypass surgery. Additionally, it can also be used to reduce 
the size of large tumours such as ovarian cancer so that subsequent treatment by 
radiation therapy or chemotherapy will be even more effective (King & Primrose 2003). 
Meanwhile, radiation therapy uses radiation or high-energy rays to kill or shrink 
tumour cells by damaging their genetic material, making these cells impossible to 
continuously grow and divide. Radiation therapy is the principal treatment for various 
skin cancers, cancers of the mouth, nasal cavity, pharynx and larynx, brain tumours, and 
many gynecological cancers, as well as lung and prostate cancer (Ota et al. 2007). 
However, the potential role of radiation therapy depends greatly on the relative risk of 
the disease to the patient. If a patient has large metastases that cause a greater risk to the 
patient’s life, systemic chemotherapy is the best option. On the contrary, if a patient has 
relatively small mass of asymptomatic metastases, radiation therapy should be a better 
option (Saltz 2004). 
On the other hand, there are several roles for cytotoxic chemotherapy in cancer 
treatment. Curative chemotherapy only works for a small number of chemosensitive 
tumours that may show response to an individual cytotoxic agent while adjuvant 
chemotherapy involves administration of chemotherapy after primary local treatment to 
improve the cure rate when chemotherapy alone does not ensure a curative solution. 
Palliative chemotherapy helps to relieve symptoms of bulky and metastatic tumour  that 
has low cure possibility (Parnell & Woll 2003, Bhosle & Hall 2009). Chemotherapy can 
be grouped into several classes of drugs based on their chemical structure and modes of 
action: (a) topoisomerase I and II inhibitors that inhibit the action of DNA 
topoisomerases which break and rejoin DNA molecules to control the topological state 
of DNA, (b) platinum compounds that form complexes with DNA, hence inhibiting 
DNA polymerase which results in the blockage of replication and transcription 
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processes, (c) alkylating agents that act on DNA directly, resulting in cross-linking or 
breaking of DNA strands as well as abnormal base pairing, (d) antibiotics that bind to 
the DNA of cancer cells and prevent RNA (ribonucleic acid) synthesis which is an 
important step for the protein synthesis that is necessary for cell survival, (e) anti-
metabolites that replace natural substances by acting as building blocks in DNA 
molecules, resulting in the alteration of the function of enzymes which is essential for 
cell metabolism and protein synthesis, (f) mitotic inhibitors that mainly affect tubulin, 
hence disrupting formation of the spindle for chromosomes migration during mitosis 
(Wijen et al., 2000; Calatayud et al., 2002; Parnell & Woll, 2003; Elisa et al., 2004; 
Kanaan et al., 2009). 
1.4.1 PLANT-DERIVED CHEMOTHERAPEUTICS 
Cancer chemotherapy began in the 1940s as a consequence of toxicological 
studies of nitrogen mustard-based war gas. It is approximated that more than 60% of the 
anticancer drugs applied in cancer chemotherapy have originated from natural source, 
whether they are original natural products, products derived semi-synthetically from 
natural products, or even synthetic products based on natural products models. For 
example, vincristine, irinotecan, and etoposide were derived from herbal sources while 
doxorubicin, bleomycin, and dactinomycin were extracted from marine sources (Sardari 
et al. 2009). The abundance of plants that have anticancer properties have been in 
existence for thousands of years in countries such as China, India, and Central America 
where they still play an essential role in primary health care of under-developed 
countries (Avila et al. 2004, Yineger et al. 2008). 
In the past two decades, the National Cancer Institute (NCI) had established a 
system for scientific approach to develop chemopreventive agents. It began from 
epidemiological and basic laboratory data, stepwise clinical trials, and finally led to the 
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Food and Drug Administration (FDA) to apply the chemoprevention to human subjects 
(Russo 2007). Among the nature-derived anticancer drugs discovered, only 11% of the 
compounds that entered clinical trial successfully made their entry into the market 
place. Others were mostly withdrawn from subsequent studies mainly for issues related 
to their efficacy, toxicity, drug metabolism and pharmacokinetics (Sardari et al. 2009). 
Nevertheless, even those compounds that were marketed were not considered flawless. 
First, chemotherapy drugs are most effective against rapidly dividing cells such as 
cancer cells. However, certain body cells such as bone marrow cells, immune cells and 
hair follicle cells that rapidly divide were also targeted in a similar manner (Lupulescu 
1999). Hence, this treatment may cause a range of side effects to the patient with 
varying degrees of severity (Parnell & Woll 2003, Bhosle & Hall 2009).  
Second, inhibition of cancer cell proliferation as well as induction of apoptosis 
have been thought as the markers to evaluate the effectiveness of the anticancer drugs or 
cancer chemopreventive agents to eliminate genetically damaged or pre-neoplastic cells 
before manifestation of malignancy (Lv et al. 2008, Lee et al. 2011a). Hence, most of 
the currently available natural product-derived chemotherapeutic drugs kill cancer cells 
primarily by inducing apoptosis. Since malignancy of tumors is often also attributed to 
their invasive and metastatic ability, a chemotherapeutic agent that only possesses the 
ability to induce apoptosis may not be entirely effective (Lee et al. 2011a). Therefore, 
the use of chemotherapy in the metastatic disease most often is just to palliate symptoms 
and prolong survival (Bhosle & Hall 2009). 
Moreover, tumor cells tend to acquire resistance towards apoptosis because of 
conventional chemotherapy (Soto-Cerrato et al. 2005). Chemoresistance can be divided 
into two types, primary and secondary resistance. Primary resistance occurs when the 
chemotherapy fails to show any effects on the tumor cells from the beginning of 
treatment as a result of biological resistance, physiological resistance, or 
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pharmacological resistance. Primary resistance could also be due to insufficient dosing 
or inappropriate administration route. Meanwhile, secondary resistance reflects the 
ability of tumor cells to handle the toxic metabolites or substances after exposure to the 
chemotherapy (Bhosle & Hall 2009). Therefore, this poses a great problem in cancer 
treatment and the search for a more effective natural product-based chemotherapy drug 
is an ongoing process. 
1.4.2 PHYLLANTHUS 
A successful chemotherapeutic agent should be able to interfere with more than 
one phase of the multistep carcinogenesis process (Lv et al. 2008). Various 
phytochemicals have been shown to be present in a diet rich in fruit and vegetables, 
therefore having the potential to act as chemopreventive agents. These components can 
be grouped into two categories, depending whether they are blocking the cancer or 
suppressing the cancer. Cancer-blocking agents basically stop the carcinogens from 
hitting their cellular targets to avoid the initiation process through several mechanism, 
either increase carcinogen detoxification, modifying carcinogen uptake and metabolism, 
scavenging reactive oxygen species, or enhancing DNA repair. On the other hand, 
cancer-suppressing agents stop cancer promotion and progression after pre-neoplastic 
cells formation via interference with cell cycle regulation, signal transduction, 
transcriptional, regulation and apoptosis (Russo 2007). Besides that, it also relies on 
their extent to which they would selectively induce tumor cell death while allowing the 
survival of normal tissue (Lv et al. 2008).  
The genus Phyllanthus is a large genus of trees, shrubs, and rare herbs of the 
family Euphorbiaceae, and is one of the most widely distributed plants throughout the 
Amazon rainforests as well as other tropical and subtropical countries (Bagalkotkar et 
al. 2006, Eldeen et al. 2011, Lee et al. 2011a). The genus Phyllanthus consists of about 
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500 temperate and tropical species whereby most of them are used as medicine in 
various countries. They are actually a rainy season weed that can be found in both 
cultivated fields and wastelands, with height varying from 30 to 60 centimeters. All 
parts of the plant, including their roots, leaves, fruits, milky juice, and even the whole 
plant can be exploited for medicinal usages (Shakil et al. 2008). 
The wide range of pharmacological activities exhibited by Phyllanthus can be 
attributed to the presence of varying phytochemicals within the plant. For instance, P. 
emblica is reported to contain ellagitannins, flavanoids, apigenin glucoside, 
norsesquiterpenoid glycosides, methyl ester, phenolics, gallic acid, chebulinic acid, 
quercetin, corilagin and isostrictiniin (Mehmood et al. 2011). Meanwhile, the major 
active components in P. amarus are lignans, flavanoids, terpenes, alkaloids, steroids, 
ellagitannins, hydrolysable and condensed tannins (Nayak et al. 2011). On the other 
hand, some of the active compounds present in P. niruri are flavanone glycosides, 
lignans, niranthin, nirtetralin, phyltetralin, acyclic triterpene, glycoflavones and flavones 
sulfonic acid (Shakil et al. 2008). 
Numerous research studies on Phyllanthus spp. began in the late 1980’s when P. 
niruri showed clinical efficacy against Hepatitis B virus (Lee et al. 2011a). Due to their 
wide therapeutic usage in folk medicine, wide distribution, as well as presence of 
diverse secondary metabolite entities, various pharmacological properties of different 
Phyllanthus species became focals point for studies (Eldeen et al. 2011). In addition, 
Phyllanthus has shown to be either non-toxic or to exert minimal toxicity when tested in 
vitro against a number of normal cell lines in various studies, including MRC5-
fibroblast cells, 184B5-breast epithelial, NL20-epithelial cells, CCD-1127Sk-skin cells, 
as well as RWPE-1-prostate epithelial (Ngamkitidechakul et al. 2010, Tang et al. 2010, 
Lee et al. 2011a). 
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1.4.2.1 ANTIBACTERIAL ACTIVITY 
Aqueous and methanolic extracts of P. amarus aerial parts were active against 
numerous bacteria tested, including E. coli, P. aeruginosa, S. typhii, S. aureus, and C. 
albicans. Moreover, methanolic P. amarus demonstrated broad-spectrum antimicrobial 
activity with a minimum inhibitory concentration of 1.56mg/ml (Alli et al. 2011). 
Besides that, both extend spectrum β-lactamase producing E. coli isolated from the stool 
samples of HIV sero-positive patients with or without diarrhea showed susceptibility to 
varying doses of ethanolic P. amarus extracts (Akinjogunla et al. 2010). Essential oils 
and fractions from leaves and seeds of P. amarus also demonstrated activity against 11 
microorganisms that include yeast, gram-positive as well as gram-negative bacterias 
(Oluwafemi & Debiri 2010). 
1.4.2.2 ANTIOXIDANT ACTIVITY 
Streptozotocin-induced diabetic male Wistar albino mice were fed with 
200mg/kg of aqueous extract of P. amarus to evaluate its antioxidant activity and there 
was a significant decrease in the renal LPO as well as protein oxidation while an 
increase in the antioxidant enzymes such as GR, GPX, GST, and GSH (Karuna et al. 
2011). Moreover, there were high phenolic contents in Phyllanthus extracts that have a 
strong correlation with free radical-scavenging activities and lipid peroxidation 
inhibiting capacity (Guha et al. 2010). Boiling water extracts were also shown to exhibit 
stronger antioxidant potential due to greater solubility of compounds, breakdown of 
tannins and cellular constituents (Lim & Murtijaya 2007). Nevertheless, Kumaran and 
Karunakaran found that P. debilis possessed greatest antioxidant activity among the five 
species tested while P. amarus showed the weakest activity (Kumaran & Joel 
Karunakaran 2007). 
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1.4.2.3 ANTIVIRAL ACTIVITY 
Water-alcohol extracts of P. amarus leaves had the ability to block HIV-1 
attachment in vitro as well as inhibiting HIV-1 integrase, reverse transcriptase, and 
protease enzymes to varying degrees due to the presence of gallotannin containing 
fraction, isolated ellagitannins geraniin and corilagen (Notka et al. 2003). Besides that, 
inhibitory actions of methanolic extract of root and leaves of P. amarus were tested 
against NS3 and NS5B enzymes of hepatitis-C virus (HCV). Their results indicated that 
the root extract showed significant inhibition on HCV-NS3 while leaves extract showed 
better inhibition on HCV-NS5B protease enzyme. Nevertheless, both of them were 
capable of inhibiting replication of HCV monocistronic replicon RNA and HCV H77S 
viral RNA in HCV cell culture system (Ravikumar et al. 2011). On top of that, antiviral 
activity of aqueous P. amarus extract was observed against white spot syndrome virus 
in shrimp at 150mg/kg of animal body weight (Balasubramanian et al. 2007). Moreover, 
25 compounds isolated from P. multiflorus, P. amarus, P. tenelus, and P. virgatus 
suppressed both hepatitis B surface and effective antigens’ expression at a non-toxic 
concentration of 50µm (Huang et al. 2003). However, P. amarus was not effective 
against duck hepatitis virus as shown in two different group of studies (Munshi et al. 
1993a, Munshi et al. 1993b). 
1.4.2.4 ANTIAMNESIC ACTIVITY 
Aqueous extract of stems and leaves of P. amarus was tested in male Swiss 
albino mice on their cognitive functions and brain cholinesterase activity. Results 
obtained showed that P. amarus successfully reversed the amnesia induced by a 
combination of scopolamine and diazepam as well as reducing the brain cholinesterase 
activity. In addition, the memory scores of both young and older mice were also 
improved (Joshi & Parle 2010). 
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1.4.2.5 DIURETIC ACTIVITY 
Administration of 400mg/kg of P. sellowianus into rats was shown to 
significantly increase the urinary volume as compared to the placebo group after 8 hours 
(Hnatyszyn et al. 1999) while P. corcovadensis increased urinary volume 8 hours after 
its administration (Ribeiro Rde et al. 1988). Meanwhile, in a human clinical study, 40-
60 years old subjects were required to ingest P. amarus for 10 days and their urinary 
volume was found to be significantly increased (Srividya & Periwal 1995, Wright et al. 
2007). 
1.4.2.6 ANTIINFLAMMATORY ACTIVITY 
The 75% methanolic extract of whole plant P. amarus significantly inhibited 
carrageenan, bradykinin, serotonin and prostaglandin E1-induced paw edema at a dose 
of 250mg/kg body weight (Mahat & Patil 2007). Paw edema suppression was also 
observed after treatment with the hexane and methanolic extracts of Phyllanthus 
(Raphael & Kuttan 2003, Kassuya et al. 2005). In a separate study, aqueous, ethanolic 
and hexane extracts of P. amarus also inhibited LPS-induced production of nitric oxide 
and secretion of TNF-α in RAW264.7, KC and human blood (Kiemer et al. 2003).  
1.4.2.7 ANTICANCER ACTIVITY 
Cytotoxicity of methanolic and aqueous extracts of four Phyllanthus (P. niruri, 
P. urinaria, P. watsonii, and P. amarus) species were shown to selectively cause 
toxicity to various cancer cell lines (MCF-7, A549, PC-3, and MeWo) with little effect 
on normal cell lines (NL20, 184B5, RWPE-1, and CCD-1125Sk). These Phyllanthus 
extracts were capable of inducing apoptosis in all those cell lines with the presence of 
DNA fragmentation and increased caspase activity. In addition, a dose-dependent 
antimetastatic effect was observed on A549 and MCF-7 (Tang et al. 2010, Lee et al. 
2011a). In a separate study, P. urinaria induced apoptosis in human osteosarcoma 143B 
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cells by triggering Fas ligand binding with its receptor through intracellular adaptor 
protein (FADD) to activate caspase 8 (Wu et al. 2012). Hari Kumar and Kuttan also 
demonstrated that elevated cytochrome P450 activity in vitro and in vivo was reduced 
by alcoholic extract of P. amarus (Hari Kumar & Kuttan 2006). In another in vivo 
experiment, oral administration of 75% methanolic extract of P. amarus aerial parts 
enhanced the life span of leukemia harboring animals with decreased anemia incidence 
by reducing the infiltration of leukemic cells into the sinusoidal space (Harikumar et al. 
2009). Other animal studies via oral administration of Phyllanthus extracts also 
exhibited their ability to reduce myelosuppression while improving white blood cell 
count (Kumar & Kuttan 2005), protect against carcinogenesis (Joy & Kuttan 1998, 
Kumar & Kuttan 2004), as well as prolonging the life span of DLA and EAC bearing 
mice and reduce the volume of the solid tumors (Rajeshkumar et al. 2002).  
1.4.2.8 OTHER THERAPEUTIC AND PHARMACOLOGICAL ACTIVITIES 
Some of the other therapeutic functions of Phyllanthus include hypoglycemic, 
treatment of digestive disorders, jaundice and coughs. From pharmacological point of 
view, Phyllanthus could inhibit micronuclei formation, clastogenecity, sister chromatid 
exchanges, cytoprotective and immunomodulating activities. In addition, Phyllanthus 
can be used to treat gastroenteritis, urethritis, wound healing, intestinal infections, 
diabetes, antihypertensive, antidiarrheal and antilithic (Lin et al. 2008, Agyare et al. 
2011, Brusotti et al. 2011, Mehmood et al. 2011, Thaweboon & Thaweboon 2011, 
Woottisin et al. 2011). 
1.5 JUSTIFICATION AND OBJECTIVES OF STUDY 
Cancer has been the second leading cause of death of the human population after 
cardiovascular disease with more than 11 million deaths every year. Lung cancer is by 
  
62 
 
far the most common cause of cancer-related mortality in the world. Despite the 
advances in diagnostic imaging and therapeutic improvements over the decade, lung 
cancer has a poor prognosis with the 5-year patient survival rate. Meanwhile, breast 
cancer is the second most common cancer in the world and is the leading cause of 
morbidity and mortality in women. Currently available chemotherapy drugs expose 
cancer patients to a wide range of side effects with varying degrees of severity. 
Inhibition of cancer cell proliferation as well as induction of apoptosis has been thought 
as the ideal phenomenon to evaluate the effectiveness of the anticancer drugs or cancer 
chemopreventive agents. However, tumor cells tend to acquire resistance towards 
apoptosis because of conventional chemotherapy. Moreover, malignancy of tumors is 
often attributed to their invasive and metastatic ability, therefore a chemotherapeutic 
agent that only possesses the ability to induce apoptosis renders less useful. 
Thus, the anticancer properties of Phyllanthus were being evaluated in this study 
since it was previously shown to possess antiproliferative activity on cancer cells with 
minimal effect on normal cells. Although certain Phyllanthus species have been 
demonstrated to exhibit antiproliferative and apoptotic-induction activity, the detailed 
mechanisms on how Phyllanthus exerts its anticancer activities are not fully elucidated 
yet. To begin with, the toxicity of four Phyllanthus species (P. niruri, P. urinaria, P. 
watsonii, and P.amarus) were being tested on two cancer cell lines (lung carcinoma – 
A549 and breast carcinoma – MCF-7) and two normal cell lines (lung epithelial – NL20 
and breast epithelial – 184B5) to confirm the selective antiproliferative activity against 
cancer cells. Subsequently, the mode of cell deaths induced by Phyllanthus in cancer 
cells was being determined. In addition, the antimetastatic activity of Phyllanthus on the 
cancer cell lines was being assessed. To further study on how the anticancer activities 
were being exerted, signaling pathway studies were being conducted to determine the 
upstream signaling events activated. 
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The objectives of my study include: 
1. To determine the antiproliferative effect of four Phyllanthus spp. (P. niruri, P. 
urinaria, P. watsonii, P. amarus) in vitro on two cancer cell lines (A549 – lung 
carcinoma; MCF-7 – breast carcinoma) and two normal cell lines (NL20 – lung 
epithelium; 184B5 – breast epithelium). 
2. To study the mechanism of cell death in cancer cells upon treatment with 
Phyllanthus spp.  
3. To determine the antimetastatic properties of Phyllanthus spp.  
4. To determine the signal transduction pathways involved in anticancer activities 
induced by Phyllanthus spp. 
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CHAPTER 2: METHODOLOGY 
2.1 TEST COMPOUNDS 
2.1.1 PHYLLANTHUS PLANT EXTRACTS 
The crude extracts (aqueous and methanolic) and their two fractions of each 
Phyllanthus spp., namely P. niruri, P. urinaria, P. watsonii, and P. amarus, were 
obtained from the Malaysian Agriculture and Research Development Institute 
(MARDI), Malaysia. The aqueous extracts and fractions were prepared by dissolving 
10mg in 1ml of sterile phosphate buffered saline (PBS) (final concentration 10mg/ml), 
whereas, the methanolic extracts were prepared by dissolving 40mg in 1ml of DMSO 
(final concentration 40mg/ml). The tubes containing the extracts were wrapped with 
aluminium foil and stored at -20ºC until use. A single batch of extracts was used for all 
the experiments. 
The polyphenol contents of Phyllanthus were identified by performing High 
Performance Liquid Chromatography (HPLC) coupled with Electron Spray Ionization 
(ESI) and Mass Spectrometry (LC-MS-MS) analysis. Supernatant of the aqueous extract 
sample was dried using a vacuum concentrator (Concentrator 5301 Eppendorf, 
Germany). For LC-MS-MS analysis, the lyophilized sample was redissolved into 
20mg/ml with 30% methanolic. Meanwhile, the total supernatant of the methanolic 
extract samples were evaporated using a rotary evaporator (Rotavapor RII, BUCHI, 
Switzerland) and redissolved in 20% methanol. The resulting products were then 
subjected to a solid phase extraction (SPE) column (LiChrolut RP-18 1000mg/6ml, 
Merck Millipore, Germany) with mobile phase of 60% and 70% methanol. All eluates 
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collected were concentrated to 0.5ml, and then diluted 8 times with 40% methanol 
before the LC-MS-MS analysis was performed. 
The HPLC system used consisted of a HPLC binary pump, diode array detector 
(DAD) and an auto-sampler injector compartment (1200 series, Agilent Technologies, 
Germany). For separation, C-18, 150mm x 4.6mm i.d, 5µm particle size Thermo 
Hypersil GOLD column (Thermo Fisher Scientific, USA) was chosen as the reverse 
phase while the mobile phase was 0.1% formic acid in water (solvent A) and 0.1% 
formic acid in acetonitrile (solvent B) with the gradient setting of solvent B: 5% (5min), 
5-90% (60 min), 5% (4min) at a flow rate of 1ml/min. Detection wavelengths were both 
set at 280nm and 360nm with constant injection volume at 20µl. A 3200 QTrap 
LC/MS/MS system (Applied Bioscience–MDS Sciex) was used for the mass 
spectrometry analysis, with the iron source and voltage maintained at 500 ˚C and -4.5 
kV for negative ionization, respectively. The nitrogen generator was set at 60 psi curtain 
gas flow, 60 psi exhaust gas flow, and 90 psi source gas flow. The scanning modes 
chosen were Enhance Mass Spectrometer (EMS) and Enhance Ion Product (EIP) for full 
scan mass spectra that ranged from mass to charge ratio (m/z) of 100-1200. 
2.1.2 STANDARD DRUGS 
The standard drugs used in this study were Cisplatin and Doxorubicin (Merck 
Millipore, Germany). These standard drugs were prepared by dissolving 1mg in 1ml of 
sterile PBS to achieve a stock concentration of 1mg/ml. They were wrapped with 
aluminium foil and stored at -20ºC until use. 
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2.2 CELL CULTURE 
2.2.1 CELL LINES 
The cancer cell lines used in this study included human lung carcinoma (A549) 
and human breast carcinoma (MCF-7), whereas the normal cell lines used were human 
bronchus epithelium (NL20) and human breast epithelium (184B5). All cells were 
purchased from American Type Culture Collection (ATCC, USA). A549 and MCF-7 
were grown in RPMI-1640 (Roswell Park Memorial Institute) and DMEM (Dulbecco’s 
modified Eagles Medium), respectively, while NL20 and 184B5 were grown in F-12 K 
(ATCC, USA) and Mammary Epithelial Growth Medium (Lonza, Switzerland) 
respectively. Upon receipt of the frozen vials of cells, they were thawed in a water bath 
at 37ºC. Subsequently, the cells were transferred into different T-25 flasks (Nunc, 
Denmark) containing 5ml of their respective growth medium and left overnight in a 5% 
CO2 incubator at 37ºC to allow their attachment to the flask surface. To ensure growth 
and viability of the cells, the growth mediums were supplemented with 10% fetal 
bovine serum (FBS) (JR Scientific, US). On the following day, the cells were checked 
for their viability. Viable cells were adhered onto the surface while dead cells remained 
suspended in the medium. The used medium containing dead cells was replaced with 
fresh growth medium and the culture flask was returned into the incubator for cell 
growth.  
The A549 tumor-cell line, a human alveolar cell carcinoma, was initiated by D. 
J. Giard et. al. through explant culture of lung carcinomatous tissue from a 58 year old 
Caucasian male. It has been continuously passaged in vitro for more than 3 years and 
exhibits a human karyotype and appears to have been derived from a single parent cell. 
Examination of A549 cells by electron microscopy at both early and late passage levels 
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showed that they contain multilamellar cytoplasmic inclusion bodies commonly present 
in type II alveolar epithelial lung cells (Lieber et al. 1976, Honma et al. 1996). 
A stable cell line, MCF-7, was derived from the free-floating cells of a primary 
culture, 734B, that was grown from a pleural effusion of a 69 year old Caucasian 
woman with metastatic mammary carcinoma. It has been maintained for over 90 weekly 
passages and maintained several features of differentiated mammary epithelium, 
including the ability to display discrete multilayered post-confluent growth or foci in the 
presence of 17-β-estradiol. The observed foci are solid cell aggregates with a morula-
like structure on a confluent monolayer background during post-confluent growth 
(Soule et al. 1973, Bradley et al. 2008). 
2.2.2 CELL MAINTENANCE 
Used medium was removed from the culture flask containing cells of about 70 – 
80% confluence. Two milliliters of phosphate buffered saline (PBS) (Oxoid, England) 
were added to rinse the cells and remove the traces of serum that may inhibit the action 
of the trypsin enzyme. Subsequently, 1ml of trypsin-EDTA (HyClone, Thermo Fisher 
Scientific, USA) was added into the flask and incubated in the 5% CO2 incubator at 
37ºC for about 5 minutes. After the cells had completely detached from the flask 
surface, 2ml of fresh growth medium was then added into the flask to stop the action of 
trypsin enzyme and to flush the cell clumps to separate the cells. Half a milliliter of the 
cell suspension was then dispensed into a new culture flask containing 5ml of growth  
medium and kept at 37ºC in a 5% CO2 incubator. Cells were checked daily and 
repeatedly maintained until they were required for use in experiments. Cells with eighty 
percent confluence were at their optimal condition and hence were used for all the 
experiments. 
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2.2.3 CELL COUNTING 
The trypsinized cell suspension was gently resuspended to disperse the cells into 
a single-cell suspension that is desirable to ensure an accurate cell count. A 
hemocytometer was cleaned with 70% ethanol before a cover slip was affixed onto it 
and 10µl of the cell suspension was mixed thoroughly with 10µl of 0.4% trypan blue 
solution. Subsequently, approximately 10µl of the mixture was loaded at the edge of the 
cover slip. The total number of cells at four large corner squares were counted under the 
inverted microscope (Olympus) using the 10× objective lens. Viable cells appeared 
unstained, clear, and surrounded by a refractile ring. In contrary, dead cells were stained 
blue and non-refractive. The number of viable cells can be determined using the 
following formula: 
Total Viable Cells = 
Dilution factor × Average viable cell number in one set of corner square × 104 ×  
Cell suspension volume 
2.2.4 CELL CRYOPRESERVATION 
Cells at low passage numbers resembled most closely to their original 
phenotype. Therefore, stocks of these cells were kept by cryopreserving them in cell 
freezing media before storing them in a liquid nitrogen tank. The freezing media was 
made up of 50% FBS, 40% growth medium, and 10% dimethyl sulfoxide (DMSO) 
(Sigma, US). Eighty percent confluence cells were trypsinized and pelleted by 
centrifuging for 5 minutes at 1500rpm. The cell pellet was gently resuspended with the 
freezing media at 1 × 107 viable cells/ml and aliquoted into cryotubes (Nunc, Denmark). 
The cells were first kept in a Mr. Frosty (Nunc, Denmark) at -80ºC for 24 hours before 
transferring them into a liquid nitrogen tank for long-term storage. 
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2.3 ANTIPROLIFERATIVE EFFECTS OF PHYLLANTHUS 
The antiproliferative effects of Phyllanthus were examined by performing both 
cytotoxicity and cell cycle analysis. This is because Phyllanthus could exert its 
inhibitory action on cells’ proliferation either by causing a cytotoxic or a cytostatic 
effect. Cytotoxicity is defined as the cumulative effect of a compound on a particular 
cell number over a specific period, usually due to apoptosis or necrosis (Xia et al. 2008). 
Meanwhile, cytostatic agents inhibit cell growth and multiplication by inhibiting signal 
transduction and they lack obvious cytotoxic properties (Petit et al. 1997). In addition, 
the effects of Phyllanthus on cellular morphologies were also studied. 
2.3.1 MORPHOLOGICAL ANALYSIS 
Cells were cultured overnight in 6-well plates using medium supplemented with 
10% FBS for overnight. After 24 hours, cultured cells were treated with various 
aqueous and methanolic Phyllanthus extracts. Their effects on the cells were observed 
under a light microscope (Olympus) and images were taken at a magnification of 200×. 
2.3.2 CYTOTOXICITY ANALYSIS 
For each Phyllanthus extract, fraction and standard drug, a serial dilution was 
performed in order to determine the cytotoxic effectiveness of each test compounds at 
varying concentrations. The desired serial concentrations for each extract and fraction 
were prepared up to 1000µg/ml and subsequently diluted using a two-fold serial 
dilution. Therefore, from the sub stock solution which contained 1000µl at a 
concentration of 1000µg/ml, 500µl was dispensed into a new 1.5ml tube containing 
500µl of fresh medium and resuspended to prepare a diluted extract of 500µg/ml. The 
re-suspension steps were repeated for the subsequent tubes containing 500µl medium 
each to prepare the final desired concentrations. Sub stock solution for standard drugs 
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were prepared at 20µg/ml for Cisplatin and 2µg/ml for Doxorubicin and further diluted 
using the same serial dilution method. 
Eighty percent confluence cells were trypsinized and pelleted by centrifugation 
at 1500rpm for 5 minutes. The cell pellet was then resuspended with fresh medium, 
counted using a hemocytometer, and adjusted to 1 × 105 cells/ml. One hundred 
microliters (1 × 104 cells) of this cell suspension were then dispensed into each well of a 
96-well microtiter plate and incubated overnight to allow cell attachment. After that, 
they were treated with Phyllanthus fractions as well as both the aqueous and methanolic 
Phyllanthus extracts at a 6-point serial dilution up to a final concentration of 
1000µg/ml. Vehicle-control wells with cells only and compound-control wells with 
extracts only were included. Each of these treatment conditions and controls was 
performed in triplicates. The plates were incubated at 37ºC, 5% CO2 and 100% 
humidity for 24, 48, and 72 hours. 
At the end of each incubation period, the cell viability was determined using 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, USA) in 
accordance to the manufacturer’s protocols. This assay contains phenazine methosulfate 
(PMS) that acts as an eletron coupling reagent as well as a novel tetrazolium compound 
(3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) which was bioreduced by dehydrogenase enzymes present in viable cells 
into formazan product that is soluble in tissue culture medium. The amount of formazan 
product is measured using GloMax Multi Detection System (Promega, USA) at a 
wavelength of 490nm with a reference wavelength of 750nm and is directly 
proportional to the number of viable cells. The background absorbance was corrected by 
subtracting the average absorbance for compound-control wells from the average 
absorbance for other treatment conditions and vehicle-control wells. A graph of 
corrected absorbance (Y axis) versus concentration of test compounds (X axis) was 
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plotted and the respective Half Maximal Inhibitory Concentration [IC50] (Budzinski et 
al. 2000, DeBonis et al. 2004) values at 24, 48, and 72 hours incubation for individual 
plant extracts, fractions, and standard drugs were determined and used in succeeding 
assays. 
2.3.3 CELL CYCLE ANALYSIS – PROPIDIUM IODIDE STAINING 
Cell cycle analysis allows separation of cells at different stages of the cell cycle 
based on their DNA content. Propidium iodide (PI) dye is frequently used for DNA 
content analysis due to its high capability of binding to DNA with low specificity 
through intercalation process between the major grooves of double stranded DNA 
(Riccardi & Nicoletti 2006). Cells at different phases of its cell cycle contain a distinct 
amount of DNA content as shown in Figure 2.1. Cells were seeded at 105 cells/well, 
treated with extracts at their IC50 values, and incubated for various time points from 0 to 
72 hours. At the end of each incubation period, cells treated with or without Phyllanthus 
extracts were harvested by trypsinization and fixed with ice-cold 70% ethanol for at 
least 1 hour at -20ºC. Cells were then pelleted, washed once with PBS, resuspended in 
the PI solution [10µg/ml PI (Sigma-Aldrich, USA) and 1mg/ml RNase A (Sigma-
Aldrich, USA) in PBS], and incubated in a 37ºC water bath for 30 minutes. Data 
acquisition was performed using a Becton Dickinson FACSCalibur flow cytometer (BD 
Biosciences, USA) and the CellQuest software. The results were subsequently analyzed 
using WinMDI 2.9 software. The distribution of cell percentages in each cell cycle 
phase was determined by setting gates based on their amount of DNA content. 
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Figure 2.1: Histogram for cell population distribution based on cell DNA content 
2.4 ANTIMETASTASIS EFFECTS OF PHYLLANTHUS 
Metastasis involves a series of complex processes governed by complicated 
mechanisms, beginning with the detachment of tumor cells, invasion, motility, adhesion 
and reestablishment of growth at a distant site (Lee et al. 2010). This process is often 
associated with the destruction of the extracellular matrix (ECM) and the basement 
membrane components by proteolytic enzymes such as matrix metalloproteinases 
(MMPs) (Yang et al. 2008). Hence, various assays were performed to find out the 
ability of Phyllanthus to halt metastasis, including cell invasion assay, cell migration 
assays, cell adhesion assays, as well as zymography assay to observe the MMPs 
expression in response to Phyllanthus treatment. 
2.4.1 CELL INVASION ASSAY 
Cell invasion was determined using 24-well transwell chamber with 8µm pore 
polycarbonate filter coated with basement membrane extracts according to the 
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manufacturer’s instructions provided by Cultrex, Trevigen (USA). This assay was 
carried out to screen the compounds that may influence the cell’s invasive potential 
through extracellular matrices or basement membrane, which is fundamental to tumor 
metastasis. The basement membrane extract was purified from Engelbroth-Holm-
Swarm (EHS) tumor and consists of major components in the basement membrane such 
as laminin I, collagen IV, entactin and heparin sulfate proteoglycan. A transwell 
chamber was utilized. It has a simplified Boyden chamber design with upper and lower 
compartments. Cells were seeded into the upper compartment at a concentration of 2 × 
106 cells/ml in a volume of 100µl/well. The lower compartment contained 500µl of 
medium supplemented with extracts and 10% FBS as chemoattractants while serum-free 
medium was used as control. After 48 hours incubation at 37ºC, cells that had passed 
through the filters were detached using Cell Detachment Solution (Thermo Fisher 
Scientific, USA) mixed with calcein-acetoxymethylester supplied in the kit. Calcein-
AM is originally a non-fluorescent but cell permeant compound, which is converted by 
intracellular esterases into calcein that is an anionic fluorescent (Uggeri et al. 2004). 
The free calcein emits a bright fluorescence and was used to quantitate the number of 
cells that have invaded through the artificial basement membrane and 8µm pore. 
Fluorescence intensity was measured with excitation wavelength at 485 nm and 
emission wavelength at 520 nm. Invasion inhibition rate was calculated using the 
following formula: 
Cell Invasion (%) =  
Mean fluorescence of (experimental wells – medium control wells) / Mean fluorescence 
of (cell control wells – medium control wells) × 100 
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2.4.2 CELL MIGRATION ASSAY 
MultiScreen-MIC 96-well plates with 8µm polycarbonate membranes (Merck 
Millipore, Germany) were used in this migration experiment to study the chemotaxis of 
cancer epithelial cells. Cells were seeded into the upper compartment of the transwell 
chamber at a concentration of 1 × 105 cells/ml in a volume of 100µl/well. Medium for 
the experimental and control groups were added into the lower compartment of the 
transwell chamber at 500µl/well. At the end of 24 hours incubation, cells that did not 
penetrate the polycarbonate membrane to the bottom of chamber were scraped off using 
a cotton sticker. The chamber plate was then placed onto a new 96-well feeder tray 
containing 150µl of prewarmed Cell Detachment Solution in wells and incubated at 
37ºC for 30 minutes. During the incubation, the plate was gently tilted several times to 
facilitate dislodgement of cells. One hundred microliters of 2× CyQuant NF (Invitrogen, 
USA) dye binding solution were then added into each well and further incubated for 1 
hour to allow dye-DNA binding to produce a stable fluorescent endpoint. Fluorescence 
intensity was measured with excitation wavelength at 485 nm and emission wavelength 
at 530 nm. Migration inhibition rate was calculated using the following formula: 
Cell Migration (%) =  
Mean fluorescence of (experimental wells – medium control wells) / Mean fluorescence 
of (cell control wells – medium control wells) × 100 
2.4.3 SCRATCH MOTILITY ASSAY 
This assay was also performed in tissue culture research to estimate the 
migration and proliferation rates of different cells in response to variable experimental 
culture conditions. Cells were seeded in a 24-well microtiter plate at 1 × 105 cells/well 
and were allowed to grow overnight to reach confluence. The monolayer was then 
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scratched with a pipette tip, washed with PBS twice to remove floating cells and treated 
with extracts at their respective IC50 values. At the end of each incubation (0 – 48 
hours), the cells that migrated into the scratched area were photographed and counted at 
5 randomly selected fields. The migrated cells were expressed as mean value per field. 
2.4.4 CELL ATTACHMENT ASSAY 
Cell adhesion is a critical factor for the maintenance of tissue structure, 
promotion of cell migration, as well as for transduction of microenvironment 
information across the plasma membrane. Cells that were unable to attach themselves 
are prone to death fate. Briefly, cells were seeded at 1 × 105 cells/well in a 24-well 
microtiter plate, treated with extracts at their respective IC50 concentrations and 
incubated for 72 hours. After that, cells treated with Phyllanthus extracts were detached 
using 0.5% trypsin-EDTA and plated back onto a new culture plate. After each 
incubation period of 4 to 24 hours, the cell attachment status and morphology were 
observed and photographed. 
2.4.5 CELL-MATRIX ADHESION ASSAY 
Cells usually interact with the extracellular matrix (ECM) that is composed of a 
complex variety of proteins and carbohydrates found in spaces between cells. It forms a 
layer beneath epithelial and endothelial cells and surrounds all connective tissue cells. 
Therefore, this assay tests the adhesion ability of cells to ECM that has an essential role 
in regulating cellular activities. ECM gel (Sigma-Aldrich, USA) was thawed overnight 
at 4°C before being diluted 2× with cold medium. One hundred microliters of diluted 
ECM gel were then added into each well of a 96-well microtiter plate and incubated for 
2 hours at 37°C. The coated wells were subsequently washed once with PBS and 
blocked with 2% bovine serum albumin (BSA) (Sigma-Aldrich, USA) dissolved in 
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serum free medium.  Three wells not coated with ECM gel were also blocked with 2% 
BSA to check for non-specific cell adhesion. Meanwhile, cells were harvested, washed 
with PBS and resuspended at 1 × 105 cells/ml in freshly prepared serum free medium 
containing various Phyllanthus extracts. One hundred microliters of the respective cell 
suspension was then added into the ECM gel-coated wells. After 2 hours, the 
supernatant in each well was discarded and the wells were washed with 200µl of PBS to 
remove unattached cells. The number of adhered cells was determined using CellTiter 
96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, USA) according to 
the manufacturer’s instructions. Absorbance was measured using GloMax Multi 
Detection System (Promega, USA) at a wavelength of 490nm with a reference 
wavelength of 750nm. Adhesion inhibition rate was calculated using the following 
formula: 
Cell – Matrix Adhesion (%) =  
Mean absorbance of (experimental wells – medium control wells) / Mean absorbance of 
(cell control wells – medium control wells) × 100 
2.4.6 ZYMOGRAPHY ASSAY 
Zymography is a technique employed to study extracellular matrix-degrading 
proteases such as MMPs, from various biological samples including cell cultures. It is a 
simple and sensitive method to identify MMPs based on their substrate specificity and 
molecular weight. Briefly, cells were seeded at 1 × 105 cells/well in a 24-well microtiter 
plate, treated with extracts at their respective IC50 concentrations and incubated for 72 
hours. At the end of the incubation period, the supernatants were collected and 
centrifuged to remove the debris. After that, they were stored at -20°C to be used as 
conditioned media. The conditioned media was mixed with one part of 2× Tris-Glycine 
  
77 
 
SDS Sample Buffer and was incubated for 10 minutes at room temperature. The 
prepared samples were subsequently loaded onto a 12.5% SDS-polyacrylamide gels that 
had been copolymerized with 0.1% gelatin or 0.2% casein. The gel was then run with 
1× Laemmli running buffer at approximately 125V for about 60 minutes. When the 
proteins were completely resolved, the gel was washed twice with renaturing buffer on a 
shaker at room temperature, 1 hour for each washing. Next, the gel was incubated with 
developing buffer overnight at 37°C before it was stained with 0.1% Coomasie blue for 
1 hour. Finally, the gel was destained with destaining solution and the presence of 
matrix metalloproteinase enzyme was indicated as an opaque, unstained band against a 
dark blue background. 
2.5 MECHANISM OF CELL DEATH INDUCED BY PHYLLANTHUS 
There are two distinct types of cell death that could be induced by Phyllanthus in 
cancer cells, either apoptosis or necrosis. In order to study the apoptotic mode of cell 
death induced by Phyllanthus, three different assays were conducted including caspases 
assay, TUNEL assay and DNA fragmentation assay. Meanwhile, lactate dehydrogenase 
assay was carried out to observe whether Phyllanthus induces necrosis in the cancer 
cells. 
2.5.1 APOPTOSIS 
2.5.1.1 CASPASE-GLO 3/7 ASSAY 
Caspases activity was determined using Caspase-Glo 3/7 Assay (Promega, 
USA) according to the manufacturer’s instructions. This assay contains a luminogenic 
caspase-3/7 substrate for cleavage by the caspases to generate a stable luminescence 
signal that is proportional to the amount of caspase activity present. Cells were seeded, 
treated with extracts at their respective IC50 values and incubated at 37°C, 5% CO2 and 
  
78 
 
100% humidity for 72 hours. Lyophilized Caspase-Glo 3/7 substrate was resuspended in 
its buffer and 100µl of this reagent were added into each well. The contents of the wells 
were mixed gently and incubated at room temperature for 1 hour. Luminescence of each 
sample was measured using Glomax-Multi Detection System (Promega, USA). The 
caspases-3/7 activity can be determined by using the following formula: 
Caspase Activity (%) =  
Mean luminescence of (experimental wells – medium control wells) / Mean 
luminescence of (cell control wells – medium control wells) × 100 
2.5.1.2 TUNEL ASSAY 
Terminal Deoxynucleotidyl-Transferase mediated dUTP Nick End Labelling 
(TUNEL) assay was performed using ApopTag® Plus Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon® International, Merck Millipore, Germany). In this assay, the 
DNA strand breaks generated upon DNA fragmentation were detected in situ by 
enzymatically labeling the free 3’-OH termini with modified nucleotides. One hundred 
thousand cells were harvested, fixed in 1% paraformaldehyde in PBS, pH 7.4 and dried 
on a silanized microscope slide. The specimen was then post-fixed in pre-cooled 
ethanol/acetic acid (2:1) and quenched in 3% hydrogen peroxidase in PBS. Excess 
liquid was tapped off before 75µl/5cm2 of equilibration buffer was immediately applied 
on the specimen. Next, 55µl/5cm2 of working strength terminal deoxynucleotidyl 
transferase (TdT) enzyme were added and incubated at 37ºC for 1 hour. After 
incubation, the specimen was placed in a coplin jar containing working strength 
stop/wash buffer followed by an addition of 65µl/5cm2 of antidigoxigenin peroxidase 
conjugate. Specimen was washed in four changes of PBS, stained with 75µl/5cm2 of 
peroxidase substrate, counterstained in 0.5% (w/v) methyl green followed by several 
washes with distilled water, n-butanol, and xylene. Finally, the specimen was mounted 
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under a glass coverslip in Permount fluid and observed under a light microscope 
(Olympus BX51) at a magnification power of 200×. Images were captured using 
Olympus U-CMAD3 at three fields per slide. 
2.5.1.3 DNA FRAGMENTATION ASSAY 
The ultimate DNA fragments exist in multimers of about 180bp nucleosomal 
units that often appear as DNA ladder on a standard agarose electrophoresis gels. In 
order to demonstrate this, DNA had to be first extracted from the apoptotic cells. Five 
hundred microliters of 5 × 105 treated cells were lysed in 55µl DNA lysis buffer [1M 
Tris-HCI (pH 8.0), 0.5M EDTA, and 100% Triton X-100] and incubated at 4ºC for 30 
minutes. DNA was extracted from the supernatant with an equal volume of 
phenol/choloroform/isoamyl alcohol (25:24:1). Samples were spun and the upper 
aqueous layer transferred to a new tube, to which an equal volume of ice-cold 100% 
ethanol and 1/10 volume of 3M sodium acetate (pH 5.2) were added and incubated 
overnight at -20ºC. After spinning the sample, supernatant was decanted, the pellet air 
dried, and then dissolved in deionized water-RNase solution [10mg/ml RNase I] and 
incubated at 37ºC for 30 minutes. Equal amounts of DNA (10µg/well) were 
electrophoresed in 1.2% agarose gel impregnated with ethidium bromide at 5V for the 
first 5 minutes and increased to 100V for 1 hour. DNA fragments were then visualized 
and imaged using a UV transilluminator. 
2.5.2 NECROSIS 
Lactate Dehydrogenase (LDH) is a cytosolic enzyme released into cell culture 
supernatant due to compromised membrane integrity, which is associated with necrotic 
cell death. The extent of its activity in converting tetrazolium salt into red formazan 
product is proportional to the number of necrotic cells (Lee et al. 2011a). Detection of 
LDH leakage was achieved using CytoTox-ONE® Homogeneous Membrane Integrity 
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Assay (Promega, USA) in accordance to the manufacturer’s instructions. This assay 
measures the amount of LDH released from non-viable cells without damaging the 
viable cells by detecting the fluorescent resorufin products generated from the 
enzymatic conversion of resazurin substrate. Cells were seeded, treated, and incubated 
for 72 hours. No-cell control, untreated cells control, and maximum LDH release 
control wells were included in each plate. At the end of incubation, lysis solution was 
added to positive wells and further incubated for 30 minutes to generate maximum LDH 
release. Subsequently, an equal volume of CytoTox-ONE® reagent (50µl) was added 
into each well and incubated at room temperature for 10 minutes with a subsequent 
addition of stop solution (50µl). Fluorescence was recorded with an excitation 
wavelength of 560nm and an emission wavelength of 590nm within 1 hour to avoid 
increased background fluorescence. The percentage of LDH released can be determined 
by using the following formula: 
LDH Released (%) =  
Mean fluorescence of (experimental wells – medium control wells) / Mean fluorescence 
of (maximum LDH released wells – medium control wells) × 100 
2.6 EFFECTS OF PHYLLANTHUS ON CELL’S ANGIOGENIC ABILITY 
Expressions of inducible nitric oxide synthase (iNOS) and vascular endothelial 
growth factor (VEGF) are two indexes for tumor angiogenesis. Their high expressions 
increase the microvascular density that is involved in the advancement of tumor 
metastasis (Song et al. 2002). Therefore, the effects of Phyllanthus on the expressions of 
these angiogenic components were studied by performing a cell-based ELISA assay. In 
addition, a western blot assay was performed for VEGF as a confirmatory test. 
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2.6.1 PRODUCTION OF VASOACTIVE AGENT, INOS 
Inducible nitric oxide synthase (iNOS) is often upregulated in tumor cells and is 
an important regulator for vascularization and angiogenesis. In order to measure the 
total iNOS in whole cells, a cell-based ELISA, Human Total iNOS Immunoassay (R&D 
Systems, USA) was used. One hundred microliters (approximately 10000 cells) of cell 
suspension were seeded into each well of a black 96-well microplate with clear bottom 
and incubated overnight at 37°C. After that, the cells were treated with varying 
Phyllanthus extracts at their respective IC50 concentrations. At the end of treatment, the 
medium was discarded and replaced with 100µl of 4% formaldehyde diluted in PBS 
followed by incubation for 20 minutes at room temperature. Next, the cells were washed 
with wash buffer three times, 5 minutes for each wash with gentle shaking. 
Subsequently, 100µl of quenching buffer were added and incubated at room 
temperature for 20 minutes. After 20 minutes, the cells were washed again three times, 
followed by the addition of blocking buffer for 1 hour at room temperature. After that, 
washing steps were performed three times before primary antibody mixture (total iNOS 
and total GADPH antibody) was added into each well and incubated overnight at 4°C. 
Then, the primary antibody mixture was removed, washed, and replaced with secondary 
antibody mixture for 2 hours at room temperature. Next, the secondary antibody mixture 
was discarded and the cells were washed twice each with wash buffer and PBS. Finally, 
substrate F1 was added into each well and incubated for 60 minutes at room 
temperature, followed by addition of substrate F2 for 40 minutes. Both substrates F1 
and F2 were provided in the kit and contain the fluorogenic substrate for horseradish-
peroxidase (HRP) and alkaline phosphatase (AP) respectively. The plate was then first 
measured using GloMax Multi Detection System (Promega, USA) with excitation at 
450nm and emission at 600nm, followed by a second measurement with excitation at 
360nm and emission at 450nm. The readings at 600nm represent the amount of total 
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iNOS in the cells while readings at 450nm represent the amount of total GADPH in the 
cells. Normalized results were obtained by dividing the total iNOS fluorescence at 
600nm by the total GADPH fluorescence at 450nm in each well. 
2.6.2 PRODUCTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR 
(VEGF) 
VEGF is an essential angiogenic growth factor to induce vessel sprouting from 
existing capillary bed for metastasis. Production of vascular endothelial growth factor 
(VEGF) in cells was measured by performing two assays. First, the quantification for 
VEGF production in whole cell was carried out using a cell-based ELISA assay that is 
similar to the assay described in Section 2.6.1. Subsequently, expression of VEGF by 
cells was also determined by carrying out western blot assay as described in Section 
2.8.4. Anti-VEGF mouse monoclonal antibody used in both assays was purchased from 
Merck Millipore, Germany. 
2.7 EFFECTS OF PHYLLANTHUS ON CELL’S ENDOTHELIAL TO 
MESENCYHMAL TRANSITION (EMT) 
Epithelial to mesenchymal transition (EMT) is the fundamental mechanism to 
diversify the cells found in complex tissues and is also a well-recognized mechanism to 
initiate metastasis in epithelial cancers (Kalluri & Neilson 2003). During this process, 
epithelial cells lose their polarity and cell-cell contacts while acquiring migratory 
behavior to travel away from their community (Xu et al. 2009). Thus, cell aggregation 
and cell-cell adhesion assays were performed to determine the capability of Phyllanthus 
to suppress this EMT process. 
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2.7.1 HANGING DROP AGGREGATION ASSAY 
Transformed cells produce bigger cell aggregates than its corresponding normal 
cells when suspended in liquid media, a characteristic that is associated with 
tumorigenicity (Rhim 1983). Therefore, a cell aggregation assay was perfomed to 
evaluate the tumorigenic potential of the malignant cells. Cells used for this assay were 
passaged at least two to three times. Cells were first trypsinized and washed twice with 
PBS. Subsequently, the cells were counted and adjusted to 2.5 × 105 cells/ml in medium 
containing 10% FBS as control and varying Phyllanthus extracts with 10% FBS for 
experiments. About 20µl (5000 cells) of each cell suspension was added onto the inner 
surface of the lid of a 24-well microtiter plate. The lid was then carefully placed back 
onto the plate to ensure that the droplets of cell suspension were hanging from the lid 
with cells suspended within them. Eight milliliters of serum-free culture medium was 
added into each well to eliminate evaporation from the droplets. Cells were incubated 
for up to 60 hours at 37°C and were photographed every 12 hours interval using a 
Nikon ECLIPSE TE2000-E UV/Phase contrast microscope at 400× magnification. 
2.7.2 CELL-CELL ADHESION ASSAY 
Adhesion of cells to one another is a primary feature of the architecture of many 
tissues. Successful metastasis usually requires the disruption of cell-cell adhesion to 
release the neoplastic cells from the primary tumor. In this assay, human umbilical vein 
endothelial cells (HUVEC) which were passaged for at least two to three times were 
used. Firstly, HUVEC were cultured in a 96-well microtiter plate so that it will reach 
monolayer confluency after 24 hours. The cells were then kept in the incubator until it 
was used the next day. On the day of use, A549 or MCF-7 cells were trypsinized, 
centrifuged and resuspended in serum free Opti-MEM I reduced serum medium 
(Invitrogen, USA). Cells were carefully prepared to ensure single-cell suspension. 
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These cells were then counted and adjusted to 3 × 105 cells/ml in freshly prepared Opti-
MEM medium containing 2% FBS and various Phyllanthus extracts. The cells and 
medium-containing extracts mixture were incubated for 2 hours before they were 
centrifuged to collect the extracts-treated cell pellet. This cell pellet was subsequently 
incubated with BCECF AM (Invitrogen, USA) solution for 30 minutes to stain the cells. 
Cell pellet was collected and resuspended in Opti-MEM medium containing 2% FBS. 
After these cells were prepared, the medium for HUVEC cells cultured on the day 
before was discarded and 100µl of cell suspension were added onto the monolayer of 
HUVEC. The plate was then further incubated for 30 minutes at 37°C before 
fluorescence reading was determined at excitation wavelength 488nm and emission 
wavelength 535nm. The percentage of cell-cell adhesion was calculated using the 
following formula: 
Cell – cell Adhesion (%) =  
Mean fluorescence of (experimental wells – medium control wells) / Mean fluorescence 
of (cell control wells – medium control wells) × 100 
2.8 EFFECTS OF PHYLLANTHUS ON CELLULAR SIGNALLING 
TRANSDUCTION PATHWAYS 
Cancer is a group of diseases strongly correlated with defects in signal 
transduction proteins whereby various key signaling pathways were implicated in 
human tumorigenesis. Therefore, Cignal Finder Cancer 10-pathway Reporter Array kit 
(SABiosciences, QIAGEN, USA) was used to screen the signaling pathways affected by 
Phyllanthus to halt the uncontrolled proliferation and metastasis of malignant tumor 
cells. Findings from this array were further confirmed by performing western blot 
analysis. Subsequently, two-dimensional gel electrophoresis assay was carried out to 
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study the differences in protein expressions as a result of perturbations in cellular 
signaling pathways by Phyllanthus. Prior to western blot and two-dimensional gel 
electrophoresis assays, cytoplasmic protein lysate was prepared and quantified to ensure 
consistency. 
2.8.1 SIGNALING PATHWAY ANALYSIS USING CANCER 10-PATHWAY 
REPORTER ARRAY 
Transient transfection was performed using TransIT-LT1 (Mirus Bio, USA). 
Plasmid DNAs for respective signalling pathways provided in the Cignal Finder Cancer 
10-pathway Reporter Array kit (SABiosciences, QIAGEN, USA) and TransIT-LT1 was 
diluted using Opti-MEM I reduced serum medium (Invitrogen, USA) and incubated at 
room temperature for 5 minutes. Plasmid DNAs and the TransIT-LT1 prepared earlier 
were mixed and further incubated for 20 minutes at room temperature to allow TransIT-
LT1/DNA complex formation. During the incubation period, cells were trypsinized and 
adjusted to 1.1 × 105 cells/ml. Subsequently, 90µl (approximately 10000 cells) of the 
cell suspension were mixed with 10µl of the complex and added into the designated 
wells of a 96-well cell culture white microplate (Nunc, Thermo Fisher Scientific, USA). 
The culture plate was rocked for 5 minutes on a rocker to ensure even distribution of the 
complexes before it was incubated overnight in a 5% CO2 incubator at 37ºC. 
After the transfection of cells with various plasmid DNAs for the respective 
signaling pathways, the cells were incubated with different Phyllanthus extracts at their 
IC50 concentrations for another 24 hours. On the next day, results were developed using 
Dual-Glo® Luciferase Assay System (Promega, USA) which contains genes for both 
firefly and Renilla luciferases. Dual-Glo Luciferase reagent was added into each well 
and incubated at room temperature for 10 minutes. This reagent induces cell lysis and 
acts as a substrate for firefly luciferase to produce a stable firefly luminescent signal. 
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The firefly luminescence generated was taken using GloMax Multi Detection System 
(Promega, USA). This was followed by the addition of Dual-Glo Stop & Glo reagent to 
all wells. Addition of this reagent quenches luminescence from the firefly reaction by at 
least 10000 fold while providing substrates for Renilla luciferase. Similarly, renilla 
luminescence reading was obtained after the plate was incubated for another 10 
minutes. The firefly constructs monitor changes in the activity of a key transcription 
factor that is a downstream target of a particular signalling pathway. Meanwhile, renilla 
construct acts as an internal control for transfection efficiencies normalization as well as 
to monitor cell viability. Luminescence for each wells were determined by calculating 
the ratio of its firefly to renilla luminescence. 
Luminescence Ratio =  
Firefly luminescence for individual wells / Renilla luminescence for individual wells 
Gene Expression (%) =  
(Experimental ratio – Medium control ratio) / (Cell control ratio – Medium control 
ratio) × 100 
2.8.2 PREPARATION OF CYTOPLASMIC PROTEIN LYSATE 
Protein lysates were prepared for western blotting and proteomic analysis for 
both Phyllanthus-treated and untreated samples. Cells treated with Phyllanthus extracts 
were detached from the culture plates using 0.5% trypsin-EDTA and washed twice with 
phosphate buffered saline (PBS), centrifuging at 1500rpm for 5 minutes. For extraction 
of cytoplasmic proteins, 200μl of cell lysis buffer were added to the cell pellet and 
incubated on ice for 30 minutes before centrifuging at 14000rpm for 15 minutes at 4°C. 
Supernatant is then collected into a new 1.5ml tube followed by addition of 4× sample 
volume of iced-cold acetone. After that, the sample was incubated for at least 4 hours at 
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-20°C and centrifuged at 14000rpm for 15 minutes at 4°C. After centrifugation, the 
supernatant was discarded while the cytoplasmic protein pellet was diluted in 150μl of 
rehydration buffer. The cytoplasmic protein lysate can either be kept at -80°C for 
storage or proceed with sample quantification for subsequent experiments. 
Protein lysate concentration was determined with 2-D Quant kit (GE Healthcare, 
USA) following manufacturer’s instructions to ensure equal protein amount used in 
each experiments. Prior to starting with the quantification steps, working color reagent 
was prepared by mixing 100 parts of color reagent A with one part of color reagent B. A 
standard curve was prepared according to Table 2.1 using the 2mg/ml BSA standard 
solution supplied in the kit. Subsequently, 3µl of each protein sample were pipetted into 
different microcentrifuge tubes. The quantification began with addition of 500µl 
precipitant into each tube (standards and samples), followed by vortexing and 2 – 3 
minutes incubation at room temperature. Next, 500µl of co-precipitant were added, 
briefly mixed and centrifuged at 14000×g for 5 minutes. After that, supernatant was 
completely removed so that there was no visible liquid remained in the tubes. One 
hundred microliters of copper solution and 400µl of deionized water were then added 
into each tube and thoroughly vortexed to dissolve the precipitated protein. Finally, 1ml 
of working color reagent prepared earlier was pipetted into each tube and incubated for 
20 minutes. Absorbance at 480nm was read for each samples and standards using 
GloMax Multi Detection System (Promega, USA). Protein concentrations of samples 
were estimated by comparison to the standard curve drawn. 
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Table 2.1: Preparation of standard curve for protein quantification 
Tube Number 1 2 3 4 5 
Volume (µl) 0 5 10 15 20 
Protein Quantity (µg) 0 10 20 30 40 
2.8.3 WESTERN BLOT ASSAY 
Western blotting is a technique that allows the production of a replica of proteins 
separated through sodium dodecyl sulfate–polyacrylamide gel onto a nitrocellulose 
membrane and subsequently probed with various antibodies to detect the presence or 
relative abundance of specific proteins (MacPhee 2010). 
The Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories, USA) 
was used for western blot assay. Two sequential gels (resolving and stacking gels) were 
involved in western blot described in Laemmlli method (Laemmli 1970). Glass plates 
with and without spacers were cleaned with 70% ethanol to remove the debris and 
contaminants before they were assembled using a setting rig. Resolving gel mixture was 
then added between the glass plates, leveled with deionized water, and left on the bench 
for about 30 minutes to polymerize. Once set, the water was poured off followed by 
addition of stacking gel mixture onto the resolving gel. After inserting the comb, the 
stacking gel was left to set for another 30 minutes. When the stacking gel had 
polymerized, the comb was removed while the wells were washed with Laemmli buffer 
to wash off excess acrylamide at the sides of the wells. Subsequently, the gel was fixed 
into the running rig, placed in the running tank and filled with 1× Laemmli buffer until 
the plates were completely covered. 
One hundred and fifty micrograms protein of each sample were mixed with 4× 
sample buffer before they were loaded into a 12.5% of SDS-polyacrylamide gel. Five 
microliters of 10 – 170kDa PageRuler™ Prestained Protein Ladder (Thermo Fisher 
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Scientific, USA) were added to monitor the proteins separation. The proteins were 
separated at 100V for approximately 1 hour. Alternatively, protein samples were 
separated by two-dimensional (2D) gel electrophoresis method using 7cm IPG gel strips 
with pH 3–11 NL range (GE Healthcare, USA) as described in Section 2.8.4.  
After electrophoresis, the gel was disassembled and the stacking gel was 
truncated from the front of the resolving gel. The “sandwich stack” was then assembled 
using a black and white cassette, sponge, blotting paper, and nitrocellulose membrane 
(GE Healthcare, USA) pre-soaked in 1× transfer buffer according to Figure 2.2. Once 
assembled, the “sandwich” was placed into the transfer tank and completely filled with 
iced-cold transfer buffer. The proteins were transferred at 250mA for 1 hour. Once the 
protein transfer was completed, the membrane was checked by Ponceaus S stain before 
being blocked at room temperature for 2 hours with Tris buffered saline buffer 
containing 0.1% Tween 20 (TBST) and 5% dry milk. Subsequently, the membranes 
were incubated with various primary antibodies diluted in blocking buffer at 4°C 
overnight. After that, the membrane was washed three times with TBST before further 
incubation with peroxidase-conjugated secondary antibodies at a dilution of 1:2000 in 
blocking solution. The immune-reacted proteins were detected via chromogenic method 
by addition of DAB substrate that was converted by Horseradish peroxidase enzyme 
into insoluble, coloured products that precipitated onto the membrane to form a protein 
band. Color development was terminated when the noise ratio was satisfied by placing 
the membrane in deionized water. Anti-pan-Ras (~ 21kDa), anti-c-Raf (~ 74kDa), anti-
c-Myc (~ 60 – 67kDa), anti-Bcl-2 (~ 24 – 26kDa), anti-Hif-1α (~ 120kDa), anti-c-
Jun/AP-1 (~ 39kDa), anti-p53 (~ 53kDa), anti-Elk1 (~ 47 – 60kDa), anti-JNK1/2 (~ 
49kDa JNK1 and ~ 55kDa JNK2), anti-VEGF (~ 42kDa), goat anti-mouse IgG 
peroxidase conjugate, and goat anti-rabbit IgG peroxidase conjugate antibodies were 
purchased from Merck Millipore, Germany while anti-RSK (~ 100kDa) antibody was 
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purchased from Thermo Fischer Scientific, USA. These antibodies were chosen based 
on their essential roles in the pathways modulated by Phyllanthus as detected using 
Cignal Finder Cancer 10-pathway Reporter Array. Meanwhile, p53 antibody was 
included to find if p53 pathway was involved in the response to Phyllanthus treatment. 
 
Figure 2.2: Assembly of western blot “Sandwich Stack” 
2.8.4 TWO-DIMENSIONAL (2D) GEL ELECTROPHORESIS ASSAY 
High resolution 2D electrophoresis gel is necessary for quantitative analysis of 
differentially expressed proteins and this could be achieved by separation of proteins 
extracted from cell sample based on their charge and mass via isoelectric focusing (IEF) 
and polyacrylamide gel electrophoresis (PAGE) respectively (Liao & Huang 2011). 
Protein concentrations for each sample were quantitated, followed by overnight 
rehydration of the same protein amounts for both treated and untreated samples at room 
temperature. Five hundred microgram of proteins for both A549 and MCF-7 cells were 
rehydrated on 13cm IPG gel strips with pH 3–11 NL range (GE Healthcare, USA). 
Rehydrated strips were then transferred into IPG chambers and covered with mineral 
oil. Electrodes were placed over the hydrated electrode pads positioned at the ends of 
IPG strips. Proteins were then focused on an Ettan IPGphor Isoelectric Focusing unit 
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(GE Healthcare, USA), set at 20°C with a current of 50 mA per strip. The parameter 
setting began with 500V for 1 hour, then inclined to 8000V over 3.5 hours, and finally 
maintained at 8000V for another 30 minutes. Meanwhile for 7cm IPG gel strips with 3–
11 NL range, it began with 300V for 30 minutes, then ramped to 5000V over 1 hour 50 
minutes, and finally maintained at 5000V for an additional 25 minutes. The completely 
focused strips were transferred into equilibration tubes to be stored at -80°C. 
Before proceeding with SDS-PAGE, the strips were first subjected to a two-step 
equilibration procedure for 15 minutes each. First, they were equilibrated with an SDS-
PAGE equilibration base buffer composed of 6M urea, 75mM Tris-HCl (pH 8.8), 30% 
glycerol, 2% SDS, and 2% (w/v) dithiothreitol (DTT). This was followed by 
equilibration with a similar buffer composition, replacing DTT with 2.5% (w/v) 
iodoacetamide (IAA). The strips were then placed onto a 12.5% SDS-PAGE gel and 
sealed with 0.5% agarose sealing solution. Second dimensional separation was carried 
out using Ettan Dalttwelve Separation Unit (GE Healthcare, USA) with an initial low 
voltage at 100V for 45 minutes, followed by a constant 400V until the separation was 
completed. The gels were then stained with hot 0.1% Coomasie blue dye for 30 minutes 
and subsequently fixed using gel fixative solution for another 30 minutes. Finally, the 
gel was destained with destaining solution and kept in ultrapure water until they were 
imaged. The gels with stained protein spots were scanned using an Ettan DIGE Imager 
(GE Healthcare, USA). Three independent gels were run for each treatment (n = 3). Gel 
images were analyzed using PDQuest 2-D Analysis Software (Bio-Rad Laboratories, 
USA) which performed background removal, normalization, and automatic matching of 
the detected protein spots. Protein spots with more than 2-fold differential expression 
that showed significant difference (p < 0.05) were selected and excised for mass 
spectrometry analysis. 
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2.8.5 PROTEIN IDENTIFICATION BY MATRIX-ASSISTED LASER 
DESORPTION IONISATION-TIME OF FLIGHT MASS 
SPECTROMETRY 
Protein spots excised from polyacrylamide gels were first destained using 50% 
acetonitrile (ACN) in 50mM ammonium bicarbonate. When the gel plugs became clear, 
they were incubated with 10mM DTT in 100mM ammonium bicarbonate for 30 minutes 
at 60°C followed by incubation with 55mM iodoacetamide in 100mM ammonium 
bicarbonate for 20 minutes in the dark. The gel plugs were then washed with 50% ACN 
in 100mM ammonium bicarbonate 3 times, each time for 20 minutes. After that, they 
were incubated with 100% ACN for 15 min on a shaker and dried using SpeedVac. 
Next, the dried gel plugs were incubated with 6ng/μl trypsin in 50mM ammonium 
bicarbonate overnight at 37°C. On the next day, the gel plugs were vortexed briefly and 
spun down before 50% ACN were added to them and shaked for 15 minutes. The 
supernatant of the gel spot was then transferred into a fresh tube. Subsequently, the gel 
plug was incubated with 100% ACN and shakened for another 15 minutes. Similarly, 
the supernatant was also transferred into the previous tube before the digested samples 
were completely dried using SpeedVac. The samples can be kept at -20°C until further 
use. Otherwise, extracted peptides were concentrated or desalted using ZipTip C18 
microcolumns (Merck Millipore, Germany). 
Prior to MALDI-TOF/TOF analysis, 3µl of each extracted peptide sample 
solution was mixed with 3µl of alpha-cyano-4-hydroxycinnamic acid (Sigma-Aldrich, 
USA) matrix solution dissolved in 50% aqueous ACN containing 0.1% trifluoroacetic 
acid (Sigma-Aldrich, USA). A volume of 0.7µl of each sample was applied onto a 
MALDI plate and was allowed to air dry at room temperature. Analysis was performed 
with ABSCIEX 4800 MALDI-TOF/TOF (AB SCIEX, USA) operated in the reflector 
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for MALDI-TOF/TOF with fully automated mode using the 4800 Series Explorer 
software at an accelerating voltage of 20kV. Calibration was performed using Mass 
Standards Kit for Calibration of AB SCIEX TOF/TOFTM Instruments (AB SCIEX, 
USA). Data collected from the MALDI-TOF/TOF were submitted to the SwissProt 
database using the MASCOT search algorithm (version 2.1.0, Matrix Science, London, 
UK). Typical search parameters for both search engines were defined as follows: trypsin 
digestion allowing up to two tryptic-mass cleavages, variable modifications of oxidation 
and carbamidomethyl, maximal mass tolerance of 0.1Da, precursor tolerance of 
100ppm, and taxonomy Homo sapiens. Protein scores greater than 55 were considered 
significant (p < 0.05). The protein with the highest number of peptides was considered 
as those corresponding to the spot if multiple proteins were identified in a single spot. 
The proteins identified were then compared with Uniprot KB/Swiss-Prot database and 
grouped according to the Eukaryotic Orthologous Group of Classifications (COGs). 
2.9 DATA ANALYSIS 
Results were expressed as the mean  Standard Error Mean (SEM) of data 
obtained from three independent experiments. All data were analyzed using one way 
ANOVA, followed by Dunnett’s test for pairwise comparison. P < 0.05 was considered 
statistically significant for all tests. 
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CHAPTER 3: RESULTS 
3.1 POLYPHENOLS IDENTIFICATION IN PHYLLANTHUS SPP. 
Tables 3.1 and 3.2 show the polyphenol compounds present in both aqueous and 
methanolic-soluble extracts obtained from four species of Phyllanthus (P. niruri, P. 
urinaria, P. watsonii, and P. amarus) after analysis by HPLC coupled with photodiode 
array (PDA) and MS-MS detection. Twelve main compounds were identified based on 
their retention times, UV spectra, parent mass spectra and secondary fragmentation 
patterns. These compounds include gallic acid, galloylglucopyronside, 
digalloylglucopyronside, trigalloylglucopyronside, tetragalloylglucopyronside, 
corilagen, geraniin, rutin, quercetin glucoside, quercetin diglucoside, quercetin 
rhamnoside, and caffeolquinic acid. Generally, aqueous extracts of Phyllanthus were 
found to contain a higher number of polyphenol compounds with the presence of ten 
compounds out of the twelve compounds detected, as compared to methanolic extracts 
that contain only four compounds. Meanwhile among the four Phyllanthus species, the 
polyphenol contents in both aqueous (9/10) and methanolic (3/4) P. urinaria extracts 
were found to be the highest. This was followed by P. watsonii (aqueous - 9/10 and 
methanolic – 1/4), P. niruri (aqueous - 8/10 and methanolic – 2/4), and P. amarus 
(aqueous - 8/10 and methanolic – 1/4). 
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Table 3.1: Polyphenol Compounds Detected in Aqueous Extracts of Phyllanthus species 
Compounds 
Retention 
time  
[M-H] 
m/z 
MS-MS fragmentation Phyllanthus species 
Gallic acid 3.8 169 125,169 P. amarus, P. niruri, P. urinaria, P. watsonii 
Galloylglucopyronside 2.8 331 125, 169, 211, 271 P. amarus, P. niruri, P. urinaria, P. watsonii 
Corilagen 18.0 633 301, 125, 169 P. amarus, P. niruri, P. urinaria, P. watsonii 
Geraniin 22.0 951 301, 125, 169, 463 P. amarus, P. niruri, P. urinaria, P. watsonii 
Rutin 26.0 609 301, 179, 151 P. amarus, P. niruri, P. urinaria, P. watsonii 
Quercetin glucoside 27.0 463 301, 179, 151 P. amarus, P. niruri, P. urinaria, P. watsonii 
Caffeolquinic acid 23.0 353 191 P. amarus, P. niruri, P. urinaria, P. watsonii 
Digalloylglucopyronside 15.0 483 125, 169, 211, 271, 313 P. amarus, P. niruri, P. watsonii 
Quercetin rhamnoside 30.0 447 301, 151 P. urinaria, P. watsonii 
Trigalloylglucopyronside 23.0 635 125, 169, 211, 271, 313, 465 P. urinaria 
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Table 3.2: Polyphenol Compounds Detected in Methanolic Extracts of Phyllanthus species 
Compounds 
Retention 
time  
[M-H] 
m/z 
MS-MS fragmentation Phyllanthus species 
Geraniin 12.0 951 301, 125, 169, 463 P. amarus, P. niruri, P. urinaria, P. watsonii 
Quercetin diglucoside 9.0 625 463, 301 P. niruri 
Trigalloylglucopyronside 13.0 635 125, 169, 211, 271, 313, 465 P. urinaria 
Tetragalloylglucopyronside 15.0 787 169, 211,  313, 465 P. urinaria 
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3.2 ANTIPROLIFERATIVE EFFECTS OF TEST COMPOUNDS 
Cellular morphological alterations are usually a result of some biological 
modifications in the cells’ internal environment. Treatment of the cancer cells with 
Phyllanthus extracts produced some changes in the cellular morphologies and these 
alterations were most probably associated to the antiproliferative effects that the 
Phyllanthus exerted on the A549 and MCF-7 cells, attributed to either a cytotoxic or a 
cytostatic (cell cycle arrest) effect. 
3.2.1 MORPHOLOGICAL ANALYSIS OF PHYLLANTHUS-TREATED CELLS 
Upon treatment with Phyllanthus extracts for 72 hours, both A549 and MCF-7 
cells displayed significant morphological changes. Observations showed that some of 
the cells were already detached from the monolayer and some were rounded up (Figure 
3.1A). This suggests that those cells have lost their viability since they no longer have 
the adherence capability. Furthermore, some of the cells showed some granulation and 
vacuolation (Figure 3.1B), a sign that the cells were undergoing stress in response to 
Phyllanthus treatment. They also possessed condensed chromatin (Figure 3.1C) and 
displayed membrane blebbing with the presence of apoptotic bodies (Figure 3.1D), 
some of the characteristic morphological features in cells that were undergoing the 
programmed cell death machinery. 
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Figure 3.1: Morphological changes of treated A549 and MCF-7 cells. 
Red arrows are pointing to each of these morphologies; (A) detached and rounded cells; 
(B) granulated and vacuolated cells; (C) cells with condensed chromatin; (D) membrane 
blebbing or apoptotic bodies. (Magnification power = 200×) 
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3.2.2 CYTOTOXIC EFFECTS OF PHYLLANTHUS CRUDE EXTRACTS, 
FRACTIONS, AND STANDARD DRUGS 
The MTS assay was used to investigate the potential cytotoxic effects of 
Phyllanthus extracts and fractions on different cell lines, where the cells were treated at 
increasing concentrations up to 1000µg/ml for 24, 48, and 72 hours. Two standard 
drugs, namely Cisplatin and Doxorubicin were used as positive controls in this study, 
where the cells were treated at increasing concentrations up to 10µg/ml. The effects of 
aqueous and methanolic Phyllanthus extracts as well as standard drugs against A549 
and MCF-7 cells were shown in Figures 3.2 to 3.6 while their effects against NL20 and 
184B5 were depicted in Figures 3.7 to 3.11. Their cytotoxicity was recorded as IC50 
(µg/ml) values, which resembles the concentration of extracts, fractions or drugs that 
kills or inhibits the growth of 50% of the population. 
Data obtained showed that Phyllanthus extracts have the potential to inhibit 
growth of A549 and MCF-7 in a time- and dose-dependent manner with minimal effect 
on NL20 and 184B5. This is because the percentage of cell viability dropped to 
approximately 25% for A549 (Figures 3.2A, 3.3A, 3.4A, and 3.5A) and 10% for MCF-7 
(Figures 3.2B, 3.3B, 3.4B, and 3.5B) after treatment with the aqueous extracts of four 
Phyllanthus species at 500µg/ml for 72 hours. At this similar treatment conditions, the 
cell viability of NL20 and 184B5 remained above 80% in response to aqueous P. niruri 
(Figures 3.6A and 3.6B) and P. amarus (Figures 3.9A and 3.9B) extracts, while their 
cell viability remained above 60% in response to aqueous P. urinaria (Figures 3.7A and 
3.7B) and P. watsonii (Figures 3.8A and 3.8B) extracts. Likewise, cell viability of NL20 
(Figures 3.6C, 3.7C, 3.8C, and 3.9C) and 184B5 (Figures 3.6D, 3.7D, 3.8D, and 3.9D) 
remained above 50% when they were treated with 250µg/ml of the methanolic extracts 
of four Phyllanthus species for 72 hours, which had caused 100% lethality on both 
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A549 and MCF-7 cancer cells. This showed that Phyllanthus extracts selectively 
inhibited cancer cells growth without causing major effects on the normal cells. 
On the other hand, both Doxorubicin and Cisplatin showed strong cytotoxicity 
on A549 and MCF-7 cells with IC50 values < 10g/ml. Complete death of cancer cells 
were observed at 2g/ml for Doxorubicin (Figures 3.10A and 3.10B) while 20g/ml for 
Cisplatin (Figures 3.10C and 3.10D). They were also very toxic to the NL20 and 184B5 
normal cell lines (Figure 3.11) with IC50 values comparable to the IC50 values for cancer 
cells. One hundred percent NL20 cells were killed at 1.25g/ml of Doxorubicin and 
5g/ml of Cisplatin, while 100% 184B5 cells lethality was observed at 5g/ml for 
Doxorubicin and 10g/ml for Cisplatin. 
Apart from that, the four Phyllanthus species displayed different growth 
inhibitory patterns on both A549 and MCF-7 cells. For A549 cells, they responded 
towards the presence of the extracts as early as 24 hours post-treatment since IC50 
values were obtained for three of the aqueous Phyllanthus extracts (P. urinaria - 
820µg/ml; P. watsonii - 780µg/ml; P. amarus - 840µg/ml) except P. niruri (Figures 
3.2A, 3.3A, 3.4A, and 3.5A). Contrarily, no IC50 values were available for MCF-7 cells 
after treatment with the aqueous extracts at 1000µg/ml for 24 hours. Nevertheless, upon 
prolonged incubation for 48 and 72 hours, the cell viability of MCF-7 cells drastically 
decreased to approximately 20% and 10% respectively (Figures 3.2B, 3.3B, 3.4B, and 
3.5B). However, the drop in A549 cell viability became slower at 48 and 72 hours post-
treatment. This showed that A549 cells responded more quickly towards Phyllanthus 
but slowed down after the initial exposure, while MCF-7 cells requires a longer 
exposure time to elicit an abrupt response. 
The data also demonstrated that methanolic extracts of Phyllanthus exhibited 
greater cytotoxicity compared to the aqueous extracts. This is because 100% lethality of 
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both A549 and MCF-7 were achieved after the cells were treated with 250µg/ml of the 
methanolic extracts. Nonetheless, treatment with aqueous extracts at 1000µg/ml 
(highest treatment concentration applied in this study) resulted only about 90% growth 
inhibition.  
Among the four Phyllanthus species, P. watsonii showed the strongest 
cytotoxicity with lowest IC50 values obtained for both aqueous and methanolic extracts 
on A549 and MCF-7 respectively, followed by P. urinaria, P. amarus, and P. niruri 
(Table 3.3). In contrast, fractions of Phyllanthus were not as effective as the Phyllanthus 
extracts. Fraction 1 showed little growth inhibitory activity against both cancer cell lines 
due to the high IC50 values. Since IC50 is defined as the concentration of the test 
compound that causes 50% growth inhibition of the cell population, a higher IC50 value 
signifies the need of a greater amount of the test compound to exert a similar 50% 
growth inhibition and is therefore rendered less effective. Although fraction 2 was 
relatively more toxic to cancer cells compared to fraction 1, but it is not as effective as 
Phyllanthus extracts as a whole. In addition, fraction 2 also displayed toxicity to the 
normal cells that renders them less useful. 
In order to evaluate the pharmacological effects of Phyllanthus extracts on A549 
and MCF-7 cells, it was necessary to choose a non-toxic but effective dose. From the 
toxicity testing, we obtained three sets of IC50 values at three different incubation time 
points (24, 48, and 72 hours). However, IC50 values at 72 hours incubation as shown in 
Table 3.3 were chosen for subsequent experiments (highlighted in yellow) since the 
cells’ viability remained above 80% when the cells were treated at these concentrations 
for 24 and 48 hours. The maximum incubation time for most of the pharmacological 
assays was only up to 48 hours. 
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Figure 3.2: Growth inhibition effect of P. niruri on A549 and MCF-7. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
A549; (C) aqueous extracts and (D) methanolic extracts on MCF-7. Error bar indicates 
the standard error mean of three independent experiments. 
 
 
Figure 3.3: Growth inhibition effect of P. urinaria on A549 and MCF-7. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
A549; (C) aqueous extracts and (D) methanolic extracts on MCF-7. Error bar indicates 
the standard error mean of three independent experiments. 
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Figure 3.4: Growth inhibition effect of P. watsonii on A549 and MCF-7. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
A549; (C) aqueous extracts and (D) methanolic extracts on MCF-7. Error bar indicates 
the standard error mean of three independent experiments. 
 
 
Figure 3.5: Growth inhibition effect of P. amarus on A549 and MCF-7. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
A549; (C) aqueous extracts and (D) methanolic extracts on MCF-7. Error bar indicates 
the standard error mean of three independent experiments. 
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Figure 3.6: Growth inhibition effect of P. niruri on NL20 and 184B5. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
NL20; (C) aqueous extracts and (D) methanolic extracts on 184B5. Error bar indicates 
the standard error mean of three independent experiments. 
 
 
Figure 3.7: Growth inhibition effect of P. urinaria on NL20 and 184B5. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
NL20; (C) aqueous extracts and (D) methanolic extracts on 184B5. Error bar indicates 
the standard error mean of three independent experiments. 
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Figure 3.8: Growth inhibition effect of P. watsonii on NL20 and 184B5. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
NL20; (C) aqueous extracts and (D) methanolic extracts on 184B5. Error bar indicates 
the standard error mean of three independent experiments. 
 
 
Figure 3.9: Growth inhibition effect of P. amarus on NL20 and 184B5. 
Figure above shows the effects of (A) aqueous extracts and (B) methanolic extracts on 
NL20; (C) aqueous extracts and (D) methanolic extracts on 184B5. Error bar indicates 
the standard error mean of three independent experiments. 
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Figure 3.10: Growth inhibition effect of standard drugs on A549 and MCF-7. 
Figure above shows the effects of (A) doxorubicin and (B) cisplatin on A549; (C) 
doxorubicin and (D) cisplatin on MCF-7. Error bar indicates the standard error mean of 
three independent experiments. 
 
 
Figure 3.11: Growth inhibition effect of standard drugs on NL20 and 184B5. 
Figure above shows the effects of (A) doxorubicin and (B) cisplatin on NL20; (C) 
doxorubicin and (D) cisplatin on 184B5. Error bar indicates the standard error mean of 
three independent experiments. 
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Table 3.3: Cytotoxic effect (IC50) of Phyllanthus extracts, fractions, and standard drugs. 
Table below showed the IC50 (µg/ml) values of various test compounds against two cancer (A549, MCF-7) and two normal cell lines (NL20, 184B5) 
after 72 hours incubation. Data is expressed as a mean of three independent experiments ± Standard Error Mean (SEM). 
   IC50 (g/ml)  SEM 
   Cancer Cell Lines Normal Cell Lines 
  Solvents A549 MCF-7 NL20 184B5 
Plant Extracts P. niruri (P.n) Aqueous 466.7  41.63 179.7  0.58 > 500.0 > 500.0 
  Methanolic 128.3  17.56 62.3  9.07 > 500.0 > 500.0 
 P. urinaria (P.u) Aqueous 215.0  21.79 139.3  1.16 > 500.0 > 500.0 
  Methanolic 69.0  11.53 48.7  10.02 > 500.0 > 500.0 
 P. watsonii (P.w) Aqueous 198.3  10.41 104.0  10.39 > 500.0 > 500.0 
  Methanolic 61.3  16.17 49.0  8.19 > 500.0 > 500.0 
 P. amarus (P.a) Aqueous 240.0  26.46 156.7  5.77 > 500.0 > 500.0 
  Methanolic 126.7  7.64 56.3  6.66 > 500.0 > 500.0 
Standard Drugs Cisplatin 7.6  1.10 1.4  0.54 0.9  0.05 3.0  0.03 
 Doxorubicin 0.6  0.08 0.4  0.05 0.3  0.02 0.6  0.03 
Fraction 1 P. niruri (P.n) Aqueous 380.0  18.03 438.3  11.55 266.7  41.93 283.3  25.17 
 P. urinaria (P.u) Aqueous > 500.0 > 500.0 > 500.0 231.7  18.93 
 P. watsonii (P.w) Aqueous 395.0  8.66 376.7  2.89 241.7  20.21 230.0  26.46 
 P. amarus (P.a)  Aqueous > 500.0 > 500.0 > 500.0 > 500.0 
Fraction 2 P. niruri (P.n) Aqueous 228.3  5.77 81.7  16.07 108.3  5.77 230.0  50.74 
 P. urinaria (P.u) Aqueous 225.0  13.23 61.7  12.58 95.0  5.00 230.0  13.23 
 P. watsonii (P.w) Aqueous 225.0  43.30 46.7  10.41 105.0  5.00 201.7  20.21 
 P. amarus (P.a) Aqueous 264.3  45.24 70.0  17.32 106.7  7.64 213.3  54.85 
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3.2.3 PHYLLANTHUS DID NOT MODULATE CELL CYCLE 
Cell cycle study was carried out by staining the DNA contents of cells with 
fluorescent propidium iodide dye. In repeated experiments, our data did not demonstrate 
any cell cycle phase arrest in both the A549 and MCF-7 cells treated with various 
Phyllanthus extracts since the percentage of gated cells for each cell cycle phases 
(G0/G1, S, and G2/M) did not change significantly (p > 0.05) between the untreated and 
extracts-treated cells (Figures 3.12 and 3.13). However, at increasing incubation time 
points (24, 48, and 72 hours), the percentage of gated cells for each of the cell cycle 
phases decreased gradually for both A549 and MCF-7 cell lines with a concurrent 
increase in the percentage of dead cells (increase in Sub G1 phase). A Sub G1 phase 
increase was considered as one of the indicators for the presence of apoptotic cells. 
On the other hand, there is an accumulation of cells at G2/M phase for both 
A549 and MCF-7 treated with Cisplatin and Doxorubicin drugs for 72 hours (Figures 
3.12C and 3.13C). Nonetheless, a cell cycle arrest was more profound in MCF-7 cells 
since the G2/M phase increase compared to untreated control was already significant 
after 24 hours incubation (Cisplatin – 17%; Doxorubicin – 34%), and continuously 
increased after 48 hours (Cisplatin and Doxorubicin – 37%) and 72 hours (Cisplatin – 
45%; Doxorubicin – 43%). Contrarily, the increase in G2/M phase of treated A549 cells 
was only significant after 48 hours (Cisplatin – 10%; Doxorubicin – 32%) and 72 hours 
(Cisplatin – 27%; Doxorubicin – 41%) incubation. Similarly, an increase in the number 
of cells arrested at Sub G1 phase was noted. 
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Figure 3.12: Cell cycle phase distribution of A549 in response to Phyllanthus extracts. 
Figure above shows the percentage distribution of A549 cells in different phases of the 
cell cycle after treatment with both aqueous and methanolic Phyllanthus extracts and 
standard drugs at their IC50 (g/ml) concentrations for (A) 24 hours, (B) 48 hours, and 
(C) 72 hours. Error bar indicates the standard error mean of three independent 
experiments. Aq – Aqueous; MeOH – Methanolic; Control – untreated cells. *P < 0.05 
vs untreated control. 
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Figure 3.13: Cell cycle phase distribution of MCF-7 in response to Phyllanthus extracts. 
Figure above shows the percentage distribution of MCF-7 cells in different phases of 
the cell cycle after treatment with both aqueous and methanolic Phyllanthus extracts and 
standard drugs at their IC50 (g/ml) concentrations for (A) 24 hours, (B) 48 hours, and 
(C) 72 hours. Error bar indicates the standard error mean of three independent 
experiments. Aq – Aqueous; MeOH – Methanolic; Control – untreated cells. *P < 0.05 
vs untreated control. 
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3.3 ANTIMETASTASIS EFFECTS OF PHYLLANTHUS 
Metastasis is often the pivotal factor that determines the survival of a cancer 
patient. It is a multistep process beginning with cell invasion, migration, adhesion, as 
well as tumor establishment at a secondary site, and these steps are often associated 
with their ability to express matrix metalloproteinase enzymes. Treatment with 
Phyllanthus had demonstrated its ability to halt these various stages in metastasis, hence 
blocking the spreading of cancer cells from its primary site to other parts of the body. 
3.3.1 EFFECTS OF PHYLLANTHUS EXTRACTS ON CELL INVASION 
The antiinvasive effect of Phyllanthus was studied by using a transwell chamber 
coated with basement membrane extract that occludes the pores of the membrane. This 
is to avoid non-invasive cells from migrating through the membrane while allowing the 
invasive cells to detach themselves from surrounding cells and invade through the 
matrix in response to a chemoattractant. Therefore, the number of cells that were able to 
pass through the matrix and 8µm pore into the lower well emulates their invasive 
potential.  
As shown in Figure 3.14, the Phyllanthus extracts prevented the invasion of both 
A549 and MCF-7 cells in a dose-dependent manner (P < 0.05). When the cells were 
treated with extracts at their respective IC50 concentrations, they inhibited invasion of 
A549 cells (20% - 40%) more strongly as compared to MCF-7 cells (less than 10%). At 
higher concentrations however, both cancer cells’ invasion was inhibited to a greater 
extent (40% - 60% for A549 cells and 30% - 50% for MCF-7 cells). Among the four 
Phyllanthus species, P. watsonii and P. amarus showed better inhibitory activity on 
A549 cells invasion while aqueous P. niruri and methanolic P. urinaria is more 
effective in inhibiting MCF-7 cells invasion. 
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Figure 3.14: Invasion inhibition percentage induced by aqueous and methanolic extracts 
of Phyllanthus on (A) A549 and (B) MCF-7 cells treated at varying concentrations. 
High – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic extracts 
respectively; APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. 
watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - methanolic P. 
urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; Control – 
untreated cells. Error bar indicates the standard error mean of three independent 
experiments. *P < 0.05 vs untreated control. 
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3.3.2 EFFECTS OF PHYLLANTHUS EXTRACTS ON CELL MOTILITY 
The effect of Phyllanthus on A549 and MCF-7 cell motility was determined by 
cell migration and scratch motility assays. From the cell migration assay, Phyllanthus 
exhibited a reduction in the migration of A549 and MCF-7 cells in a dose-dependent 
manner (Figure 3.15). The migration of cells was significantly decreased (P < 0.05) 
when treated with increasing concentrations of aqueous extracts (50 - 500g/ml) and 
methanolic extracts (20 - 200g/ml). Even at the lowest concentration tested, migration 
inhibition exerted by Phyllanthus was greater than 20% for A549 cells and greater than 
40% for MCF-7 cells. Meanwhile at the highest concentration tested, inhibition of A549 
and MCF-7 cells migration was greater than 70% and 80% respectively.  
When the A549 cells were treated at the lowest and highest concentrations, there 
was not a great difference between the activities of the four Phyllanthus species and the 
two types of extracts. However, A549 cells treated at the respective IC50 concentrations 
of methanolic extracts showed a lesser capability to migrate than the aqueous extracts. 
This phenomenon was not observed in MCF-7 cells treated with the respective IC50 
concentrations of the aqueous and methanolic Phyllanthus extracts. 
Figures 3.16, 3.17, 3.18, 3.19, 3.20, and 3.21 shows the wound closure activity 
of A549 and MCF-7 cells in the presence of the four Phyllanthus species. From the 
figures, both the untreated A549 and MCF-7 cells exhibited a complete wound closure 
activity after 24 and 48 hours incubation respectively. A shorter duration needed by 
A549 cells to close the wound revealed that they have a higher capability to migrate 
than MCF-7 cells. Nonetheless, the Phyllanthus-treated cells exhibited decreased ability 
to close the wound at the end of their respective incubation time by forming asymmetric 
lamellipodial protrusions into the denuded zone as marked by the red arrows. Generally, 
methanolic Phyllanthus extracts had a greater inhibitory activity on the A549 cells 
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migration since the gap of cells treated with methanolic extracts was more clearly 
visible compared to the aqueous extracts after 24 hours. Meanwhile, both aqueous and 
methanolic extracts were equally effective to inhibit MCF-7 cells migration since only a 
limited closure of wound was noticed after 48 hours incubation.  
The numbers of migrated cells were calculated from five randomly selected 
fields per sample and were represented as migration inhibition rate for A549 and MCF-
7 cells in Figures 3.22A and 3.22B respectively. As the incubation time increased, the 
migration inhibition rate were also significantly increased (P < 0.05). A more rapid 
migration inhibitory action of Phyllanthus was observed at 6 hours post-treatment in 
A549 cells and 12 hours post-treatment in MCF-7 cells. Approximately 85% of A549 
cells migration and 95% of MCF-7 cells migration were inhibited at the end of their 24 
and 48 hours incubation respectively. Among the four Phyllanthus species, P. urinaria 
and P. watsonii displayed enhanced activity compared to the other two species. 
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Figure 3.15: Migration inhibition percentage of aqueous and methanolic extracts of 
Phyllanthus on (A) A549 and (B) MCF-7 cells treated at varying concentrations. 
High – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic extracts 
respectively; Low – treatment at 50µg/ml and 20µg/ml for aqueous and methanolic 
extracts respectively; APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - 
aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; 
Control – untreated cells. Error bar indicates the standard error mean of three 
independent experiments. *P < 0.05 vs untreated control. 
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Figure 3.16: Wound closure activity of A549 in response to P. niruri and P. urinaria. 
Figure above shows the migration activity of A549 cells across the wound after treated with aqueous (Aq) and methanolic (MeOH) P. niruri and P. 
urinaria extracts for 24 hours. Typical result from three independent experiments is shown. (Magnification power: 40×) 
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Figure 3.17: Wound closure activity of A549 in response to P. watsonii and P. amarus. 
Figure above shows the migration activity of A549 cells across the wound after treated with aqueous (Aq) and methanolic (MeOH) P. watsonii and P. 
amarus extracts for 24 hours. Typical result from three independent experiments is shown. (Magnification power: 40×) 
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Figure 3.18: Wound closure activity of MCF-7 in response to P. niruri. 
Figure above shows the migration activity of MCF-7 cells across the wound after 
treated with aqueous (Aq) and methanolic (MeOH) P. niruri extracts for 48 hours. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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Figure 3.19: Wound closure activity of MCF-7 in response to P. urinaria. 
Figure above shows the migration activity of MCF-7 cells across the wound after 
treated with aqueous (Aq) and methanolic (MeOH) P. urinaria extracts for 48 hours. 
Typical result from three independent experiments is shown. (Magnification power: 
200×) 
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Figure 3.20: Wound closure activity of MCF-7 in response to P. watsonii. 
Figure above shows the migration activity of MCF-7 cells across the wound after 
treated with aqueous (Aq) and methanolic (MeOH) P. watsonii extracts for 48 hours. 
Typical result from three independent experiments is shown. (Magnification power: 
200×) 
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Figure 3.21: Wound closure activity of MCF-7 in response to P. amarus. 
Figure above shows the migration activity of MCF-7 cells across the wound after 
treated with aqueous (Aq) and methanolic (MeOH) P. amarus extracts for 48 hours. 
Typical result from three independent experiments is shown. (Magnification power: 
200×) 
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Figure 3.22: Quantitative assessment of migration inhibition rate of aqueous and 
methanolic extracts of Phyllanthus on (A) A549 and (B) MCF-7 cells. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA 
- aqueous P. amarus; MPN - methanolic P. niruri; MPU - methanolic P. urinaria; 
MPW - methanolic P. watsonii; MPA - methanolic P. amarus. Error bar indicates the 
standard error mean of three independent experiments. *P < 0.05 vs untreated control. 
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3.3.3 EFFECT OF PHYLLANTHUS EXTRACTS ON CELL ATTACHMENT 
The effect of Phyllanthus on cell adhesion was examined by detaching the 
treated cells from the cultured flasks and plating them onto a new culture plate with the 
same number of viable treated cells in each group. The rounded cells represent the 
unattached cells, but all cells ultimately will attach themselves to the plate. Therefore, 
the higher number of rounded (unattached) cells at a given time point as compared to 
the untreated control signifies a delay or defect in their attachment.  
Figures 3.23 and 3.24 showed the different attachment ability between the 
Phyllanthus-treated A549 cells and the untreated control cells. Meanwhile, the 
attachment ability of MCF-7 cells treated with various Phyllanthus extracts was 
illustrated in Figures 3.25 and 3.26. As can be seen from those figures, most of the 
untreated cells (both A549 and MCF-7) have begun to adhere to the plate after 6 hours 
of incubation. They even began to multiply and formed a monolayer after incubation for 
24 hours, as marked by the red box in the figures. In contrast, most of the treated A549 
and MCF-7 cells remained in their suspension form after incubation for 6 hours and 
began to adhere slightly only after incubation for 12 hours. Twenty-four hours later, 
some of the treated cells were still unattached as indicated by the red arrows, hence 
suggesting that the attachment capability of the Phyllanthus-treated cells was retarded. 
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Figure 3.23: Cell attachment status of A549 in response to P. niruri and P. urinaria. 
Figure above shows the attachment of A549 cells (indicated by red arrows) treated with aqueous (Aq) and methanolic (MeOH) P. niruri and P. 
urinaria extracts after 24 hours incubation. Typical result from three independent experiments is shown. (Magnification power: 100×) 
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Figure 3.24: Cell attachment status of A549 in response to P. watsonii and P. amarus. 
Figure above shows the attachment of A549 cells (indicated by red arrows) treated with aqueous (Aq) and methanolic (MeOH) P. watsonii and P. 
amarus extracts after 24 hours incubation. Typical result from three independent experiments is shown. (Magnification power: 100×) 
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Figure 3.25: Cell attachment status of MCF-7 in response to P. niruri and P. urinaria. 
Figure above shows the attachment of MCF-7 cells (indicated by red arrows) treated with aqueous (Aq) and methanolic (MeOH) P. niruri and P. 
urinaria extracts after 24 hours incubation. Typical result from three independent experiments is shown. (Magnification power: 100×) 
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Figure 3.26: Cell attachment status of MCF-7 in response to P. watsonii and P. amarus. 
Figure above shows the attachment of MCF-7 cells (indicated by red arrows) treated with aqueous (Aq) and methanolic (MeOH) P. watsonii and P. 
amarus extracts after 24 hours incubation. Typical result from three independent experiments is shown. (Magnification power: 100×) 
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3.3.4 EFFECTS OF PHYLLANTHUS ON CELL-MATRIX ADHESION 
In order to examine further the effects of Phyllanthus on cell’s adhesion ability, 
cell-matrix adhesion assay is necessary since attachment of cancer cells to basement 
membrane or extracellular matrices is the first barrier for successful metastasis. As 
shown in Figure 3.27, the adhesion ability of A549 and MCF-7 cells to matrix 
decreased when they were treated at increasing concentrations of Phyllanthus extracts.  
At low concentrations of the aqueous and methanolic Phyllanthus extracts, there 
was only about 20 – 30% adhesion inhibition of A549 cells. However, when the extracts 
concentrations were increased, the adhesion inhibition increased up to 40 – 50% (IC50 
treatments) and 55 – 62% (treatment at 500µg/ml for aqueous and 200µg/ml for 
methanolic). Among the four Phyllanthus species, P. watsonii showed the best 
inhibition on A549 cells’ adhesion to the matrix. Meanwhile, Cisplatin and Doxorubicin 
caused 46% and 54% suppression on A549 cell-matrix adhesion. 
For MCF-7 cells, there was 13 – 30% cell-matrix adhesion inhibition when they 
were treated at low extracts concentrations. This inhibition percentage increased when 
MCF-7 cells were treated at IC50 (40 – 52%) and higher (66 – 92%) concentrations. 
Generally, methanolic Phyllanthus extracts caused greater inhibition of MCF-7 cells’ 
adhesion to matrix as compared to aqueous extracts. Cisplatin and Doxorubicin also 
caused 33% and 42% cell-matrix adhesion inhibition on MCF-7 respectively. 
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Figure 3.27: Cell-matrix adhesion percentage of (A) A549 and (B) MCF-7 cells treated 
with Phyllanthus extracts at varying concentrations. 
Low – treatment at 50µg/ml and 20µg/ml for aqueous and methanolic extracts 
respectively; High – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic 
extracts respectively; APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - 
aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; 
CIS – Cisplatin; DOX – Doxorubicin; Control – untreated cells. Error bar indicates the 
standard error mean of three independent experiments. *P < 0.05 vs untreated control. 
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3.3.5 EFFECTS OF PHYLLANTHUS ON MATRIX METALLOPROTEINASES 
(MMPs) EXPRESSION 
MMPs play an important role during tumor metastasis and angiogenesis since its 
expression level is often correlated with the tumor invasiveness. Among the variety of 
MMPs, MMP2, MMP7, and MMP9 were more commonly associated with cancer 
metastasis as they have the ability to degrade collagen type IV that is the major 
component of basement membrane.  
In A549 cells, expression of all three MMPs (MMP2, MMP7, and MMP9) was 
detected as shown in Figure 3.28. Among these MMPs, MMP7 probably plays a greater 
role in A549 metastasis since its expression was higher with brighter and clearer bands 
as compared to MMP2 and MMP9. Nonetheless, their expressions decreased in a dose-
dependent manner. Subsequent quantitative assessment of these bands intensity further 
confirmed the gradual reduction in MMPs expression when the cells were treated at 
increasing extracts concentrations (Figure 3.29). Generally, methanolic Phyllanthus 
extracts demonstrated greater inhibition on the MMPs’ expression than aqueous 
extracts, with P. urinaria showing the greatest inhibitory activity compared to the other 
Phyllanthus species. Contrarily, only MMP-2 and MMP-9 were expressed in MCF-7 
cells, with MMP-2 expression higher than MMP-9, therefore suggesting a more 
prominent role of MMP-2 in MCF-7 cells’ metastasis. Nevertheless, comparison of the 
untreated control and Phyllanthus-treated bands’ intensity in Figure 3.30 demonstrated 
that the expression for both MMP2 and MMP9 in MCF-7 cells was reduced in a dose-
dependent manner. Similarly, quantitative assessment of the bands’ intensity as shown 
in Figure 3.31 revealed that methanolic Phyllanthus extracts exerted greater inhibition 
on the MMP2 and MMP9 expression. Among the four Phyllanthus species, P. urinaria 
showed the greatest inhibition, followed by P. watsonii, P. niruri, and P. amarus. 
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Figure 3.28: Matrix metalloproteinases 2, 7, and 9 (MMP2, MMP7, and MMP9) expression levels in A549 cells in response to Phyllanthus extracts. 
Figure above shows the MMP2, MMP7, and MMP9 expressions in A549 cells treated with (A and C) aqueous Phyllanthus extracts and (B and D) 
methanolic Phyllanthus extracts. M – protein marker; C – untreated control; L – treatment at 50µg/ml and 20µg/ml for aqueous and methanolic 
extracts respectively; I – treatment at their respective IC50 concentrations; H – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic 
extracts respectively; PN – P. niruri; PU – P. urinaria; PW – P. watsonii; PA – P. amarus. 
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Figure 3.29: Quantitative assessment of (A) MMP2, (B) MMP7, and (C) MMP9 
expressions in A549 cells in response to aqueous and methanolic Phyllanthus extracts. 
Low – treatment at 50µg/ml and 20µg/ml for aqueous and methanolic extracts 
respectively; High – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic 
extracts respectively; APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - 
aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus. 
Error bar indicates the standard error mean of three independent experiments. *P < 0.05 
vs untreated control. 
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Figure 3.30: Matrix metalloproteinases 2 and 9 (MMP2 and MMP9) expression levels 
in MCF-7 in response to Phyllanthus extracts. 
Figure above shows the MMP2 and MMP9 expressions in MCF-7 cells treated with (A) 
aqueous Phyllanthus extracts and (B) methanolic Phyllanthus extracts. M – protein 
marker; C – untreated control; L – treatment at 50µg/ml and 20µg/ml for aqueous and 
methanolic extracts respectively; I – treatment at their respective IC50 concentrations; H 
– treatment at 500µg/ml and 200µg/ml for aqueous and methanolic extracts 
respectively; PN – P. niruri; PU – P. urinaria; PW – P. watsonii; PA – P. amarus. 
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Figure 3.31: Quantitative assessment of (A) MMP2 and (B) MMP9 expressions in 
MCF-7 cells in response to aqueous and methanolic Phyllanthus extracts. 
Low – treatment at 50µg/ml and 20µg/ml for aqueous and methanolic extracts 
respectively; High – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic 
extracts respectively; APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - 
aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus. 
Error bar indicates the standard error mean of three independent experiments. *P < 0.05 
vs untreated control. 
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3.4 MECHANISM OF CELL DEATH INDUCED BY PHYLLANTHUS 
Treatment with chemotherapeutic agents would normally induce one of the two 
distinct modes of cell death in cancer cells, via either apoptosis or necrosis. Apoptosis is 
a preferable mode of cell death in cells since it does not provoke an inflammatory 
response unlike necrosis. Nevertheless, some of the agents have the capability to 
stimulate both cell death machineries, which include Phyllanthus that mainly induces 
apoptosis in cancer cells with little involvement of necrotic cell death. 
3.4.1 EFFECTS OF PHYLLANTHUS EXTRACTS ON CASPASE-3 AND -7 
ACTIVITIES 
Caspase-3 and -7 play crucial roles as early apoptosis biochemical markers in 
mammalian cells. Caspase-Glo® 3/7 Assay uses a luminogenic substrate containing the 
DEVD sequence that is selective for caspase-3 and -7. The caspases activity in both 
untreated and Phyllanthus-treated cancer cells were measured after 72 hours and are 
shown in Figure 3.32. Our findings showed that caspase-3 and -7 activities were 
detected in untreated A549 and MCF-7 control cells, which corresponded to the portion 
of apoptotic cells present in the naturally growing population due to natural aging. 
Therefore, the caspases fold change in treated cells was calculated by assuming the 
caspases activity present in untreated cells as the basal level and was set to zero. Results 
obtained revealed that activities of caspase-3 and -7 increased to a range from 3-fold to 
5-fold (P < 0.05) over basal levels in treated cells, hence signifying an activation of 
these caspases in both A549 and MCF-7 cells treated with Phyllanthus extracts. Besides 
that, A549 and MCF-7 cells treated with standard drugs also showed a greater fold 
increase in their caspase-3 and -7 activity (Cisplatin – 6 fold increase; Doxorubicin – 7 
fold increase). 
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Figure 3.32: Caspase-3 and -7 levels released from A549 and MCF-7 cells treated with aqueous and methanolic Phyllanthus extracts. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; CIS – Cisplatin; DOX – Doxorubicin; Control – untreated cells. 
Error bar indicates the standard error mean of three independent experiments. *P < 0.05 vs untreated control. 
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3.4.2 EFFECTS OF PHYLLANTHUS EXTRACTS ON CELLULAR 
MEMBRANE INTEGRITY 
Lactate Dehydrogenase (LDH) is a cytosolic enzyme released into cell culture 
supernatant due to compromised membrane integrity, which is associated with necrotic 
cell death. The extent of its activity in converting tetrazolium salt into red formazan 
product is proportional to the number of necrotic cells. Figure 3.33 shows the 
percentage of LDH released from A549 and MCF-7 cells after 72 hours of treatment 
with various aqueous and methanolic extracts of Phyllanthus. As the positive control for 
this assay, maximal LDH release was induced in the cells by addition of a lysis 
compound provided by the supplier that lysed the cell membrane. From the data, the 
LDH amount released by Phyllanthus-treated cells remained at low levels (less than 
20%) that is comparable to the level of LDH released from the untreated cells (< 10%). 
This therefore suggests that Phyllanthus induces minimal cytotoxicity by disrupting 
membrane integrity that led to necrosis. On the other hand, Cisplatin-treated A549 and 
MCF-7 cells released 30 – 35% of LDH from its compromised membrane while 20 – 
25% LDH was detected from Doxorubicin-treated cells. 
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Figure 3.33: Lactate dehydrogenase (LDH) released from A549 and MCF-7 cells treated with aqueous and methanolic Phyllanthus extracts. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; CIS – Cisplatin; DOX – Doxorubicin; Control – untreated cells; 
Max – maximal LDH released. Error bar indicates the standard error mean of three independent experiments. *P < 0.05 vs untreated control. 
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3.4.3 EFFECTS OF PHYLLANTHUS EXTRACTS ON NUCLEAR 
FRAGMENTATION 
DNA fragmentation in condensed chromatin and formation of apoptotic bodies 
are some of the events of late apoptosis. In order to demonstrate the ability of 
Phyllanthus extracts to induce apoptosis, DNA fragmentation assay was used to verify 
the presence of apoptotic cells in the treated A549 and MCF-7 cells. Isolation of DNA 
from the treated cells and their subsequent separation on an agarose gel presented a 
typical ladder-like pattern of multiples of approximately 180 - 200 bps DNA fragments, 
one of the hallmarks of apoptosis (Figures 3.34A and 3.34B).  
Additionally, cell apoptosis was determined in situ based on the enzymatic 
labelling of free 3’-OH terminus of non-random DNA single-stranded and double-
stranded breaks with modified nucleotides, resulting in the brown staining of the 
apoptotic cells. Figures 3.35, 3.36, 3.37, and 3.38 show the TUNEL-positive A549 and 
MCF-7 cells after treatment with various aqueous and methanolic extracts of four 
Phyllanthus species. After 72 hours of extracts treatment, the percentage of apoptotic 
cells in both A549 and MCF-7 increased tremendously as compared to the untreated 
control cells. Since the cells were treated with the IC50 concentrations of each extracts, 
the mean percentage of apoptotic cells observed from 3 views per slide varied from 30% 
up to 55%.  
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Figure 3.34: Agarose gel electrophoretic analysis of DNA fragmentation in (A) A549 
and (B) MCF-7 cells in response to Phyllanthus extracts and standard drugs. 
Red arrows at the right are pointing to the bands of DNA fragments. M: Molecular-
weight marker; Lane 1 - 4: aqueous extracts of P. niruri, P. urinaria, P. watsonii, and P. 
amarus; Lane 5 – 8: methanolic extracts of P. niruri, P. urinaria, P. watsonii, and P. 
amarus; Lane 9: Cisplatin; Lane 10: Doxorubicin; Lane 11: Untreated control. Typical 
result from three independent experiments is shown. 
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Figure 3.35: TUNEL-positive A549 in response to aqueous Phyllanthus extracts. 
Red arrows showing (A) untreated A549 cells and TUNEL-positive cells treated with 
(B) aqueous P. niruri; (C) aqueous P. urinaria; (D) aqueous P. watsonii; (E) aqueous P. 
amarus; (F) Cisplatin. Typical results from three independent experiments are shown. 
(Magnification power: 200×)  
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Figure 3.36: TUNEL-positive A549 in response to methanolic Phyllanthus extracts. 
Red arrows showing (A) untreated A549 cells and TUNEL-positive cells treated with 
(B) methanolic P. niruri; (C) methanolic P. urinaria; (D) methanolic P. watsonii; (E) 
methanolic P. amarus; (F) Doxorubicin. Typical results from three independent 
experiments are shown. (Magnification power: 200×) 
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Figure 3.37: TUNEL-positive MCF-7 in response to aqueous Phyllanthus extracts. 
Red arrows showing (A) untreated MCF-7 cells and TUNEL-positive cells treated with 
(B) aqueous P. niruri; (C) aqueous P. urinaria; (D) aqueous P. watsonii; (E) aqueous P. 
amarus; (F) Cisplatin. Typical results from three independent experiments are shown. 
(Magnification power: 200×) 
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Figure 3.38: TUNEL-positive MCF-7 in response to methanolic Phyllanthus extracts. 
Red arrows showing (A) untreated MCF-7 cells and TUNEL-positive cells treated with 
(B) methanolic P. niruri; (C) methanolic P. urinaria; (D) methanolic P. watsonii; (E) 
methanolic P. amarus; (F) Doxorubicin. Typical results from three independent 
experiments are shown. (Magnification power: 200×) 
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3.5 EFFECTS OF PHYLLANTHUS ON CELL’S ANGIOGENIC ABILITY 
Angiogenesis or blood vessel formation is the key process for tumor’s survival 
and metastasis in hypoxic environment. During hypoxia, cytoplasmic HIF-1α subunit 
stabilization will lead to the activation of various genes to promote their survival, 
including vascular endothelial growth factor (VEGF) and inducible nitric oxide 
synthases (iNOS). This was verified with the high expression of both VEGF and iNOS 
detected in the untreated-control A549 and MCF-7 cells (Figures 3.39, 3.40, 3.41, and 
3.42) using cell-based ELISA and western blotting assays.  
After A549 treatment with various Phyllanthus, both the aqueous and 
methanolic extracts for all four species were observed to demonstrate inhibition on 
iNOS (Figure 3.39A), whereby most of their expressions dropped markedly to 
approximately 20 - 30% except for methanolic P. urinaria that retained 40% iNOS 
expression. Generally, P. urinaria (78% reduction) scored highest iNOS inhibition 
among aqueous extracts while P. watsonii (82% reduction) exhibited strongest activity 
among methanolic extracts. This suppression ability was comparable to Cisplatin and 
Doxorubicin effects, with 15% and 10% iNOS expression remained after their treatment 
respectively. Meanwhile, methanolic Phyllanthus extracts showed better suppression on 
VEGF expression with 60 – 80% reduction compared to aqueous extracts that caused 20 
– 50% reduction (Figure 3.39B). Among the four methanolic extracts, P. amarus 
displayed better VEGF repression with only 20% VEGF expression. In addition to this 
ELISA assay, expression of VEGF was also confirmed by western blot assay as shown 
in Figure 3.40. The bands’ intensity for Phyllanthus-treated A549 cells was thinner as 
compared to the untreated cells, with methanolic extracts exhibiting a better suppression 
on VEGF. Similarly, VEGF expression dropped 30 – 75% after A549 cells were treated 
with various aqueous and methanolic Phyllanthus extracts. 
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Meanwhile, iNOS and VEGF expression falls significantly to a range from 15 – 
40% and 20 – 65% respectively after the MCF-7 cells were treated with various 
Phyllanthus extracts (Figure 3.41). Among the four species, aqueous P. urinaria (16% 
expression) and methanolic P. urinaria (20% expression) showed better inhibition on 
iNOS expression. This iNOS suppression ability was comparable to the Cisplatin and 
Doxorubicin that reduced iNOS expression in MCF-7 cells to 26% and 20% 
respectively. On the other hand, methanolic P. amarus (19% expression) was the most 
effective among the different Phyllanthus extracts and species in suppressing VEGF 
expression. Likewise, methanolic Phyllanthus extracts showed better inhibition on 
VEGF expression compared to the aqueous extracts. This observation was further 
confirmed using western blotting as shown in Figure 3.42 whereby the VEGF bands’ 
intensity were decreased for Phyllanthus-treated MCF-7 cells. Quantitative assessment 
also revealed the drop in VEGF expression to 5 – 55% after MCF-7 cells were treated 
with various aqueous and methanolic Phyllanthus extracts. 
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Figure 3.39: Expression levels of (A) iNOS and (B) VEGF in untreated and 
Phyllanthus-treated A549 cells. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA 
- aqueous P. amarus; MPN - methanolic P. niruri; MPU - methanolic P. urinaria; 
MPW - methanolic P. watsonii; MPA - methanolic P. amarus; Cis – Cisplatin; Dox – 
Doxorubicin. Error bar indicates the standard error mean of three independent 
experiments. *P < 0.05 vs untreated control. 
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Figure 3.40: Western blotting of VEGF expression in A549 in response to Phyllanthus 
extracts. 
Figure above shows western blot and expression level of VEGF protein in untreated 
control and Phyllanthus-treated A549 cells analyzed using Image J software. APN - 
aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA - 
aqueous P. amarus; MPN - methanolic P. niruri; MPU - methanolic P. urinaria; MPW 
- methanolic P. watsonii; MPA - methanolic P. amarus. *P < 0.05 vs untreated control. 
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Figure 3.41: Expression levels of (a) iNOS and (b) VEGF in untreated and Phyllanthus-
treated MCF-7 cells. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA 
- aqueous P. amarus; MPN - methanolic P. niruri; MPU - methanolic P. urinaria; 
MPW - methanolic P. watsonii; MPA - methanolic P. amarus; Cis – Cisplatin; Dox – 
Doxorubicin. Error bar indicates the standard error mean of three independent 
experiments. *P < 0.05 vs untreated control. 
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Figure 3.42: Western blotting of VEGF expression in MCF-7 in response to Phyllanthus 
extracts. 
Figure above shows western blot and expression level of VEGF protein in untreated 
control and Phyllanthus-treated MCF-7 cells analyzed using Image J software. APN - 
aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA - 
aqueous P. amarus; MPN - methanolic P. niruri; MPU - methanolic P. urinaria; MPW 
- methanolic P. watsonii; MPA - methanolic P. amarus. *P < 0.05 vs untreated control. 
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3.6 EFFECTS OF PHYLLANTHUS ON CELL’S ENDOTHELIAL TO 
MESENCHYMAL TRANSITION (EMT) 
Enhancement of cell motility for metastasis requires the conversion of an 
epithelial cell to a mesenchymal-like cell via epithelial-mesenchymal transition (EMT) 
process to release the epithelial tumor cells from its neighbouring tissue. Treatment of 
the cancer cells with Phyllanthus had showed some reversal of this EMT process to 
reduce their motility mainly via enhanced adhesion between cells. 
3.6.1 EFFECTS OF PHYLLANTHUS ON CELL AGGREGATION 
Metastatic cancer cells are usually characterized by loss of cell polarity as well 
as epithelial tight junctions to break their adhesions with the surrounding cells. This 
phenomenon was apparent in the untreated A549 (Figures 3.43, 3.44, 3.45, and 3.46) 
and MCF-7 (Figures 3.47, 3.48, 3.49, and 3.50) cells that remained in their individual 
cell suspension form up to 36 hours. However, they began to die after 48 hours 
incubation as shown by the clumped cells due to the absence of a flat surface for them 
to adhere onto and grow. In order to determine whether Phyllanthus could reverse this 
EMT process, cells were treated with the various aqueous and methanolic extracts of the 
four Phyllanthus species. A successful EMT reversion is signified by increased cell 
adhesions to each other to form cell aggregates. Indeed, the extracts-treated cells began 
to show appearance of cell aggregation after 24 hours of treatment as indicated by the 
red arrows. The cell aggregates became even more obvious after 36 hours incubation. 
Nevertheless, the cells started to die and formed clumps at 48 and 60 hours post-
treatment, similar to the untreated control cells due to their inability to attach and grow. 
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Figure 3.43: Cell aggregation status of A549 in response to P. niruri. 
Figure above shows aggregation of A549 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. niruri extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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Figure 3.44: Cell aggregation status of A549 in response to P. urinaria. 
Figure above shows aggregation of A549 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. urinaria extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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Figure 3.45: Cell aggregation status of A549 in response to P. watsonii. 
Figure above shows aggregation of A549 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. watsonii extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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Figure 3.46: Cell aggregation status of A549 in response to P. amarus. 
Figure above shows aggregation of A549 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. amarus extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
  
156 
 
 
Figure 3.47: Cell aggregation status of MCF-7 in response to P. niruri. 
Figure above shows aggregation of MCF-7 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. niruri extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
  
157 
 
 
Figure 3.48: Cell aggregation status of MCF-7 in response to P. urinaria. 
Figure above shows aggregation of MCF-7 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. urinaria extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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Figure 3.49: Cell aggregation status of MCF-7 in response to P. watsonii. 
Figure above shows aggregation of MCF-7 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. watsonii extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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Figure 3.50: Cell aggregation status of MCF-7 in response to P. amarus. 
Figure above shows aggregation of MCF-7 cells (indicated by red arrows) treated with 
aqueous (Aq) and methanolic (MeOH) P. amarus extracts after 60 hours incubation. 
Typical result from three independent experiments is shown. (Magnification power: 
40×) 
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3.6.2 EFFECTS OF PHYLLANTHUS ON CELL-CELL ADHESION 
Cell-cell adhesion is mediated by the homotypic interactions of the cadherin 
molecules located on their cell surface. Expression of cadherins is mainly tissue type 
specific, as E-cadherins are usually confined to the epithelial cells. Hence, this assay 
was performed to determine whether Phyllanthus could increase the E-cadherin 
expression on the A549 and MCF-7 cells that is correlated to the suppression of cell 
metastasis. Figure 3.51 shows the cell-cell adhesion percentage between the untreated 
cells and the cells treated with various Phyllanthus extracts. 
For A549, the percentage of cell-cell adhesion of the untreated cells to HUVEC 
cells was 20%. When the cells were treated at low concentrations, only the aqueous 
extracts showed approximately 10% increased cell-cell adhesion activity. However, 
when the extracts concentrations were increased, cell-cell adhesion activity was notably 
enhanced (increased approximately 40 – 50% adhesion activity) hence showing a dose-
dependent effect (Figure 3.51A). Among the extracts, aqueous Phyllanthus has greater 
cell-cell adhesion promoting capability compared to methanolic extracts, in particular P. 
niruri, followed by P. amarus, P. watsonii, and P. urinaria. However, the cell-cell 
adhesion was not increased greatly when the A549 cells were treated with standard 
drugs due to their low adhesion percentage (Cisplatin – 32% and Doxorubicin – 25%). 
For MCF-7 cells, the percentage of cell-cell adhesion of the untreated MCF-7 
cells to HUVEC cells was approximately 35% (Figure 3.51B). Treatment of the cells 
with low concentrations of extracts did not promote the cell-cell adhesion activity 
except for aqueous P. niruri and P. amarus. Nevertheless, the cell-cell adhesion activity 
increased about 40% when the cells were treated with higher concentrations of the 
extracts. Likewise, aqueous Phyllanthus extracts especially P. niruri had higher 
effectiveness while treatment with standard drugs barely increased cell-cell adhesion. 
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Figure 3.51: Cell-cell adhesion percentage of (A) A549 and (B) MCF-7 cells treated 
with Phyllanthus extracts at varying concentrations. 
Low – treatment at 50µg/ml and 20µg/ml for aqueous and methanolic extracts 
respectively; High – treatment at 500µg/ml and 200µg/ml for aqueous and methanolic 
extracts respectively; APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - 
aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; 
CIS – Cisplatin; DOX – Doxorubicin; Control – untreated cells. Error bar indicates the 
standard error mean of three independent experiments. *P < 0.05 vs untreated control. 
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3.7 SIGNALING PATHWAYS ANALYSIS 
Antiproliferative, antimetastatic, and induction of apoptosis is usually the result 
of a series of events known as signal transduction. Treatment with Phyllanthus will 
usually lead to receptor binding which in turn stimulates or inhibits a particular 
signaling cascade that is made up of various components to exert a biological response. 
Various signaling pathways could be activated or suppressed at the same time to cause 
the different inhibitory activities in cancer cells. 
3.7.1 DETERMINATION OF SIGNALING PATHWAYS AFFECTED BY 
PHYLLANTHUS 
In order to find out the pathways that were affected by Phyllanthus to exert its 
anticancer activities, a cignal finder cancer 10-pathway reporter array was used as it 
permits the concurrent screening of 10 major cellular pathways. The pathways included 
in this array include Wnt, Notch, p53/DNA damage, TGFβ, Cell cycle/pRb-E2F, NFκB, 
Myc/Max, Hypoxia, MAPK/ERK, and MAPK/JNK, with GFP construct plasmid DNA 
as the positive control for this array. As shown in Figures 3.52 (aqueous and methanolic 
extracts-treated A549) and 3.53 (aqueous and methanolic extracts-treated MCF-7), the 
expression of GFP construct was consistent in both the extracts-treated and untreated 
control cells, hence the results obtained were deemed valid.  
Among the 10 pathways studied, NFκB, Myc/Max, Hypoxia, and MAPK (ERK 
and JNK) pathways were highly expressed in untreated A549 as compared to the other 
pathways (Figure 3.52), therefore suggesting their major role to ensure A549 cells 
growth and survival. Upon treatment with various aqueous and methanolic extracts, 
most of these pathways’ expression decreased significantly (p < 0.05) except for NFκB 
which indicate Phyllanthus probably did not modulate this pathway to cause cell growth 
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or metastasis inhibition. However, aqueous Phyllanthus extracts showed better 
inhibitory activity on the expression of both ERK (20 - 43% reduction) and JNK (44 - 
50% reduction) pathways, while the methanolic extracts showed enhanced inhibition on 
the expression of Hypoxia (42 - 76% reduction) and Myc/Max (92 - 97% reduction) 
pathways. Among the four plant species, P. watsonii exhibited greatest suppression on 
Hypoxia (aqueous – 60% and methanolic – 86%), ERK (aqueous – 47% and methanolic 
– 27%), and JNK (aqueous - 50% and methanolic – 26%) pathways, followed by P. 
urinaria, P. amarus, and P. niruri. On the other hand, other pathways including Wnt, 
Notch, p53/DNA damage, TGFβ as well as cell cycle/pRb-E2F could be playing 
insignificant roles in A549 since they were lowly expressed in both the treated and 
untreated cells. From the flow cytomery-based cell cycle analysis (Section 3.2.1.3), we 
did not observe cell cycle phase arrest in the A549 cells treated with Phyllanthus 
extracts since the percentage of gated cells for each cell cycle phases (G0/G1, S, and 
G2/M) did not change significantly (p > 0.05) between the untreated and extracts-treated 
cells. Thus, this further explained the low expression level of cell cycle/pRb-E2F 
pathway obtained in this assay for both the untreated and treated A549 cells. 
Likewise, Myc/Max, Hypoxia, and JNK pathways were highly expressed in 
untreated MCF-7 as compared to the other pathways (Figure 3.53). Thus, these 
pathways are most likely constitutively activated by MCF-7 cells to guarantee their 
continuous growth and survival. However, treatment with various aqueous and 
methanolic Phyllanthus extracts reduced the expression of these pathways significantly 
(p < 0.05), leading to an inhibition of cell growth and metastasis. Comparing the effect 
of both extracts, methanolic Phyllanthus generally demonstrated approximately 10 – 
20% increased inhibitory activity on those pathways than the aqueous extracts. There 
were no significant differences (p > 0.05) between the four Phyllanthus species 
although P. urinaria might appear to be a little more effective in inhibiting those 
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pathways. NFκB is probably another pathway utilized by MCF-7 to ensure their growth 
due to its high expression in the untreated cells. Yet, data obtained suggests that both 
aqueous and methanolic Phyllanthus did not modulate this pathway to exert 
antiproliferative action except for methanolic P. niruri and P. watsonii that showed 
significant differences (p < 0.05) than the untreated cells. Besides that, cell cycle/pRb-
E2F pathway was also observed to be expressed in untreated MCF-7 and showed 
reduction after extracts treatment. However, their percentages of expression were 
noticed to be lower than the GFP construct expression and for that reason, its 
contribution in suppression of cell growth and survival was inconclusive. Nevertheless, 
results obtained from flow cytometry-based cell cycle analysis (Section 3.2.3) 
confirmed that Phyllanthus did not exhibit cell cycle phase arrest in the MCF-7 cells. 
Other pathways including Wnt, Notch, p53/DNA damage, as well as TGFβ were also 
not involved in MCF-7 to ensure their growth and survival due to low expressions in 
both the untreated and extracts-treated cells. 
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Figure 3.52: Expression level of ten cellular signalling pathways in A549 as determined by cignal finder cancer 10-pathway reporter array. 
Figure above shows the expression level of pathways in A549 cells treated with (a) aqueous Phyllanthus extracts and (b) methanolic Phyllanthus 
extracts. PN – P. niruri; PU – P. urinaria; PW – P. watsonii; PA – P. amarus. Error bar indicates the standard error mean of three independent 
experiments. *P < 0.05 vs untreated control. 
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Figure 3.53: Expression level of ten cellular signalling pathways in MCF-7 as determined by cignal finder cancer 10-pathway reporter array. 
Figure above shows the expression level of ten pathways in MCF-7 cells treated with (a) aqueous Phyllanthus extracts and (b) methanolic Phyllanthus 
extracts. PN – P. niruri; PU – P. urinaria; PW – P. watsonii; PA – P. amarus. Error bar indicates the standard error mean of three independent 
experiments. *P < 0.05 vs untreated control. 
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3.7.2 WESTERN BLOTTING OF SIGNALING PATHWAYS AFFECTED BY 
PHYLLANTHUS 
Phyllanthus was shown to suppress MAP kinases and Hypoxia pathways to 
inhibit A549 and MCF-7 cell’s growth, survival, and metastasis. However, it was 
unclear as to which specific protein within the pathway was targeted by Phyllanthus to 
suppress its activation since the pathways cascade involves many different kinases and 
proteins (Figure 3.54). So, western blots were performed with available antibodies 
(Anti-pan-Ras, anti-c-Raf, anti-c-Myc, anti-Bcl-2, anti-Hif-1α, anti-c-Jun/AP-1, anti-
p53, anti-Elk1, anti-JNK1/2, anti-VEGF, and anti-RSK) to determine the specific targets 
of Phyllanthus, whether it affects during the early or late stages of the cascade. Figure 
3.55 shows the blots for untreated A549 control as well as the A549 treated with various 
aqueous and methanolic extracts while Figure 3.56 depicted the expression level of each 
protein. Similarly, Figure 3.57 represents the blots for untreated MCF-7 control as well 
as the cells treated with various aqueous and methanolic extracts while Figure 3.58 
illustrated the expression level of each protein. In both untreated A549 and MCF-7 
cells, the proteins detected were Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, and HIF-1α. 
The presence of these proteins reflects the specific involvement of MAPK/ERK and 
Hypoxia pathways in regulating the cells growth and survival. In addition, Bcl-2 protein 
was also detected in both untreated A549 and MCF-7 which explains its role as an 
antiapoptotic agent in cancer cells to ensure their survival (Teijido & Dejean 2010).  
As expected, Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, HIF-1α, Bcl-2, and 
FUSE-binding proteins’ expressions were decreased when A549 was treated with 
various Phyllanthus extracts (Figures 3.55 and 3.56). Among the four species, P. 
urinaria shows better inhibition on those proteins, followed by P. amarus, P. watsonii, 
and P. niruri for both the aqueous and methanolic extracts. However, expression of Pan-
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Ras and Elk-1 proteins were only mildly affected as compared to the other proteins. 
Besides that, FUSE-binding proteins were also detected although antibody specific to 
this protein was not included in this experiment. This could be attributed to its role for 
proper regulation of the c-Myc protooncogene (Weber et al. 2008), hence having certain 
percentage of similarity with c-Myc protein and was therefore detected when c-Myc 
antibody was used. P53 expression was also hardly seen in both the treated and 
untreated A549 cells via western blot technique and this confirmed the finding obtained 
from the previous cancer 10-pathway array that demonstrated to be low p53 expression 
in A549. 
Likewise, the expressions of Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, HIF-1α, 
and Bcl-2 proteins were decreased when MCF-7 was treated with different aqueous and 
methanolic Phyllanthus extracts (Figures 3.57 and 3.58). Generally, methanolic extracts 
exhibited better suppression on these proteins compared to the aqueous extracts, in 
particular methanolic P. watsonii and P. amarus. Similar phenomenon was also 
observed among aqueous extracts whereby both P. watsonii and P. amarus showed 
enhanced activity than the other two species. Decreased expression of HIF-1α might 
also contribute to the suppression of cell metastasis and survival that is further 
supported by the evidence of decreased Bcl-2 expression that predisposes MCF-7 to 
apoptosis. Nonetheless, p53 expression remained undetected in both treated and 
untreated MCF-7 cells. 
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Figure 3.54: Pathways cascade activation. 
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Figure 3.55: Western blotting of pathways activated in A549 in response to Phyllanthus 
extracts. 
Expression levels of Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, HIF-1α, Bcl-2, and 
FUSE-binding proteins in (A) untreated A549 cells and cells treated with (B) aqueous 
P. niruri; (C) aqueous P. urinaria; (D) aqueous P. watsonii; (E) aqueous P. amarus; (F) 
methanolic P. niruri; (G) methanolic P. urinaria; (H) methanolic P. watsonii; (I) 
methanolic P. amarus. Green boxes indicate the protein spots corresponding to the 
proteins that are numbered. Typical results from three independent experiments are 
shown. 
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Figure 3.56: Percentage of individual protein expressions in untreated and Phyllanthus-treated A549 analyzed using Image J software. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; Control – untreated cells. *P < 0.05 vs untreated control. 
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Figure 3.57: Western blotting of pathways activated in MCF-7 in response to 
Phyllanthus extracts. 
Expression level of Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, HIF-1α, and Bcl-2 
proteins in (A) untreated MCF-7 cells and cells treated with (B) aqueous P. niruri; (C) 
aqueous P. urinaria; (D) aqueous P. watsonii; (E) aqueous P. amarus; (E) aqueous P. 
amarus; (F) methanolic P. niruri; (G) methanolic P. urinaria; (H) methanolic P. 
watsonii; (I) methanolic P. amarus. Green boxes indicate the protein spots 
corresponding to the proteins that are numbered. Typical results from three independent 
experiments are shown.  
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Figure 3.58: Percentage of individual protein expressions in untreated and Phyllanthus-treated MCF-7 analyzed using Image J software. 
APN - aqueous P. niruri; APU - aqueous P. urinaria; APW - aqueous P. watsonii; APA - aqueous P. amarus; MPN - methanolic P. niruri; MPU - 
methanolic P. urinaria; MPW - methanolic P. watsonii; MPA - methanolic P. amarus; Control – untreated cells. *P < 0.05 vs untreated control. 
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3.7.3 DIFFERENTIALLY EXPRESSED PROTEINS IN PHYLLANTHUS-
TREATED CELLS 
MAPK/ERK and Hypoxia cellular signaling pathways were shown to be 
targeted by Phyllanthus to exert an inhibitory effect on cancer cells growth and 
metastasis. Perturbation of these pathways will eventually lead to the expression of a 
differential array of proteins in the treated cancer cells as demonstrated by the two-
dimensional gel electrophoresis analysis. Figures 3.59 and 3.60 presented 2D-PAGE 
gels for untreated control, aqueous Phyllanthus-treated, and methanolic Phyllanthus-
treated A549 samples. PD-Quest software analysis picked out 68 and 79 protein spots 
differentially expressed in aqueous and methanolic extracts-treated groups respectively. 
Subsequent mass spectrometry analysis and database examination using MASCOT 
identified 52 protein spots significantly downregulated by aqueous Phyllanthus extracts. 
Figure 3.61A depicts the categorization of these proteins according to Clusters of 
Orthologous Groups (COGs) classification while Table 3.4 lists the important proteins 
that play an essential role in post-translational modification, protein turnover, and 
chaperones  (17%), cytoskeleton (11%), energy production and conversion (11%), 
transcription (4%), as well as drug detoxification and survival (6%). Meanwhile, 64 
proteins significantly suppressed by methanolic Phyllanthus extracts were grouped as 
shown in Figure 3.61B and Table 3.5 where most of these proteins fell into the category 
of signal transduction mechanisms (16%), transcription (11%), drug detoxification and 
survival (9%), energy production and conversion (3%), as well as cytoskeleton (2%). 
Likewise, Figures 3.62 and 3.63 showed representative 2D-PAGE gels for 
untreated control, aqueous Phyllanthus-treated, and methanolic Phyllanthus-treated 
MCF-7 samples. Proteomic analysis identified 62 and 61 protein spots differentially 
expressed in MCF-7 cells treated with aqueous and methanolic extracts respectively. 
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Examination of these proteins recognized 42 protein spots that were significantly 
downregulated by aqueous Phyllanthus extracts. These protein spots were consequently 
classified according to Clusters of Orthologous Groups (COGs) classification (Figure 
3.64A) where majority of them fell into the category of energy production and 
conversion (31%), cytoskeleton (24%), post-translational modification, protein 
turnover, and chaperones (12%), RNA processing and modification (10%), as well as 
drug detoxification and survival (2%) as tabulated in Table 3.6. For methanolic 
Phyllanthus extracts, 59 protein spots significantly suppressed in MCF-7 cells were 
categorized (Figure 3.64B) with most of these proteins falling into the category of 
cytoskeleton (32%), energy production and conversion (17%), post-translational 
modification, protein turnover, and chaperones (13%), RNA processing and 
modification (13%), as well as drug detoxification and survival (2%) as shown in Table 
3.7. 
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Figure 3.59: 2D-PAGE gels for A549 treated with aqueous Phyllanthus extracts. 
Figure above is showing the representative gels for (A) untreated A549 cells and cells 
treated with (B) aqueous P. niruri; (C) aqueous P. urinaria; (D) aqueous P. watsonii; 
(E) aqueous P. amarus. Typical result from three independent experiments is shown. 
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Figure 3.60: 2D-PAGE gels for A549 treated with methanolic Phyllanthus extracts. 
Figure above is showing the representative gels for (A) untreated A549 cells and cells 
treated with (B) methanolic P. niruri; (C) methanolic P. urinaria; (D) methanolic P. 
watsonii; (E) methanolic P. amarus. Typical result from three independent experiments 
is shown. 
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Figure 3.61: Clusters of Orthologous Groups (COGs) classification of identified 
proteins in A549 cells. 
Grouping of differentially expressed proteins in A549 cells treated with (A) aqueous 
Phyllanthus extracts and (B) methanolic Phyllanthus extracts according to COGs 
classification. 
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Table 3.4: Classification of identified proteins of A549 downregulated (-) in the 
presence of aqueous Phyllanthus extracts 
Spot 
ID 
Proteins Fold change 
APN APU APW APA 
Post-translational modification, protein turnover, and chaperones 
4 Proteasome subunit beta type 3  -1.00 -0.20 N/A -1.00 
7 Heat-shock protein beta-1  -0.12 -0.22 -0.32 -0.10 
10 60 kDa heat shock protein, mitochondrial precursor -0.46 -0.82 -0.90 -0.75 
15 Peptidyl-prolyl cis-trans isomerase A  -0.13 -0.36 -1.00 -0.42 
16 Peptidyl-prolyl cis-trans isomerase A  -1.00 -1.00 -0.32 N/A 
26 Stress-70 protein, mitochondrial precursor  -0.19 -0.22 N/A N/A 
39 T-complex protein 1 subunit epsilon  -0.89 N/A -0.20 -0.97 
40 Stress-induced-phosphoprotein 1  -0.54 -0.62 -0.44 -0.21 
Cytoskeleton 
1 Actin, cytoplasmic 1  -0.81 -0.88 -0.95 -0.84 
14 Vimentin -0.91 -0.82 -0.24 -0.79 
19 Tubulin alpha-8 chain -0.80 -0.37 N/A -0.80 
27 Actin-related protein 2/3 complex subunit 5  -1.00 -1.00 -1.00 -1.00 
46 Cofilin-1 -0.76 N/A -0.85 -0.38 
Energy production and conversion 
3 Alpha-Enolase -0.62 -0.57 -0.48 -0.58 
8 Glyceraldehyde-3-phosphate dehydrogenase -0.30 -0.93 -0.99 -0.91 
17 Glyceraldehyde-3-phosphate dehydrogenase -1.00 -0.50 -1.00 -0.71 
47 ADP-ribosylation factor 1 -1.00 -0.21 -0.15 -1.00 
48 Fructose-bisphosphate aldolase A -1.00 -1.00 -1.00 -1.00 
50 Phosphoglycerate mutase 1 -1.00 -1.00 -1.00 -1.00 
51 Triosephosphate isomerase -1.00 -1.00 -1.00 -1.00 
Transcription 
9 Eukaryotic translation initiation factor 5A-1  -0.32 -0.39 -0.27 -0.80 
25 40S ribosomal protein S19 -0.30 -0.30 -0.15 -0.38 
30 40S ribosomal protein S24 -1.00 -1.00 -1.00 -1.00 
52 Eukaryotic translation initiation factor 5A-1  -1.00 -1.00 -1.00 -1.00 
Drug detoxification 
11 Glutathione transferase omega-1 N/A -0.45 N/A -0.22 
13 Annexin A4  -0.29 -0.29 -0.21 -0.65 
Survival  
33 Peroxiredoxin-1  -0.08 -0.56 -1.00 -0.33 
APN – aqueous P. niruri; APU – aqueous P. urinaria; APW – aqueous P. watsonii, 
APA – aqueous P. amarus; N/A – Not Affected. 
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Table 3.5: Classification of identified proteins of A549 downregulated (-) in the 
presence of methanolic Phyllanthus extracts 
Spot 
ID 
Proteins Fold change 
MPN MPU MPW MPA 
Signal transduction mechanisms 
13 Probable G-protein coupled receptor 179 precursor -0.21 -0.15 -1.00 N/A 
23 Serine/threonine-protein kinase 6 -1.00 -0.96 -0.19 -1.00 
27 Putative Ras-related protein Rab-42 -1.00 N/A -0.97 -0.80 
35 GTPase HRas precursor  -0.60 -0.66 -0.59 -0.61 
63 Guanine nucleotide-binding protein gamma-5-like 
subunit -1.00 -1.00 -1.00 -1.00 
Transcription 
10 DNA-directed RNA polymerase II 16 kDa 
polypeptide -0.46 -0.59 -0.43 -0.93 
11 39S ribosomal protein L40, mitochondrial precursor  -1.00 -1.00 -1.00 -1.00 
12 Zinc finger protein 174  -1.00 -1.00 -1.00 -1.00 
20 Proliferating cell nuclear antigen  -1.00 -1.00 -1.00 -1.00 
22 Eukaryotic translation initiation factor 3 subunit 12  -1.00 -1.00 -1.00 -1.00 
31 DNA-directed RNA polymerase II 16 kDa 
polypeptide  -0.42 -0.48 -0.48 -0.45 
33 Transcription elongation factor B polypeptide 1  -0.58 -0.59 -0.56 -0.79 
52 DNA-directed RNA polymerase II 16 kDa 
polypeptide  -1.00 -1.00 -1.00 -1.00 
Drug detoxification 
7 Glutathione synthetase -0.38 -0.79 -1.00 -0.51 
34 Metallothionein-1M  -0.55 -0.52 -0.48 -0.48 
47 Metallothionein-2 -0.71 -0.17 -0.14 -0.53 
49 Metallothionein-1H  -0.52 -0.48 N/A -0.29 
50 Metallothionein-2  -0.34 -0.59 -0.49 -1.00 
59 Glutathione synthetase  -0.50 -0.45 -0.38 -0.61 
62 Metallothionein-1L -0.86 -0.79 -0.96 -0.44 
Energy production and conversion 
39 ADP-ribosylation factor-like protein 6 -0.58 -0.52 -1.00 -0.29 
40 Alpha-enolase -0.27 -0.51 N/A -0.56 
Survival 
4 Peroxiredoxin-1  -0.78 -1.00 -1.00 -1.00 
16 Bcl-2-like protein 11  -0.25 -1.00 -1.00 -0.70 
Cytoskeleton 
60 Actin-related protein 10  -0.94 -0.70 -0.13 -0.73 
MPN – methanolic P. niruri; MPU – methanolic P. urinaria; MPW – methanolic P. 
watsonii, MPA – methanolic P. amarus; N/A – Not Affected. 
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Figure 3.62: 2D-PAGE gels for MCF-7 treated with aqueous Phyllanthus extracts. 
Figure above is showing the representative gels for (A) untreated MCF-7 cells and cells 
treated with (B) aqueous P. niruri; (C) aqueous P. urinaria; (D) aqueous P. watsonii; 
(E) aqueous P. amarus. Typical result from three independent experiments is shown. 
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Figure 3.63: 2D-PAGE gels for MCF-7 treated with methanolic Phyllanthus extracts. 
Figure above is showing the representative gels for (A) untreated MCF-7 cells and cells 
treated with (B) methanolic P. niruri; (C) methanolic P. urinaria; (D) methanolic P. 
watsonii; (E) methanolic P. amarus. Typical result from three independent experiments 
is shown. 
  
183 
 
 
Figure 3.64: Clusters of Orthologous Groups (COGs) classification of identified 
proteins in MCF-7 cells. 
Grouping of differentially expressed proteins in MCF-7 cells treated with (A) aqueous 
Phyllanthus extracts and (B) methanolic Phyllanthus extracts according to COGs 
classification. 
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Table 3.6: Classification of identified proteins of MCF-7 downregulated (-) in the 
presence of aqueous Phyllanthus extracts 
Spot 
ID 
Proteins Fold change 
APN APU APW APA 
Energy production and conversion 
1 Pyruvate kinase isozymes M1/M2 -0.96 -0.42 -0.70 -0.67 
3 Alpha-Enolase -0.41 -0.64 -0.47 -0.34 
6 ATP synthase subunit alpha, mitochondrial precursor -0.32 -0.47 -0.10 -0.53 
22 Pyruvate kinase isozymes M1/M2 -0.34 -0.21 -0.32 -0.25 
24 Glyceraldehyde-3-phosphate dehydrogenase -0.72 -0.75 -0.20 -0.57 
27 Glyceraldehyde-3-phosphate dehydrogenase -0.83 -0.38 -0.96 -0.13 
34 Glyceraldehyde-3-phosphate dehydrogenase -0.50 -0.60 -0.39 -0.64 
35 Triosephosphate isomerase -0.98 -0.83 -0.74 -0.76 
40 Glyceraldehyde-3-phosphate dehydrogenase -1.00 -1.00 -1.00 -1.00 
41 L-lactate dehydrogenase A chain -1.00 -1.00 -1.00 -1.00 
42 Beta-Enolase -1.00 -1.00 -1.00 -1.00 
Cytoskeleton 
4 Tubulin beta-5 chain -0.11 -0.84 -1.00 -0.34 
10 Actin, cytoplasmic 2  -1.00 -0.55 -0.88 -1.00 
11 Tubulin beta-5 chain  -0.32 -0.49 -0.33 -0.21 
12 Actin, alpha cardiac muscle 1  -0.62 -0.12 N/A -0.28 
20 Cofilin-1 -0.59 N/A -0.15 -0.21 
21 Annexin A2  -0.14 -1.00 -1.00 N/A 
36 Cofilin-1 -1.00 -1.00 -1.00 -1.00 
39 Stathmin  -1.00 -1.00 -1.00 -1.00 
Post-translational modification, protein turnover, and chaperones 
14 Heat shock protein HSP 90-beta -0.39 -0.55 -0.30 -0.37 
16 10 kDa heat shock protein, mitochondrial  -0.57 -1.00 -0.51 -1.00 
18 Heat shock cognate 71 kDa protein  -0.49 -0.57 -0.30 N/A 
RNA processing and modification 
15 Heterogeneous nuclear ribonucleoprotein A1 -0.40 -0.45 -0.39 N/A 
19 Heterogeneous nuclear ribonucleoproteins A2/B1 -0.45 -0.24 -0.19 -0.10 
26 Heterogeneous nuclear ribonucleoproteins A2/B1 -0.28 N/A -0.30 N/A 
30 Heterogeneous nuclear ribonucleoprotein A1 N/A -1.00 -0.15 N/A 
Drug detoxification 
2 Annexin A2 -1.00 -1.00 -1.00 -1.00 
Survival 
17 Peroxiredoxin-1  -0.50 -0.25 -0.37 -0.26 
29 Peroxiredoxin-1  -1.00 -1.00 -0.25 -0.85 
33 Galectin-3  -0.66 -0.58 -0.46 -0.53 
APN – aqueous P. niruri; APU – aqueous P. urinaria; APW – aqueous P. watsonii, 
APA – aqueous P. amarus; N/A – Not Affected. 
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Table 3.7: Classification of identified proteins of MCF-7 downregulated (-) in the 
presence of methanolic Phyllanthus extracts 
Spot 
ID 
Proteins Fold change 
MPN MPU MPW MPA 
Cytoskeleton 
9 Tubulin alpha-ubiquitous chain  -0.43 N/A -0.30 -0.78 
10 Tubulin alpha-ubiquitous chain  -0.15 N/A -0.58 -0.24 
12 Actin, alpha cardiac muscle 1 precursor -0.38 N/A -0.13 -0.45 
16 Tubulin beta-5 chain  -0.96 -0.85 -0.95 -0.62 
19 Actin, alpha cardiac muscle 1 precursor -0.41 -0.70 -0.25 -0.10 
20 Tubulin beta-5 chain -0.41 N/A -0.15 -0.84 
21 Tubulin beta-5 chain -0.67 -1.00 -0.44 -0.36 
22 Actin, alpha cardiac muscle 1 precursor -0.87 -0.34 -0.74 -0.81 
23 Stathmin -0.56 N/A -0.38 -0.20 
34 Tubulin alpha-ubiquitous chain  -1.00 -0.65 -0.65 -1.00 
44 Tubulin alpha-ubiquitous chain -0.19 -0.11 -0.13 -0.26 
49 Filamin-A  -0.53 -0.61 -0.54 -0.86 
Energy production and conversion 
18 Phosphoglycerate kinase 1  -0.25 N/A -0.28 -0.41 
31 Alpha-Enolase -0.70 -0.09 -0.58 -0.68 
42 Aldose reductase -1.00 -0.82 -0.77 -0.96 
43 Pyruvate kinase isozymes M1/M2  -0.50 -0.09 -0.24 N/A 
46 Pyruvate kinase isozymes M1/M2 -0.22 -0.49 -0.51 N/A 
47 Phosphoglycerate mutase 1 -0.29 -0.09 -0.21 -0.24 
52  Phosphoglycerate kinase 1 -0.85 -0.50 -0.86 -0.87 
53 Triosephosphate isomerase -0.26 N/A -0.12 -0.34 
54 Glyceraldehyde-3-phosphate dehydrogenase -0.48 -0.69 -0.65 -0.78 
55 Glyceraldehyde-3-phosphate dehydrogenase -0.87 -0.51 -0.22 -0.47 
56 Glyceraldehyde-3-phosphate dehydrogenase -0.55 N/A -0.67 -0.82 
Post-translational modification, protein turnover, and chaperones 
27 Heat-shock protein beta-1  -0.12 N/A -0.29 -0.21 
35 Stress-70 protein, mitochondrial precursor  -0.53 N/A -0.54 -0.47 
36 Stress-70 protein, mitochondrial precursor  -0.51 -0.55 -0.20 -0.47 
57 60 kDa heat shock protein, mitochondrial precursor  -0.09 N/A -0.14 -0.21 
RNA processing and modification 
24 Splicing factor, arginine/serine-rich 3  -0.38 N/A -0.46 -0.50 
26 Heterogeneous nuclear ribonucleoprotein H N/A N/A -0.10 -0.43 
30 Heterogeneous nuclear ribonucleoprotein H -0.35 N/A -0.26 -0.17 
48 Heterogeneous nuclear ribonucleoprotein H3  -1.00 N/A -0.39 -1.00 
50 Elongation factor 2  -0.36 N/A -0.31 -0.21 
58 Heterogeneous nuclear ribonucleoproteins A2/B1  -0.81 -0.83 -0.81 -0.57 
59 Heterogeneous nuclear ribonucleoproteins A2/B1  -0.59 N/A -0.24 -0.60 
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‘Table 3.7, continued’ 
Survival 
11 Thioredoxin  -0.43 -0.26 -0.39 -0.41 
38 Peroxiredoxin-5, mitochondrial precursor -0.18 N/A -0.46 -0.66 
Drug detoxification 
13 Annexin A2  -0.70 -0.44 -0.33 -0.40 
17 Annexin A2  -0.45 -0.97 -0.51 -0.48 
25 Annexin A2  -0.34 -0.32 -0.39 -0.21 
28 Annexin A8  -0.21 N/A -0.29 -0.14 
29 Annexin A2  -0.64 -0.09 -1.09 -0.47 
MPN – methanolic P. niruri; MPU – methanolic P. urinaria; MPW – methanolic P. 
watsonii, MPA – methanolic P. amarus; N/A – Not Affected. 
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CHAPTER 4: DISCUSSION 
Statistics on cancer burden in terms of incidence, prevalence, and mortality are 
generally used to observe trends as well as for epidemiologic studies on the cause, 
prevention, and control measures of cancer. Results from these studies will guide the 
design, implementation, and assessment of comprehensive control programs for cancer 
disease (German et al. 2011). In 2008 alone, the number of new cancer cases and deaths 
worldwide were reported to be 12.7 million and 7.6 million respectively (Duffy et al. 
2012). This global cancer burden was projected to keep increasing and the most 
common cancers measured in relation to number of new cases were lung, breast, 
colorectal, stomach, and liver (Parkin et al. 2001). Lung cancer constitutes the greatest 
incidence and mortality rates with 1.6 million new cases and 1.4 million deaths each 
year, with less than 15% lung cancer patients reaching five years survival (Ye et al. 
2012). Breast malignancy is the most common malignancy in women with more than 
one million cancer incidences and 400,000 deaths each year (Yang et al. 2012). 
Cancer disease mainly poses a great deal of problems due to its capability to 
proliferate uncontrollably leading to the production of a bulky tumor mass that disrupts 
the normal organ functions (Raven et al. 2004). Following a cancer diagnosis, 
chemotherapy is the most frequently implemented treatment in conjunction with local 
therapies such as radiotherapy and surgery (Yang et al. 2012). Examples of the 
commonly used chemotherapeutic drugs for treatment of breast and lung cancers are 
Doxorubicin and Cisplatin, respectively. Doxorubicin (Adriamycin) is classified as a 
topoisomerase II poison as it inhibits the activity of this enzyme resulting in the 
genomic DNA breakage. Other mechanisms include intercalation between the DNA 
bases resulting in the blockage of DNA synthesis and transcription. It may also act 
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through sequestering irons followed by the generation of free radical. All these 
mechanisms lead to disruption of DNA that ultimately causes toxicity to cell (Swift et 
al. 2006). Meanwhile, Cisplatin causes formation of DNA adducts, which is the 
formation of complexes with DNA, resulting in the blockage of replication, 
transcription and repair mechanisms. The halting of the replication process is a result of 
the inhibitory action of the DNA adduct on the DNA polymerase, leading to cell 
toxicity (Zamble et al. 1998). Nevertheless in our study, Cisplatin and Doxorubicin not 
only showed strong cytotoxicity against both cancer cells (A549 and MCF-7), but also 
towards normal cells (NL20 and 184B5) with IC50 values generally lesser than 10g/ml. 
Therefore, they pose a wide variety of side effects such as nausea, vomiting, 
myelosuppression, neurological, mucositis, infertility, as well as lethargy, which were 
graded as mild, moderate, severe, life threatening, and death (Bhosle & Hall 2009). 
Moreover, cancer cells that normally respond to the chemotherapeutic agents initially 
will slowly develop drug resistance upon prolonged exposure leading to a more 
aggressive phenotype that is often capable of migration and distant metastasis (Ryu et 
al. 2011), hence resulting in high death rates every year which turns out to be the 
leading cause of cancer-related deaths (Ju et al. 2011, Kabir et al. 2011). Therefore, this 
therapy is still far from ideal since most of the cancer patients only benefit from their 
short-term efficacy (Karroum et al. 2010, Ju et al. 2011). 
Thus, the search for novel chemotherapeutic agents with higher selectiveness 
and effectiveness that surpass drug resistance and metastasis is crucial to improve the 
survival of patients with advanced or recurrent lung and breast cancers that have poor 
therapeutic efficacy and prognostic survival (Natarajan et al. 2011). In this connection, 
natural-product based drugs are gaining their popularity as preventive medicines or for 
health management and hence have spurred an intensive search for naturally occurring 
plant-derived anticancer compounds (Wong et al. 2012). Over the years, the plants of 
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the genus Phyllanthus from the family Euphorbiaceae, have gained reputation in folk 
and traditional medicine including ayurveda, siddha and traditional Chinese medicine 
for their myriad of healing properties. Numerous research studies on Phyllanthus spp. 
began in the late 1980’s with the clinical efficacy of Phyllanthus niruri against viral 
Hepatitis B being observed (Paranjpe 2001). In the current study, we aimed to 
investigate the antimetastatic activity of Phyllanthus on cancer cells. Prior to that, an 
effective dose which is non-toxic to the cells had to be determined. Hence, we initially 
evaluated the toxicity of both aqueous and methanolic crude extracts of four different 
species of Phyllanthus plants, namely P. niruri, P. urinaria, P. watsonii, and P. amarus, 
on two human cancer cell lines (A549 and MCF-7) and two normal human cell lines 
(184B5 and NL20). Our data showed that the crude Phyllanthus extracts were able to 
exhibit selective cytotoxicity against MCF-7 and A549 human cancer cells. Recently, 
pure natural products and roughly fractionated extracts are gaining their popularity in 
drug discovery as they would speed up the whole process from screening to a validated 
lead. Besides that, the cost will be greatly reduced when pure natural compound 
libraries are used as basic raw materials (Bindseil et al. 2001). Thus, the effects of two 
Phyllanthus fractions were also tested on both cancer and normal cell lines. 
Nevertheless, the first fraction was nontoxic or showed very little toxicity to cancer cells 
while the second fraction showed appreciable toxicity to both cancer cells and normal 
cells. Sun and Liu reported that not any individual class of components in an extract 
could be entirely held accountable for the activity produced by the whole extract itself 
(Sun & Hai Liu 2006). Therefore, it is more meaningful as well as prudent to assess the 
activity of Phyllanthus as a complete mixture of interacting bioactive compounds rather 
than evaluating them as a breakup of their individual components.  
The cytotoxic activities exhibited by natural products are mainly attributed to the 
presence of different bioactive compounds within the plant extracts (Issa et al. 2006, 
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Russo 2007, Gopalakrishnan & Tony Kong 2008). High Performance Liquid 
Chromatography (HPLC) analysis revealed the presence of various polyphenol 
compounds in both aqueous and methanolic Phyllanthus extracts. These polyphenol 
compounds were broadly classified into four categories; ellagitannins, gallotannins, 
flavonoids, and phenolic acids (Tang et al. 2010, Lee et al. 2011a). Different species of 
Phyllanthus plants have a variation in the quantity of each bioactive component, thus 
giving rise to the different extents of cytotoxicity to cancer cells. Among the four 
Phyllanthus species studied, P. urinaria and P. watsonii exhibited almost similar level 
of cytotoxicity to both A549 and MCF-7 cells in vitro, probably in part to the higher 
amount of polyphenol compounds present in their extracts. 
The half-maximal inhibitory (IC50) concentrations determined for each 
Phyllanthus crude extracts were then applied as the treatment conditions for the 
subsequent antimetastatic experiments. Malignant tumor progression depends largely on 
its capability to invade, metastasize, as well as to induce angiogenesis. Cancer 
metastasis is a complex process that normally begins with degradation of extracellular 
matrix of basement membrane, cell invasion, cell migration, and eventually tumor 
growth at distant metastatic sites. The crucial factor that affects the invasion and 
metastasis of tumor is the integrity of the basement membrane that holds the tumor cells 
together (Wang et al. 2009). During invasion process, the extracellular matrix (ECM) 
and the basement membrane components are often destroyed by a synergistic action of a 
number of proteolytic enzymes including the matrix metalloproteinases (MMPs), 
cysteine proteases, and serine proteases (Woodward et al. 2007, Yang et al. 2008a). 
From our data, Phyllanthus-treated cells exhibited greater difficulties to invade the 
extracellular matrix as compared to the untreated cells, hence suggesting the ability of 
Phyllanthus to inhibit the production of proteolytic enzymes, and thus limiting the 
invasive and metastatic capabilities of tumor cells.  
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Cell motility and adhesion are the next critical processes in metastasis upon the 
successful invasion of tumor cells into the blood or lymph capillaries. Since the lungs 
are the first organ that the detached tumor cells come upon most frequently, they 
become the main location for tumor metastasis (Kim et al. 2010). Data obtained from 
cell migration assays displayed that Phyllanthus has the ability to reduce migration of 
cancer cells. It can be argued that the reduction in cellular migration could be due to the 
cytotoxic effect exerted by Phyllanthus at high concentrations. However, a significant 
decrease of cellular mobility was also observed at IC50 and lower concentrations in 
which there were minimal cell death, indicating its ability to suppress and limit cell 
motility. Once the tumor cell is arrested at a particular organ, it must be able to adhere 
strongly before it can colonize and establish a secondary tumor at the new site. In this 
study, we showed that the Phyllanthus-treated cells had a diminished capacity to attach 
at a new location compared to the untreated cells. This ability of Phyllanthus to inhibit 
cell motility and adhesion can also be correlated with its ability to inhibit the 
invasiveness of cells since inhibition of proteolytic enzyme activities had been shown to 
be capable of reducing cells’ migration (Ha et al. 2004, Tanimura et al. 2005).  
In addition, we were interested to further investigate how Phyllanthus had 
caused the cells to lose their normal ability to metastasize, where our main hypothesis 
was that the cancer cells were dying due to Phyllanthus. A disseminating tumor cell 
faces the possibility of losing its viability during anytime throughout the metastasis 
process (Xie & Huang 2003). They could have died simply due to mechanical 
destruction during the invasion or migration process (necrosis), or by Phyllanthus 
triggered cell death (apoptosis or necrosis). Apoptosis typically involves a series of 
events (Yang et al. 2004), beginning with the release of cytochrome c from 
mitochondria, activation of a cascade of caspases, degradation of poly ADP-ribose 
polymerase (PARP), and finally the fragmentation of chromosomal DNA (Yang et al. 
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2006, Pojarova et al. 2007). As opposed to apoptosis, necrosis is usually associated with 
external damage leading to accidental cell death, resulting in mitochondrial and 
cytoplasmic swelling, followed by compromised membrane integrity that will 
eventually burst, releasing its cytoplasmic contents (Qiu et al. 1998, Woo et al. 2008). 
Based on our data, apoptosis occurred in the cells treated with Phyllanthus as the levels 
of these execution caspases were increased many fold over the basal level of untreated 
cells. This could be due to the presence of tannins (such as gallic acid and geraniin) in 
the Phyllanthus extracts which had been shown to be able to induce apoptosis in several 
human cancer cells (Lee et al. 2008, Harikumar et al. 2009). Activation of caspase-3 
will subsequently trigger the proteolytic cleavage of poly ADP-ribose polymerase 
resulting in DNA fragmentation that usually occurs during late apoptosis (Yang et al. 
2006, Wu et al. 2009). These DNA fragments appear as DNA ladder on an agarose gel 
instead of a randomized DNA breakdown which is observed as a smear in necrosis. 
However, internucleosomal DNA fragmentation is not universal, as it may not always 
occur during apoptosis (Vinatier et al. 1996). Nevertheless, further in situ staining of the 
DNA breaks confirmed the induction of apoptosis by Phyllanthus with the presence of 
TUNEL-positive cells.  
Although the data obtained suggest apoptosis as the mode of cell death, the 
complex phytochemical mixture of Phyllanthus species allows a possibility of necrosis 
as the other mechanism of action. Some of the cytotoxic agents have the ability to 
activate both apoptotic and necrotic cell death pathways (Woo et al. 2008). In addition, 
cells might also have died via necrosis as they invade or migrate through the membrane 
pores. Therefore, in order to differentiate between the dominant modes of cell death, 
release of lactate dehydrogenase (LDH) that is an indicator of necrosis was assessed in 
Phyllanthus-treated cells. Our data revealed that LDH levels released in Phyllanthus-
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treated cells remained low. Therefore, the possibility of necrosis as the main mode of 
cell death can be excluded. 
Even though the exact bioactive compounds in Phyllanthus exerting the 
antimetastatic and antiproliferative effects are not known yet, it is definite that 
Phyllanthus contains abundant flavonoids, phenolic acids and ellagitannins. Many of 
these bioactive compounds have been shown to exert antimetastatic and apoptosis-
inducing effects through activation of various mechanisms. For instance, gallic acid 
prevents the metastasis of AGS and U87 cells via inhibition of NF-κB activity, 
suppression of metalloproteinases activities, as well as downregulation of 
Ras/PI3K/AKT and Ras/MAPK signaling pathways (Ho et al. 2010, Lu et al. 2010). In 
addition, flavones and plant polyphenols have been shown to exert antimetastatic and 
antiinvasion activities by inhibiting matrix-degrading proteases (Tanimura et al. 2005, 
Yang et al. 2008b). Another phenolic compound, 5-caffeoylquinic acid isolated from 
Euonymus alatus has also been shown to be a strong MMP-9 inhibitor (Jin et al. 2005). 
Hence, the presence of flavonoids, phenolic acids, or ellagitannins in Phyllanthus plays 
a crucial role in its antimetastatic actions. 
Therefore, the subsequent phase in this study is to determine the underlying 
mechanisms that confer the antimetastatic and apoptosis-inducing abilities of 
Phyllanthus. Using 2DE-based proteomic approach, numerous differentially expressed 
proteins were identified in both A549 and MCF-7 cells in response to Phyllanthus 
treatments. In order to have a clearer understanding on how these affected proteins 
inhibit metastasis and proliferation of A549 and MCF-7 cells, a diagram was illustrated 
based on the findings obtained as shown in Figure 4.1. Both aqueous and methanolic 
Phyllanthus extracts were shown to modulate expression of different sets of proteins. 
Among the four Phyllanthus species, P. urinaria generally demonstrated the greatest 
inhibitory activity, closely followed by P. watsonii, P. amarus, and P. niruri. This could  
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Figure 4.1: Antiproliferative and antimetastatic mechanisms of Phyllanthus in A549 and 
MCF-7 cancer cells 
Phyllanthus plant at the background signifies an inhibition of the signaling molecules or 
cellular processes. 
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be delineated by the higher number of polyphenol compounds present in both the 
aqueous (9 out of 10 polyphenols) and methanolic (3 out of 4 polyphenols) P. urinaria 
extracts (Tang et al. 2010, Lee et al. 2011a), hence having a higher capability to cause 
antimetastatic activities on A549 and MCF-7 cells. Some of those proteins were 
represented by more than one spot, which represents different splicing forms of the 
same protein as a result of post-translational modification (Afjehi-Sadat et al. 2005).  
Thus, protein turnover, chaperones, and post-translational modification are 
indeed crucial to produce many variants of the common amino acid that possess 
distinctive structures and functions essential for tumor growth (Nalivaeva & Turner 
2001, Walsh & Jefferis 2006). In order to ensure uninterrupted cell growth, continuous 
protein synthesis is necessary. An accurate protein translational activity begins with 
RNA processing and modification, an important step immediately after transcription 
before translation into functional proteins or polypeptides (Alberts 2002). Hence, 
proteins that facilitate this particular step would be crucial as listed in Figure 4.1(A), 
such as heterogeneous nuclear ribonucleoproteins (hnRNPs), which are the RNA-
binding proteins required during mRNA maturation. Besides that, hnRNPs also interact 
with telomeres to promote reactivation of telomerase that is crucial during 
carcinogenesis (Hooven & Baird 2008). Another protein is arginine/serine-rich family 
of proteins which consist of essential pre-mRNA splicing factors that are critical for 
pre-mRNA splicing as well as in the consequent stages of post-transcriptional gene 
expression (Fu 1995, Sanford et al. 2005). The next step during protein synthesis is the 
translation of mRNA into proteins with the presence of a eukaryotic ribosome and its 
associating proteins. Therefore, 40S ribosomal protein is normally upregulated in the 
tumor cell as it is an essential component of the higher eukaryotic ribosome necessary 
for proper protein translational function (Ruvinsky & Meyuhas 2006). Eukaryotic 
translation initiation factor 3 subunit 12 is another important component as it binds to 
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poly(A)-binding protein to initiate translation process (Martineau et al. 2008). 
Meanwhile, elongation factor 2 functions to translocate peptidyl tRNA from the A site 
to the P site in the ribosome upon phosphorylation by CaM kinase III (Collodoro et al. 
2012). Downregulation of these proteins by Phyllanthus will lead to production of 
aberrant proteins that resulted in cell growth attenuation. 
Protein folding is the subsequent critical process upon successful protein 
translation to ensure formation of functional proteins as well as to ensure that they could 
pass through membranes and be integrated into their respective cellular organelles 
(Khalil et al. 2011). This step usually requires the presence of variety molecular 
chaperone proteins. One of these proteins is Hsp60 whose primary role is to guide the 
folding of mitochondrial proteins while facilitating proteolytic degradation of denatured 
or misfolded proteins in an ATP-dependent manner (Khalil et al. 2011). Activity of 
Hsp60 is normally regulated by its co-chaperone Hsp10 to control ATPase activity and 
substrate binding (Myung et al. 2004). Besides that, Hsp90 which is overexpressed in 
many tumor cell lines (Myung et al. 2004) is crucial to prevent misfolding and 
aggregation of pre-existing proteins under stress conditions (Martin & Hartl 1997). The 
stress-70 family of proteins such as Hsp70 also has a principal role in prevention of the 
premature misfolding of nascent polypeptides by cooperating with Hsp40 and Hip to 
help the activation of glucocorticoid receptors (Hartl & Martin 1995). Cells 
overexpressing Hsp70 are also protected against apoptosis via interaction with AIF to 
avoid chromatin condensation of induced nuclei (Ravagnan et al. 2001). Other 
chaperones include peptidyl-prolyl cis-trans isomerase A and T-complex protein 1 
subunit epsilon that also assist the proper folding of proteins (Yoo et al. 2001, Justice et 
al. 2005). Besides facilitating protein folding, chaperones also guide the proper 
assembly of other proteins for them to carry out their activities. An important example 
is stress-induced phosphoprotein 1 that facilitates association of molecular chaperones 
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Hsp70 and Hsp90 which were implicated in MMP2 activity that leads to increased 
invasiveness (Walsh et al. 2009). Suppression of these proteins by Phyllanthus is 
therefore one of the key processes for cancer cell growth and metastasis inhibition to 
reduce functional protein synthesis and suppress MMP expression.  
In addition to MMP2, suppression of other MMPs in response to Phyllanthus 
treatment was also observed including MMP7 and MMP9 (Figure 4.1(B)). The MMPs 
are a family of highly homologous, zinc- and calcium-dependent endopeptidases 
(Tanimura et al. 2005, Song et al. 2008). A genomic study done by Puente et al. 
discovered 24 distinct genes which encode for various MMPs (Puente et al. 2003), 
where MMP-2 and MMP-9 were more deeply associated with cancer invasion and 
metastasis. This is because their elevated expression has increased the metastatic 
potential of tumor cells and they had been known to be able to degrade type IV 
collagen-rich basement membrane of vessel wall (Jin et al. 2005, Tanimura et al. 2005) 
to access the vasculature to develop distant metastases (Chen et al. 2005). MMP2 is 
constitutively expressed and secreted in most tumor cells as a latent proenzyme form 
since they have the characteristics of housekeeping genes (Liu et al. 2002). Upon 
cleavage of its N-terminal propeptide by membrane-associated MMPs (MT1-MMP), 
MMP2 is activated leading to the proteolytic destruction of the basement membrane 
(Sen et al. 2009). Unlike MMP2, MMP9 is synthesized only when it was required and 
upon stimulation by various stimuli such as epidermal growth factors through their 
transmembrane receptors (Kondapaka et al. 1997). Its secretion was found to be 
upregulated particularly in multidrug resistant cancer that led to aggravation of its tumor 
invasiveness (Liu et al. 2002, Kim et al. 2009b, Karroum et al. 2010). MMP7 (28 kDa) 
is another member of the MMP family with broad substrate speciﬁcity against ECM 
components such as elastin, type IV collagen, ﬁbronectin, vitronectin, aggrecan, and 
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proteoglycans (Liu et al. 2007). Their reduced expression hence explained the decreased 
aggressiveness of A549 and MCF-7 cells’ invasion upon treatment with Phyllanthus. 
A constant activation of various growth-promoting signaling pathways is also 
required to ensure continuous cell growth and survival (Figure 4.1(C)). This activation 
often involves numerous proteins that require some form of modifications such as 
phosphorylation for their biological role. Thus, post-translational modiﬁcation process 
that alters the proteins properties is important (Li & Shang 2007, Crow & Xue-Bian 
2010). The first step for pathways activation often requires the presence of reception 
molecules on the cell surface for ligand binding. So, guanine nucleotide-binding protein, 
putative Ras-related protein Rab-42, GTPase HRas precursor protein, and ras-related 
protein Rab-11B which can be broadly grouped as G-proteins, as well as probable G-
protein coupled receptor 179 precursor expressions are usually elevated in the tumor 
cells to accommodate the large amount of extracellular signals to be transduced into the 
cells (Tuteja 2009). Both G-protein coupled receptor and G-proteins form the G-protein 
mediated signaling cascade whereby binding of ligands to receptors will lead to 
activation of G-proteins by promoting GDP/GTP exchange, which in turn regulates 
many effector molecules such as protein kinases (Tuteja 2009). Therefore, the 
subsequent upregulated protein in the tumor cell is serine/threonine-protein kinase 6 
which is a family of kinases including MAP kinase (Cross et al. 2000), which functions 
to turn on the downstream kinases via serine/threonine phosphorylation (Nishida & 
Gotoh 1993). Suppression of this cell signaling proteins by Phyllanthus will therefore 
decelerates or stops the constitutive activation of the growth-promoting pathways, 
ERK1/2 and hypoxia. 
ERK1/2 pathway is one of the MAP kinase subgroups that was frequently found 
to be inhibited in A549 and MCF-7 to repress cells’ continuous growth and metastasis 
as presented in Figure 4.1(D). In a study by Shih et al., α-tomatine found in tomatoes 
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was shown to be capable of inactivating extracellular signal-regulated kinase 1 and 2 
(ERK1/2) pathway to inhibit metastasis occurrence in A549 cell line (Shih et al. 2009). 
Similarly, A549 metastasis was inhibited by Silibinin isolated from Silybum marianum 
which suppresses ERK1/2 pathway that led to a reduced expression of MMP2 and u-PA 
concomitantly with a significant inhibition on cell invasion (Chen et al. 2005).  In a 
separate study by Kim et al., Silibinin also caused inactivation of Raf/MEK/ERK 
pathway to prevent MMP9 and VEGF expression in MCF-7 cells (Kim et al. 2009b). 
Indeed, our study also showed that Phyllanthus inhibited A549 and MCF-7 metastasis 
via targeting specifically ERK1/2 pathway. ERK1/2 module is often thought as a linear 
pathway since ERK is the effector of an evolutionarily conserved signaling component 
that is triggered exclusively by the Raf serine/threonine kinases (Hindley & Kolch 2002, 
Roberts & Der 2007). Thus, Phyllanthus might possibly downregulate Raf protein at the 
early stage of the pathway as demonstrated in A549 cells. Nevertheless, GTP-binding 
protein Ras is another upstream activator of the ERK1/2 pathway that has been shown 
to be a potent stimulus for MMPs (Liu et al. 2002). Montague et al. related the blockage 
of Ras/Rho/MAP kinase pathway to the inhibition of MMP expression since inhibition 
of Ras in vitro has been shown to stop MMPs production (Montague et al. 2004). So, 
Phyllanthus could also probably target inhibition of Ras protein as shown in MCF-7 
cells. Both Ras small GTPase and Raf kinase are the most commonly mutated 
oncogenes in a number of human cancers, hence explaining the importance of ERK1/2 
pathway in human oncogenesis (Roberts & Der 2007). Repression of these proteins by 
Phyllanthus therefore resulted in the subsequent suppression of other proteins’ 
expression down the pathway.  
One of the downstream transcription factors of ERK1/2 pathways suppressed 
include AP-1 (Figure 4.1(E)), which is a major transcription factor that has been 
associated with cancer metastasis via regulation of a number of genes involved in 
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apoptosis, cell proliferation, and MMPs production (Lee et al. 2011b). AP-1 is a dimeric 
protein consisting of either homodimers of c-Jun proteins or heterodimers of c-Jun and 
c-Fos proto-oncogenes (Scodelaro Bilbao et al. 2010). As shown via western blot 
analysis (Figures 3.55 and 3.57), suppression of AP-1 in both A549 and MCF-7 cells by 
Phyllanthus mainly involves inhibition of c-Jun proteins induction. Another 
downstream target gene of ERK1/2 includes the c-myc oncogene that is very commonly 
overexpressed in a variety of human cancers including lung and breast carcinomas. 
Downregulation of this gene could affect apoptosis as well as repressing cell cycle 
progression (Bocca et al. 2007). As a result, various biological activities controlled by 
ERK1/2 pathway to increase cell growth and malignancy are repressed, including 
regulation of transcriptional, cell cycle, apoptosis, and metastasis (Bachmann & Moroy 
2005). 
Transcription is an important biological activity in a cell as it is the first step for 
the transmission of genetic information from DNA into RNA to be translated into 
proteins (Solomon et al. 2008). With the suppression of the essential transcriptional 
proteins for eukaryotic chromosomal DNA replication such as DNA-directed RNA 
polymerase II 16kDa polypeptide, transcription elongation factor B polypeptide 1, and 
proliferating cell nuclear antigen, transcription initiation and elongation process 
becomes inefficient (Naryzhny 2008). Besides that, zinc finger protein 174 is a DNA 
binding protein by acting as a cofactor for transcription factor. Its downregulation will 
lead to increased transcription of proteins such as E-cadherin that in turn represses cell 
invasion (Comijn et al. 2001, Scicchitano et al. 2004). E-cadherin is a type of adherens 
junctions expressed on the epithelial cells to enable them to form a sheet or layers of 
cells that are tightly attached laterally (Yang & Weinberg 2008). However, they are 
often functionally inactivated or silenced by various mechanisms such as somatic 
mutations, transcriptional repressions or downregulation of gene expression during 
  
201 
 
tumor progression (Huber et al. 2005) in order for the carcinoma cells to release 
themselves from neighboring cells for invasion into adjacent cell layers (Yang & 
Weinberg 2008). Concurrent with the reduced E-cadherin expression, there is usually an 
increased N-cadherin expression and this phenomenon is known as epithelial to 
mesenchymal transition (Gravdal et al. 2007). Loss of E-cadherin in tumors was 
demonstrated to be one of the contributing factors for metastatic dissemination (Onder 
et al. 2008) while N-cadherin transcription in a prostate carcinoma cell line was found 
to be activated during metastasis (Alexander et al. 2006). Nevertheless, our results 
showed that Phyllanthus had the ability to reverse this epithelial to mesenchymal 
transition process with an increased cell-cell adhesion capability, probably due to 
enhanced expression of functional E-cadherin proteins on the cells’ surface. 
On the other hand, cell cycle disorder plays a critical role in cancer progression. 
So, modulation of cell cycle by phytochemicals from natural product sources is gaining 
worldwide attention to control carcinogenesis (Abdolmohammadi et al. 2008). 
However, our findings showed that cell cycle pathway was not modulated with the flow 
cytometric data showing insignificant shifts in each cell cycle phases for the cells 
treated with Phyllanthus extracts. Hence, cell cycle arrest was ruled out as one of the 
mechanism of actions of the extracts. Since Phyllanthus did not inflict cell cycle arrest 
on both A549 and MCF-7, the only approach to inhibit cells’ continuous growth is by 
causing toxicity. As shown previously, Phyllanthus does induce apoptosis in the cells 
with more than three-fold increase of caspases-3 and -7, the presence of DNA-
fragmentation and TUNEL-positive cells (Lee et al. 2011a). In order to determine 
whether Phyllanthus induces extrinsic or intrinsic apoptotic pathway, Bcl-2 expression 
was examined using western blot analysis since it is one of the main regulators of the 
mitochondrial outer membrane permeabilization which initiates intrinsic apoptotic cell 
death (Chipuk & Green 2008, Brunelle & Letai 2009). Agreeing to our hypothesis, the 
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data suggests that Phyllanthus probably activates the intrinsic pathway of apoptosis by 
inhibiting antiapoptotic Bcl-2 protein to release cytochrome c for caspases activation. In 
addition to this, proteomic analysis also observed downregulation of Bcl-2-like protein 
11 which is similar to bcl-2 protein that has a role as an antiapoptotic protein (Brunelle 
& Letai 2009).  
Furthermore, Phyllanthus extracts also suppressed cytoskeletal proteins such as 
actin, vimentin, tubulin alpha chain, actin-related protein, stathmin, and cofilin-1/2 
(Figure 4.1(F)). Besides being the components of the cytoskeleton, both actin and 
tubulin-binding proteins are also mediators of motility during cell migration and 
vascular remodelling (Murphy et al. 2008). Structure, conformational dynamics, and 
mechanical properties of actin filaments are mainly controlled by cofilin (Pfaendtner et 
al. 2010). On the other hand, tubulin dynamics was regulated by stathmin and 
transfection of this gene into lung cancer cell has been shown to increase their 
sensitivity to vinca alkaloids (Nishio et al. 2001). Meanwhile, vimentin constitutes the 
intermediate filaments of the cytoskeleton that stabilizes cytoskeletal interactions as 
well as affecting cell motility and movement. Elevated expression of vimentin in several 
invasive cell lines suggests the possibility of it being a representative marker for 
epithelial to mesenchymal transition (Walsh et al. 2009). Therefore, the significant 
inhibitory effects of Phyllanthus on the A549 cell’s cytoskeleton most probably involve 
the alteration of the microfilament organization and function, therefore suppressing 
motility, angiogenesis and metastasis (Fang et al. 2011).  
Hypoxia is largely perceived as another major obstacle to cancer therapy as 
increasing evidence in the cancer therapy-related literature suggests the involvement of 
proangiogenic factors in the tumor progression (Lin et al. 2011). Angiogenesis is 
essential for tumor growth and survival due to the imbalance of nutrient and oxygen 
supplies to solid tumors larger than 1mm3, resulting in tumor hypoxia (Dachs & Tozer 
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2000). In reaction to oxygen deprivation, transcription factor hypoxia-inducible factor-1 
(HIF-1), which is the chief mediator of angiogenesis and energy metabolism is normally 
upregulated (Li et al. 2006). HIF-1α is one of the major regulatory components of HIF 
(Figure 4.1(G)) and is observed in many solid tumors to ensure cell survival and to 
promote angiogenesis (Lin et al. 2011). This is in agreement with our findings that 
displayed high HIF-1α expression in the untreated A549 and MCF-7 cells. Therefore, 
HIF-1α could possibly be the target for the development of novel anticancer agents. Lin 
et al. demonstrated suppression of lung tumor angiogenesis and metastasis by 
andrographolide isolated from Andrographis paniculata which downregulates HIF-1α 
(Lin et al. 2011, Ye et al. 2012). In addition, inhibition of HIF-1α pathway by HIF-1α–
siRNA displayed a direct correlation with A549 cellular proliferation and angiogenesis, 
a prerequisite for metastasis (Hanze et al. 2003). Meanwhile, Lycium barbarum 
polysaccharides was found to be inhibiting angiogenesis in MCF-7 cells by reducing 
HIF-1α and VEGF expression levels (Huang et al. 2011). Downregulation of VEGF in 
MCF-7 by epigallocate-chin-3-gallate was also reported to suppress MMP2 activation, 
an essential gelatinase during blood vasculature formation or remodeling (Sen et al. 
2009). In agreement to these studies, our results obtained also showed the reduction of 
HIF-1α expression in both A549 and MCF-7 cells treated with Phyllanthus extracts. 
This in turn led to the suppression of various target genes controlled by HIF-1α via 
hypoxia-responsive-element (HRE) (Hanze et al. 2003), including vascular endothelial 
growth factor (VEGF) and inducible nitric oxide synthase (iNOS).  
VEGF is often overexpressed in malignant and nonmalignant cells as a response 
to numerous extracellular stimuli such as cytokine, oxygenous oxidants, growth factors, 
inflammation, and most importantly hypoxia (Kim et al. 2009b). It is a crucial 
angiogenic growth factor, which induces endothelial cell proliferation from the pre-
existing capillary bed for wound healing, tumor growth, and metastasis. Its expression is 
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therefore increased prior to an invasive and metastatic phenotype (Dachs & Tozer 
2000). Also iNOS, one of the three distinct isoforms of NOS which is widely expressed 
and often upregulated in multiple tumor tissues (Fitzpatrick et al. 2008) is expressed in 
tumor cells associated with vascularization and hence, is probably another important 
regulator of angiogenesis (Dachs & Tozer 2000, Fitzpatrick et al. 2008). It generates a 
generally higher amount of nitric oxide (NO) which contains tumor growth induction 
ability when present at low concentration (Loibl et al. 2006). Nitric oxide (NO) 
produced have been shown to affect vascular permeability, induces extracellular matrix 
degradation, triggers VEGF production, as well as stimulating endothelial cell 
proliferation and migration (Cullis et al. 2006). Hence, inhibition of VEGF and iNOS 
by Phyllanthus can greatly reduce A549 and MCF-7 angiogenesis, resulting in tumor 
cells malnutrition and hypoxia thereby preventing tumor growth, survival, and 
metastasis.  
In addition to its role as an angiogenic inducer, HIF-1α also upregulates glucose 
uptake and glycolytic enzymes as shown in Figure 4.1(H) to increase energy production 
in response to hypoxia, since one of the amazing characteristics of tumor is its ability to 
alter its metabolism including increased dependence on glucose utilization via 
glycolysis in order to produce ATP (Li et al. 2006). Adenosine 5’-triphosphate (ATP), a 
major source of energy for cells and its involvement in a variety of cellular activities 
that are ATP-dependent is often increased in tumor cells (Shigenaga et al. 1994). 
Downregulation of these enzyme activities by Phyllanthus causes cellular energy deficit 
that results in cancer cell death. This includes phosphoglycerate kinase 1 (PGK1) which 
converts 1,3-diphosphoglycerate to 3-phosphoglycerate. In addition to its role as a 
glycolytic enzyme, PGK1 gene is known to contain hypoxia responsive element (HRE) 
region which could transfer the hypoxic inducibility to other promoters both in vitro and 
in vivo (Bando et al. 2003). Knockdown of HIF-1α can therefore prevent the expression 
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of PGK1 during hypoxia (Li et al. 2006). Another downregulated protein was pyruvate 
kinase isozymes M1/M2 which is also a glycolytic enzyme induced by HIF-1 (Bando et 
al. 2003). This enzyme metabolizes phosphoenolpyruvate to sustain the high rate of 
glycolysis in cancer cells by donating the phosphate group to phosphoglycerate mutase 
(Chiaradonna et al. 2012) which subsequently catalyzed the conversion of 3-
phosphoglycerate to 2-phosphoglycerate (Pathania et al. 2009). Meanwhile, enolase 
catalyzes conversion of 2-phosphoglyceric acid (PGA) to phosphoenolpyruvate (PEP) 
in the anabolic pathway during gluconeogenesis to enhance aerobic glycolysis in cancer 
cells (Liu & Shih 2007). Elevated ATP synthase subunit alpha was also reported since it 
synthesizes most of the ATP in eukaryotes by transforming most of the energy from a 
gradient of ions across the membrane (Müller & Grüber 2003). Other glycolytic 
enzymes suppressed include lactate dehydrogenase A which converts pyruvate into 
lactate (Pelicano et al. 2006), glyceraldehyde-3-phosphate dehydrogenase that catalyzed 
glyceraldehydes-3-phosphate conversion into 1,3-biphosphoglycerate, as well as 
triosephosphate isomerase that facilitates reversible conversion of DHAP and 
glyceraldehyde-3-phosphate (Pathania et al. 2009). Suppression of these glucose uptake 
and glycolytic enzymes in cancer cells after Phyllanthus treatment could possibly 
deprive the cells of energy that lead them to their death fate. 
Besides exploiting cellular signaling pathways for their growth and metastasis, 
tumor cells possess various efficient drug detoxification (Figure 4.1I) and defense 
mechanisms (Figure 4.1J) to remove compounds that may be fatal to them. This include 
upregulation of glutathione transferase omega-1 that catalyzes binding of glutathione to 
various anticancer compounds such as cisplatin, thereby decreasing production of 
platinum-DNA adducts and rendering them useless while glutathione synthetase 
catalyzes production of glutathione substrate for the detoxifying activity (Polekhina et 
al. 1999, Stewart 2010). Similarly, metallothionein also plays a role in chemotherapy 
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binding and detoxification since its elevated expression was noticed in several cisplatin-
resistant lung cancer cell lines (Stewart 2010). In addition, Annexins are normally 
associated with chemoresistance in part by enhancing endocytosis, exocytosis, as well 
as ion channel activity for drug efflux (Zhang & Liu 2007, Kim et al. 2009a). 
Meanwhile, one of the protective mechanisms involves increased expression of 
galectin-3, a β-galactoside-binding protein that was associated with angiogenesis, cell 
proliferation, tumor progression, apoptosis, and metastasis. It is translocated into 
nucleus upon stimulation by apoptotic stimulus to inhibit cytochrome c release (Hooven 
& Baird 2008). Another defense mechanism include upregulation of peroxiredoxins 
which are antioxidant enzymes that eliminate reactive oxygen species such as H2O2 
using thioredoxin as immediate electron donor (Zhang & Liu 2007). Hence, 
thioredoxins in mammalian cells were also increased to ensure a reducing intracellular 
redox state by acting as reducing agents using thiol groups (Lillig & Holmgren 2007). 
Inhibition of these detoxification and protective enzymes expression in A549 and MCF-
7 after treatment with Phyllanthus as demonstrated from the proteomic analysis 
therefore advocates their reduced drug-resistance capability resulting in their 
susceptibility to death-inducing compounds. 
Apart from that, it is interesting to note that both A549 and MCF-7 are wild type 
p53-expressing cell lines (Sandhya & Mishra 2006, Sun et al. 2008). P53 is a versatile 
protein that triggers apoptosis via downregulating survival factors while upregulating 
proapoptotic factors (Fridman & Lowe 2003). Its activity is normally triggered in 
response to various cellular stresses such as chemo- or radiation-induced DNA 
damages, oncogene assaults, and oxidative stress to prevent cell survival (Chen et al. 
2010). For instance, epigallocatechin-3-gallate was shown to exclusively activate p53-
dependent pathway in A549 cells to induce apoptosis (Yamauchi et al. 2009). 
Furthermore, Gefitinib and zinc sulfate respectively demonstrated a phosphorylation of 
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p53 at Ser15 to stimulate tumor cell apoptosis (Chang et al. 2008, Nakagawa & 
Matsuoka 2008). Moreover, benzo(α)pyrene and selenocystine was shown to induced 
MCF-7 cell apoptosis via p53 phosphorylation at Ser392 in two separate studies 
(Tampio et al. 2008, Chen & Wong 2009). So, p53 involvement to inhibit cells’ survival 
was expected after treatment with Phyllanthus extract and yet, their expression was not 
significantly affected. This could be owing to the suppression or Hdm2-regulated 
degradation of p53 proteins via other cellular pathways which renders the p53 pathway 
nonfunctional (Wade et al. 2010). For example, dephosphorylation of p53 often leads to 
increased binding to its negative regulator, Hdm-2 resulting in enhanced ubiquitination 
and proteolysis of p53 (Vousden & Lane 2007). Otherwise, it could be attributed to the 
aberrant posttranslational modification of p53 that produces defective p53 proteins 
(Vousden & Lane 2007). Nevertheless, further research is necessary to confirm this 
hypothesis. 
4.1 CONCLUSION 
As presented in Figure 4.1, the anticancer activities demonstrated by Phyllanthus 
most probably is due to its capacity to suppress activation of ERK1/2 and hypoxia 
pathways in both A549 and MCF-7 cells. Phyllanthus suppresses ERK1/2 signaling 
mainly by preventing the stimulation of Ras and Raf kinase protein during the early 
stages of the pathway, hence leading to the reduced expression of other protein kinases 
downstream of the pathways including MEK1/2 and ERK1/2. Similarly, Phyllanthus 
also blocked the activation of HIF-1α subunit during hypoxia events, which in turn 
inhibited the association of HIF-1α and HIF-1β in the nucleus to form an active HIF-1 
protein. Decreased translocation of the activated ERK1/2 protein as well as a reduced 
amount of active HIF-1 protein in the nucleus will therefore block the activation of 
numerous transcription factors such as AP-1, c-Myc, and various promoters containing 
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hypoxia responsive element (HRE). These transcription factors govern a wide range of 
cellular biological activities and hence their diminished stimulation in response to 
Phyllanthus results in reduced expression of abundant genes.  
The first category of gene expression downregulated by Phyllanthus include the 
signal transduction components such as G proteins, G-protein coupled receptors and 
serine/threonine-protein kinase. Reduced expression of these receptors and their 
associated components on the cell surface produces a positive feedback loop 
phenomena, as increasingly lesser amounts of growth stimuli can be transmited into the 
cell. Inhibition of ERK1/2 pathway by Phyllanthus also leads to downregulation of 
various invasion and mobility proteins that are essential during cell metastasis while 
suppression of protein synthesis and transcriptional proteins expression cause the 
inability of the cells to proliferate continuously due to the lack of crucial cell replicative 
proteins. Meanwhile, inhibition of hypoxia pathway causes repression of the angiogenic 
proteins, VEGF and iNOS, resulting in the failure of the cancer cells to build new blood 
vessels that eventually reduces their chance to metastasize. Besides that, Phyllanthus 
also impair expression of various glucose uptake and glycolytic enzymes so that the 
cancer cells will become energy-deficient and die. Suppression of drug detoxification 
enzyme in cancer cells such as gluthathione transferase, gluthathione synthetase, 
metallothionein, and annexins also increases sensitivity of A549 and MCF-7 to 
Phyllanthus treatment. In addition, Phyllanthus also represses several proteins involved 
in the tumor’s survival mechanism, including antiapoptotic protein (Bcl-2), 
peroxiredoxins, thioredoxins, and galectin 3.  
Since Phyllanthus decreased the expression of numerous proteins in the cancer 
cells, they will not be able to grow uncontrollably and spread to the other organs. 
Devoid of the ability to proliferate nonstop, the cancer cells will not be able to thrive 
and will ultimately activate the cell death programme. Unlike the currently available 
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chemotherapeutic drugs, Phyllanthus have shown selectiveness where they target only 
the cancer cells without affecting the growth of normal cells, by mainly inducing 
apoptosis in the cancer cells that is associated with the activation of caspases-3 and -7 as 
well as DNA fragmentation. Meanwhile, the ability of Phyllanthus to stop metastasis is 
correlated with their inhibitory effects on the critical steps in metastasis, including cell 
invasion, migration, and adhesion. Furthermore, Phyllanthus had demonstrated the 
ability to reverse the endothelial-mesenchymal transition process, the foremost decisive 
factor for the cell metastasizing events. Generally, the antiproliferative and 
antimetastatic potential of Phyllanthus is most possibly attributed to the presence of 
abundant polyphenol compounds. Among the four Phyllanthus species tested in this 
study, P. urinaria was found to be the most effective to inhibit A549 and MCF-7 
growth and metastasis, closely followed by P. watsonii. 
Database search revealed only two reports that have reported the antimetastatic 
property of Phyllanthus thus far, and this study is one of those two. The study reported 
by Tseng et al. focused only on the effects of Phyllanthus urinaria on two different lung 
cancer cells (A549 and Lewis lung carcinoma), where their metastasis was inhibited by 
the suppression of MMP2 and MMP9 (Tseng et al. 2012). In contrary, the current study 
reported the effects of four Phyllanthus species on two different cancer cells, both lung 
(A549) and breast (MCF-7) cancers, thereby showing a broader spectrum of 
antimetastatic activity exerted by Phyllanthus. In addition to MMP2 and MMP9, MMP7 
was also found to be repressed in A549 cells to cause metastasis inhibition. Moreover, 
the underlying mechanisms in A549 and MCF-7 cells targeted by Phyllanthus to 
suppress the MMP expressions and eventually stop the cell metastasis and proliferation 
were also discovered. The molecular mechanisms of Phyllanthus reported here might 
aid those who are trying to develop this or other species as a potential antiproliferative 
or antimetastatic agent. 
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4.2 FUTURE WORK  
Phyllanthus could be a valuable candidate in the treatment of metastatic cancers. 
However, the main concern before application of Phyllanthus as an antimetastatic or 
antiproliferative agent is its in vivo effect. Hence, further testing of the extracts activity 
in vivo is necessary to investigate the antitumor effects of Phyllanthus on a tumor-
bearing mouse. The results obtained would provide information on the safe use of this 
plant for the development of potential anticancer compounds. 
The suitable mouse strain to be used in this antitumor study would be severe 
combined immunodeficient (SCID) mice. Numerous solid human tumors and 
hematological neoplasms for both cell lines and fresh biopsy tissues have been 
engrafted into SCID mice after the first report indicating the successful engraftment of 
SCID mice with human tumors was revealed. This human-SCID mouse chimeric model 
has been exploited for evaluation of a wide variety of anticancer compounds or 
therapies (Bankert et al. 2001, Belizário 2009). Preliminary work has identified low 
toxicity of Phyllanthus in SCID mice as a dosage greater than 50g/kg is needed to cause 
100% acute death in the mice tested. Meanwhile, the maximal non-toxic dose was 
determined to be 10g/kg. Development of a tumor-bearing mice model is still in 
progress before efficacy testing can be carried out. 
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APPENDICES  
APPENDIX 1: PREPARATION OF CULTURE MEDIA, REAGENTS, AND 
CHEMICALS 
1. Culture Media Preparation 
DMEM (HyClone) 
(13.4gram) 
RPMI (HyClone) 
(10.4gram) 
F-12 K 
(ATCC) 
Mammary 
Epithelial 
Growth Medium 
(Lonza) Sodium bicarbonate 
(Sigma Aldrich) 
(3.7gram/liter) 
Sodium bicarbonate 
(Sigma Aldrich) 
(2.0gram/liter) 
Dissolve in 1 liter of deionized water 
Filter sterilization through 0.2µm pore filter unit 
Growth media: Add 10% fetal bovine serum (JR Scientific) 
Maintenance media: Add 2% fetal bovine serum (JR Scientific) 
 
2. Common Use Reagents/Chemicals 
0.1% Coomasie Blue Dye (400ml) 
Chemicals Volume 
Coomasie blue R-350 (GE Healthcare) 1 tablet 
Deionized water 80.0ml 
Methanol 120.0ml 
20% Acetic acid in deionized water 200.0ml 
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Destaining Buffer (500ml) 
Chemicals Volume 
95% Ethanol 250.0ml 
100% Acetic acid 50.0ml 
Deionized water 200.0ml 
 
10% (w/v) Sodium dodecyl sulfate (SDS) 
Chemicals Volume 
SDS powder 10.0g 
Deionized water 100.0ml 
 
30% Acrylamide/Bisacrylamide 
Chemicals Volume 
Acrylamide 30.0g 
N,N’-methylenebisacrylamide 0.8g 
Deionized water 100.0ml 
 
Cell Lysis Buffer 
Chemicals Volume 
Urea 12.6g 
Thiourea 4.5g 
2% CHAPS 0.6g 
Triton X-100 1% (v/v) 
Dithiothreitol (DTT) 185.0mg 
Deionized water 30.0ml 
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12.5% SDS Polyacrylamide Resolving Gel 
Chemicals Volume Volume 
30% Acrylamide/Bisacrylamide 4.2ml 187.5ml 
1.5M Tris-HCl, pH8.8 2.5ml 112.5ml 
10% (w/v) SDS 100.0µl 4.5µl 
10% (w/v) APS 100.0µl 4.5µl 
100% TEMED 5.0µl 620.0µl 
Deionized water 3.5ml 140.5ml 
 
4% SDS Polyacrylamide Stacking Gel 
Chemicals Volume 
30% Acrylamide/Bisacrylamide 670µl 
0.5M Tris-HCl, pH6.8 1.3ml 
10% (w/v) SDS 50.0µl 
10% (w/v) APS 50.0µl 
100% TEMED 5.0µl 
Deionized water 3.1ml 
 
10× Laemmli/SDS Electrophoresis Buffer 
Chemicals Volume 
Tris base 30.0g 
Glycine 144.0g 
SDS 10.0g 
Deionized water Top up to 1000.0ml 
To prepare 1× Laemlli buffer, mix one part 10× Laemlli buffer with nine parts 
deionized water 
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Agarose Sealing Solution 
Chemicals Volume 
1× Laemmli buffer 10.0ml 
Agarose powder 50.0mg 
1% Bromophenol blue 20.0µl 
 
3. Reagents/Chemicals for DNA Fragmentation Assay 
Triton X-100 Lysis Buffer 
Chemicals Volume 
0.5M EDTA 40.0ml 
1M Tris-Cl buffer, pH8.0 5.0ml 
Triton X-100 5.0ml 
Deionized water 50.0ml 
 
4. Reagents/Chemicals for Zymography Assay 
2× Tris-Glycine SDS Sample Buffer 
Chemicals Volume 
0.5M Tris-HCl, pH6.8 2.5ml 
87% Glycerol 2.0ml 
10% (w/v) SDS 4.0ml 
0.1% Bromophenol blue 0.5ml 
Deionized water 10.0ml 
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12.5% SDS Polyacrylamide Resolving Gel with Gelatin or Casein 
Chemicals Volume 
30% Acrylamide/Bisacrylamide 4.2ml 
1.5M Tris-HCl, pH8.8 2.5ml 
10% (w/v) SDS 100.0µl 
10% (w/v) APS 100.0µl 
100% TEMED 5.0µl 
10% Gelatin or 20% Casein in deionized water 1.0ml 
Deionized water 2.5ml 
 
Renaturing Buffer (1000ml) 
Chemicals Volume 
100% Triton X-100 25.0ml 
Deionized water 975.0ml 
 
Developing Buffer 
Chemicals Amount 
Tris base 12.1g 
Tris-HCl 63.0g 
Sodium chloride 117.0g 
Calcium chloride 7.4g 
Brij35 0.2% (v/v) 
Deionized water top up to 1000.0ml 
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5. Reagents/Chemicals for Western Blot Assay 
10× Tris-Buffered Saline (TBS) Buffer  
Chemicals Volume 
Tris-HCl 24.3g 
Sodium chloride 80.1g 
6N Hydrochloric acid (HCl) adjust to pH7.6 
Deionized water top up to 1000.0ml 
 
5% Blocking Buffer  
Chemicals Volume 
1× TBS buffer 100.0ml 
Skimmed milk powder 5.0g 
 
TBS-Tween 20 Washing Buffer  
Chemicals Volume 
10× TBS buffer 100.0ml 
Tween 20 1.0ml 
Deionized water 900.0ml 
 
10× Transfer Buffer 
Chemicals Volume 
Tris-HCl 30.3g 
Glycine 144.1g 
Deionized water top up to 1000.0ml 
To prepare 1× transfer buffer, mix one part 10× transfer buffer with two parts 
methanol and seven parts deionized water 
 
 
 
  
240 
 
10× Ponceau S Dye 
Chemicals Volume 
Ponceau S 2.0g 
100% Acetic acid 10.0ml 
Deionized water 90.0ml 
Dilute one part 10× Ponceau S with nine parts deionized water before use 
 
DAB Substrate 
Chemicals Volume 
Substrate A 
4-chloro-1-napthol 0.15g 
Methanol 40.0ml 
1× TBS buffer 80.0ml 
Substrate B 
30% Hydrogen Peroxide 250.0µl 
1× TBS buffer 120.0ml 
To prepare working DAB substrate solution, mix one part of substrate A with one part 
of substrate B 
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6. Reagents/Chemicals for 2-Dimensional Gel Electrophoresis Assay 
Rehydration Buffer 
Chemicals Volume 
Urea 4.2g 
Thiourea 1.5g 
CHAPS 0.4g 
Triton X-100 1% (v/v) 
1% Bromophenol blue 20.0µl 
Deionized water 10.0ml 
Add 5.0µl IPG buffer and 2.8mg DTT to each milliliter of rehydration buffer before 
use 
 
Gel Fixative Solution 
Chemicals Volume 
95% Ethanol 400.0ml 
100% Acetic acid 100.0ml 
Deionized water 500.0ml 
 
SDS Equilibration Buffer 
Chemicals Volume 
1.5M Tris-HCl, pH8.8 10.0ml 
Urea 72.1g 
87% Glycerol 69.0ml 
SDS 4.0g 
1% Bromophenol blue 400.0µl 
Deionized water top up to 200.0ml 
Add 50.0mg dithiothreitol (DTT) or 125.0mg iodoacetamide (IAA) to 5.0ml of 
equilibration buffer before use 
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APPENDIX 2: EXAMPLE OF MASCOT SEARCH RESULT 
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APPENDIX 3: IDENTIFIED PROTEINS OF A549 AND MCF-7 DOWNREGULATED (-) IN THE PRESENCE OF PHYLLANTHUS 
EXTRACTS 
Table I: Identified proteins of A549 downregulated (-) in the presence of aqueous Phyllanthus extracts 
APN – aqueous P. niruri; APU – aqueous P. urinaria; APW – aqueous P. watsonii, APA – aqueous P. amarus; N/A – Not Affected. 
Spot 
ID 
Possible Proteins 
Fold change UNIPROT 
KB/SWISS-PROT 
Acc. Number 
Database 
APN APU APW APA 
1 Actin, cytoplasmic 1 -0.81 -0.88 -0.95 -0.84 P60709 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
2 Nicotinamide N-methyltransferase -0.50 N/A -0.28 -0.10 P40261 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
3 Alpha-Enolase -0.62 -0.57 -0.48 -0.58 P06733 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
4 Proteasome subunit beta type 3 -1.00 -0.20 N/A -1.00 P49720 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
5 Retinal dehydrogenase 1 -0.23 N/A -0.13 N/A P00352 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
6 Galectin-1 -1.00 -0.13 -0.57 -0.38 P09382 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
7 Heat-shock protein beta-1 -0.12 -0.22 -0.32 -0.10 P04792 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
8 Glyceraldehyde-3-phosphate dehydrogenase -0.30 -0.93 -0.99 -0.91 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
9 Eukaryotic translation initiation factor 5A-1 -0.32 -0.39 -0.27 -0.80 P63241 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
10 60 kDa heat shock protein, mitochondrial  -0.46 -0.82 -0.90 -0.75 P10809 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
11 Glutathione transferase omega-1 N/A -0.45 N/A -0.22 P78417 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
12 Proteasome activator complex subunit 1 -0.19 -0.18 N/A -1.00 Q06323 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
13 Annexin A4 -0.29 -0.29 -0.21 -0.65 P09525 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table I, continued’ 
14 Vimentin -0.91 -0.82 -0.24 -0.79 P08670 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
15 Peptidyl-prolyl cis-trans isomerase A -0.13 -0.36 -1.00 -0.42 P62937 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
16 Peptidyl-prolyl cis-trans isomerase A -1.00 -1.00 -0.32 N/A P62937 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
17 Glyceraldehyde-3-phosphate dehydrogenase -1.00 -0.50 -1.00 -0.71 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
18 
Voltage-dependent anion-selective channel 
protein 1 
-0.37 -0.19 -0.20 N/A P21796 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
19 Tubulin alpha-8 chain -0.80 -0.37 N/A -0.80 Q9NY65 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
20 Protein FAM24B precursor -0.51 -0.54 -0.66 -0.88 Q8N5W8 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
21 Interferon alpha-6 precursor -0.41 N/A -0.38 -0.75 P05013 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
22 ATP-dependent DNA helicase Q5 -1.00 -1.00 -0.93 -0.79 O94762 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
23 Sorting nexin-3 -0.25 -1.00 -1.00 -1.00 O60493 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
24 Gap junction beta-5 protein -0.36 -0.16 -0.32 -0.41 O95377 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
25 40S ribosomal protein S19 -0.30 -0.30 -0.15 -0.38 P39019 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
26 Stress-70 protein, mitochondrial precursor -0.19 -0.22 N/A N/A P38646 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
27 Actin-related protein 2/3 complex subunit 5 -1.00 -1.00 -1.00 -1.00 O15511 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
28 Sorting nexin-3 -0.36 -0.35 -0.37 -1.00 O60493 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
29 Complement receptor type 1 precursor -0.19 N/A -0.41 -1.00 P17927 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
30 40S ribosomal protein S24 -1.00 -1.00 -1.00 -1.00 P62847 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
31 Corticotropin-lipotropin precursor -0.73 -0.88 -1.00 -1.00 P01189 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
32 Inosine triphosphate pyrophosphatase -1.00 -0.67 -1.00 -1.00 Q9BY32 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
33 Peroxiredoxin-1 -0.08 -0.56 -1.00 -0.33 Q06830 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table I, continued’ 
34 Protein memo -0.95 -0.88 -0.56 -0.47 Q9Y316 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
35 
Voltage-dependent anion-selective channel 
protein 2 
-1.00 -0.31 -0.46 -0.21 P45880 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
36 
Thioredoxin-dependent peroxide reductase, 
mitochondrial precursor 
-0.28 -0.19 -0.27 N/A P30048 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
37 RuvB-like 2 -0.24 N/A -0.43 -0.11 Q9Y230 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
38 EF-hand domain-containing protein 2 -0.36 -0.17 -0.37 -0.29 Q5JST6 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
39 T-complex protein 1 subunit epsilon -0.89 N/A -0.20 -0.97 P48643 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
40 Stress-induced-phosphoprotein 1 -0.54 -0.62 -0.44 -0.21 P31948 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
41 Retinal dehydrogenase 1 -0.33 -0.79 -0.58 -0.61 P00352 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
42 Prostaglandin E synthase 3 -0.26 -0.36 -0.97 -0.16 Q15185 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
43 Trypsin-1 precursor -0.37 -1.00 -0.28 -0.35 P07477 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
44 Serpin B9 -0.51 -0.14 -0.21 -0.51 P50453 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
45 N-acylneuraminate cytidylyltransferase -0.64 -0.57 -0.50 -0.28 Q8NFW8 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
46 Cofilin-1 -0.76 N/A -0.85 -0.38 P23528 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
47 ADP-ribosylation factor 1 -1.00 -0.21 -0.15 -1.00 P84077 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
48 Fructose-bisphosphate aldolase A -1.00 -1.00 -1.00 -1.00 P04075 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
49 Sorting nexin-3 -1.00 -1.00 -1.00 -1.00 O60493 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
50 Phosphoglycerate mutase 1 -1.00 -1.00 -1.00 -1.00 P18669 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
51 Triosephosphate isomerase -1.00 -1.00 -1.00 -1.00 P60174 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
52 Eukaryotic translation initiation factor 5A-1 -1.00 -1.00 -1.00 -1.00 P63241 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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Table II: Identified proteins of A549 downregulated (-) in the presence of methanolic Phyllanthus extracts 
MPN – methanolic P. niruri; MPU – methanolic P. urinaria; MPW – methanolic P. watsonii, MPA – methanolic P. amarus; N/A – Not Affected. 
Spot 
ID 
Possible Proteins 
Fold change UNIPROT 
KB/SWISS-PROT 
Acc. Number 
Database 
MPN MPU MPW MPA 
1 Protein S100-A8 -0.47 -0.10 -0.48 -0.55 P05109 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
2 Transmembrane protein 35 -0.82 -0.78 -1.00 -0.50 Q53FP2 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
3 Adenylate kinase isoenzyme 6 -0.32 -0.62 -0.81 -0.73 Q9Y3D8 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
4 Peroxiredoxin-1 -0.78 -1.00 -1.00 -1.00 Q06830 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
5 Prolactin-releasing peptide precursor -0.59 -0.29 -0.23 -0.39 P81277 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
6 Putative protein SSX6 -0.46 -0.96 -1.00 -0.75 Q7RTT6 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
7 Glutathione synthetase -0.38 -0.79 -1.00 -0.51 P48637 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
8 
Nucleoside diphosphate-linked moiety X 
motif 16 
-0.61 -0.63 -0.98 -0.94 Q3MHX9 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
9 E3 ubiquitin-protein ligase ZNRF1 N/A N/A -0.47 -0.36 Q8ND25 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
10 
DNA-directed RNA polymerase II 16 kDa 
polypeptide 
-0.46 -0.59 -0.43 -0.93 Q9VEA5 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
11 
39S ribosomal protein L40, mitochondrial 
precursor 
-1.00 -1.00 -1.00 -1.00 Q9NQ50 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
12 Zinc finger protein 174 -1.00 -1.00 -1.00 -1.00 Q15697 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
13 
Probable G-protein coupled receptor 179 
precursor 
-0.21 -0.15 -1.00 N/A Q6PRD1 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
14 Histatin-1 precursor -0.24 -0.66 -0.78 -0.27 P15515 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table II, continued’ 
15 U6 snRNA-associated Sm-like protein LSm5 -0.33 -0.57 -0.19 -0.54 Q9Y4Y9 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
16 Bcl-2-like protein 11 -0.25 -1.00 -1.00 -0.70 O43521 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
17 Contactin-2 precursor -0.29 -0.60 -0.42 -0.39 Q02246 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
18 Bis(5'-adenosyl)-triphosphatase -1.00 -1.00 N/A -1.00 P49789 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
19 Trypsin-1 precursor -1.00 -0.98 -1.00 -1.00 P07477 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
20 Proliferating cell nuclear antigen -1.00 -1.00 -1.00 -1.00 P12004 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
21 Endoplasmin precursor N/A -1.00 -1.00 -0.37 P14625 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
22 
Eukaryotic translation initiation factor 3 
subunit 12 
-1.00 -1.00 -1.00 -1.00 Q9UBQ5 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
23 Serine/threonine-protein kinase 6 -1.00 -0.96 -0.19 -1.00 O14965 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
24 Phenylalanyl-tRNA synthetase beta chain -1.00 -1.00 -1.00 -1.00 Q9NSD9 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
25 Neutrophil defensin 1 precursor -0.78 -0.49 -0.20 -0.88 P59665 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
26 Proto-oncogene protein Wnt-3 precursor -0.58 N/A -0.34 -0.55 P56703 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
27 Putative Ras-related protein Rab-42 -1.00 N/A -0.97 -0.80 Q8N4Z0 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
28 UPF0404 protein C11orf59 -0.19 -0.36 N/A -0.36 Q6IAA8 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
29 Neutrophil defensin 1 precursor -0.31 -0.25 -1.00 -0.87 P59665 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
30 Agouti-signaling protein precursor -0.33 -0.67 -0.67 N/A P42127 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
31 
DNA-directed RNA polymerase II 16 kDa 
polypeptide 
-0.42 -0.48 -0.48 -0.45 Q9VEA5 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
32 Beta-defensin 107A precursor -0.21 N/A -0.62 -0.61 Q8IZN7 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
33 
Transcription elongation factor B polypeptide 
1 
-0.58 -0.59 -0.56 -0.79 Q15369 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table II, continued’ 
34 Metallothionein-1M -0.55 -0.52 -0.48 -0.48 Q8N339 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
35 GTPase HRas precursor -0.60 -0.66 -0.59 -0.61 P01112 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
36 Neuromedin-B precursor -0.24 -0.32 -0.23 -0.34 P08949 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
37 Protein-tyrosine sulfotransferase 2 -0.36 N/A N/A -0.33 O60704 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
38 Apolipoprotein A-II precursor -0.23 -0.23 -0.13 -0.37 P02652 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
39 ADP-ribosylation factor-like protein 6 -0.58 -0.52 -1.00 -0.29 Q9H0F7 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
40 Alpha-enolase -0.27 -0.51 N/A -0.56 P06733 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
41 
Serine/threonine-protein phosphatase PP1-
beta catalytic subunit 
-1.00 -1.00 -0.44 -0.71 P62140 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
42 N-acylneuraminate cytidylyltransferase -1.00 -1.00 -1.00 -1.00 Q8NFW8 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
43 Inosine triphosphate pyrophosphatase -1.00 -1.00 -1.00 -1.00 Q9BY32 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
44 Alkyldihydroxyacetonephosphate synthase -1.00 -0.55 -1.00 -1.00 O00116 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
45 Microsomal signal peptidase 18 kDa subunit -1.00 -0.57 -1.00 -1.00 P67812 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
46 Tumor suppressor candidate 2 -0.89 -0.75 -0.67 -0.21 O75896 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
47 Metallothionein-2 -0.71 -0.17 -0.14 -0.53 P02795 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
48 Protein FAM3B precursor -0.57 -0.48 -0.39 -0.48 P58499 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
49 Metallothionein-1H -0.52 -0.48 N/A -0.29 P80294 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
50 Metallothionein-2 -0.34 -0.59 -0.49 -1.00 P02795 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
51 Protein BEX5 -0.48 -0.33 -0.30 -0.48 Q5H9J7 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
52 
DNA-directed RNA polymerase II 16 kDa 
polypeptide 
-1.00 -1.00 -1.00 -1.00 Q9VEA5 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table II, continued’ 
53 Cytochrome c oxidase polypeptide VIa-liver -0.93 -0.24 -1.00 -0.14 P12074 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
54 Putative protein 15E1.2 N/A -0.94 -1.00 -0.30 - MASCOT;COGS 
55 
Voltage-dependent anion-selective channel 
protein 1 
-0.15 -0.28 -0.35 -0.27 P21796 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
56 
Voltage-dependent anion-selective channel 
protein 1 
-0.47 -0.13 -1.32 N/A P21796 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
57 
Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit 
-0.64 -0.76 -0.43 -0.32 P62136 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
58 Acetyl-CoA acetyltransferase, cytosolic -0.95 -1.00 -0.17 -1.00 Q9BWD1 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
59 Glutathione synthetase -0.50 -0.45 -0.38 -0.61 P48637 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
60 Actin-related protein 10 -0.94 -0.70 -0.13 -0.73 Q9NZ32 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
61 Enteropeptidase precursor -0.63 -0.19 -1.00 -0.70 P98073 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
62 Metallothionein-1L -0.86 -0.79 -0.96 -0.44 Q93083 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
63 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) gamma-5-like subunit 
-1.00 -1.00 -1.00 -1.00 P63218 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
64 Small inducible cytokine B14 precursor -1.00 -1.00 -1.00 -1.00 O95715 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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Table III: Identified proteins of MCF-7 downregulated (-) in the presence of aqueous Phyllanthus extracts 
APN – aqueous P. niruri; APU – aqueous P. urinaria; APW – aqueous P. watsonii, APA – aqueous P. amarus; N/A – Not Affected. 
Spot 
ID 
Possible Proteins 
Fold change UNIPROT 
KB/SWISS-PROT 
Acc. Number 
Database 
APN APU APW APA 
1 Pyruvate kinase isozymes M1/M2 -0.96 -0.42 -0.70 -0.67 P14618 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
2 Annexin A2 -1.00 -1.00 -1.00 -1.00 P07355 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
3 Alpha-Enolase -0.41 -0.64 -0.47 -0.34 P06733 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
4 Tubulin beta-5 chain -0.11 -0.84 -1.00 -0.34 P07437 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
5 Tryptophanyl-tRNA synthetase, cytoplasmic -0.18 -0.54 -0.72 -0.70 P23381 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
6 
ATP synthase subunit alpha, mitochondrial 
precursor 
-0.32 -0.47 -0.10 -0.53 P25705 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
7 Proteasome subunit alpha type 6 -0.44 -0.62 -0.35 -0.81 P60900 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
8 Calmodulin -0.37 N/A -0.47 -1.00 P62158 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
9 Nucleolin -1.00 -0.31 -0.25 -1.00 P19338 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
10 Actin, cytoplasmic 2 -1.00 -0.55 -0.88 -1.00 P63261 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
11 Tubulin beta-5 chain -0.32 -0.49 -0.33 -0.21 P07437 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
12 Actin, alpha cardiac muscle 1 -0.62 -0.12 N/A -0.28 P68032 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
13 Tubulin alpha-6 chain -0.83 -0.63 N/A -0.12 Q9BQE3 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
14 Heat shock protein HSP 90-beta -0.39 -0.55 -0.30 -0.37 P08238 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
15 Heterogeneous nuclear ribonucleoprotein A1 -0.40 -0.45 -0.39 N/A P09651 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
16 10 kDa heat shock protein, mitochondrial -0.57 -1.00 -0.51 -1.00 P61604 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table III, continued’ 
17 Peroxiredoxin-1 -0.50 -0.25 -0.37 -0.26 Q06830 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
18 Heat shock cognate 71 kDa protein -0.49 -0.57 -0.30 N/A P11142 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
19 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
-0.45 -0.24 -0.19 -0.10 P22626 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
20 Cofilin-1 -0.59 N/A -0.15 -0.21 P23528 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
21 Annexin A2 -0.14 -1.00 -1.00 N/A P07355 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
22 Pyruvate kinase isozymes M1/M2 -0.34 -0.21 -0.32 -0.25 P14618 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
23 Lamin-A/C -0.37 N/A -0.47 N/A Q6UYC3 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
24 Glyceraldehyde-3-phosphate dehydrogenase -0.72 -0.75 -0.20 -0.57 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
25 Transgelin-2 -0.81 -0.33 -0.86 -0.57 P37802 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
26 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
-0.28 N/A -0.30 N/A P22626 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
27 Glyceraldehyde-3-phosphate dehydrogenase -0.83 -0.38 -0.96 -0.13 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
28 Transgelin-2 -0.59 -1.00 -0.83 -1.00 P37802 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
29 Peroxiredoxin-1 -1.00 -1.00 -0.25 -0.85 Q06830 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
30 Heterogeneous nuclear ribonucleoprotein A1 N/A -1.00 -0.15 N/A P09651 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
31 Glyceraldehyde-3-phosphate dehydrogenase -0.73 -0.22 N/A -0.83 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
32 Glyceraldehyde-3-phosphate dehydrogenase N/A -0.42 -0.12 N/A P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
33 Galectin-3 -0.66 -0.58 -0.46 -0.53 P17931 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
34 Glyceraldehyde-3-phosphate dehydrogenase -0.50 -0.60 -0.39 -0.64 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
35 Triosephosphate isomerase -0.98 -0.83 -0.74 -0.76 P60174 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
36 Cofilin-1 -1.00 -1.00 -1.00 -1.00 P23528 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table III, continued’ 
37 
Peptidyl-prolyl cis-trans isomerase B 
precursor 
-1.00 -1.00 -1.00 -1.00 P23284 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
38 Peptidyl-prolyl cis-trans isomerase A -1.00 -1.00 -1.00 -1.00 P62937 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
39 Stathmin -1.00 -1.00 -1.00 -1.00 P16949 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
40 Glyceraldehyde-3-phosphate dehydrogenase -1.00 -1.00 -1.00 -1.00 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
41 L-lactate dehydrogenase A chain -1.00 -1.00 -1.00 -1.00 P00338 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
42 Beta-Enolase -1.00 -1.00 -1.00 -1.00 P13929 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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Table IV: Identified proteins of MCF-7 downregulated (-) in the presence of methanolic Phyllanthus extracts 
MPN – methanolic P. niruri; MPU – methanolic P. urinaria; MPW – methanolic P. watsonii, MPA – methanolic P. amarus; N/A – Not Affected. 
Spot 
ID 
Possible Proteins 
Fold change UNIPROT 
KB/SWISS-PROT 
Acc. Number 
Database 
MPN MPU MPW MPA 
1 
Myosin regulatory light chain 2, 
nonsarcomeric 
-0.90 -0.71 -0.98 -0.91 P19105 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
2 Myosin light polypeptide 6 -0.13 -0.37 -0.22 -0.17 P60660 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
3 Myosin light polypeptide 6 -1.00 -1.00 -0.55 -0.57 P60660 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
4 Myosin light polypeptide 6 -0.76 -0.67 -0.31 -0.23 P60660 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
5 
Nascent polypeptide-associated complex 
subunit alpha 
-1.00 -1.00 -0.29 -0.15 Q13765 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
6 Protein SET -1.00 -1.00 -0.51 -1.00 Q01105 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
7 Calreticulin precursor -0.42 N/A -0.35 -0.45 P27797 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
8 Calumenin precursor -0.73 -0.22 -0.46 -0.30 O43852 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
9 Tubulin alpha-ubiquitous chain -0.43 N/A -0.30 -0.78 P68363 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
10 Tubulin alpha-ubiquitous chain -0.15 N/A -0.58 -0.24 P68363 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
11 Thioredoxin -0.43 -0.26 -0.39 -0.41 P10599 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
12 Actin, alpha cardiac muscle 1 precursor -0.38 N/A -0.13 -0.45 P68032 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
13 Annexin A2 -0.70 -0.44 -0.33 -0.40 P07355 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
14 Calpain small subunit 1 -0.28 -1.00 -0.53 -0.37 P04632 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
15 Protein disulfide-isomerase precursor -0.65 N/A -0.66 -1.00 P07237 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
16 Tubulin beta-5 chain -0.96 -0.85 -0.95 -0.62 P07437 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table IV, continued’ 
17 Annexin A2 -0.45 -0.97 -0.51 -0.48 P07355 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
18 Phosphoglycerate kinase 1 -0.25 N/A -0.28 -0.41 P00558 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
19 Actin, alpha cardiac muscle 1 precursor -0.41 -0.70 -0.25 -0.10 P68032 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
20 Tubulin beta-5 chain -0.41 N/A -0.15 -0.84 P07437 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
21 Tubulin beta-5 chain -0.67 -1.00 -0.44 -0.36 P07437 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
22 Actin, alpha cardiac muscle 1 precursor -0.87 -0.34 -0.74 -0.81 P68032 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
23 Stathmin -0.56 N/A -0.38 -0.20 P16949 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
24 Splicing factor, arginine/serine-rich 3 -0.38 N/A -0.46 -0.50 B2R6F3 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
25 Annexin A2 -0.34 -0.32 -0.39 -0.21 P07355 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
26 Heterogeneous nuclear ribonucleoprotein H N/A N/A -0.10 -0.43 P31943 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
27 Heat-shock protein beta-1 -0.12 N/A -0.29 -0.21 P04792 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
28 Annexin A8 -0.21 N/A -0.29 -0.14 P13928 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
29 Annexin A2 -0.64 -0.09 -1.09 -0.47 P07355 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
30 Heterogeneous nuclear ribonucleoprotein H -0.35 N/A -0.26 -0.17 P31943 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
31 Alpha-Enolase -0.70 -0.09 -0.58 -0.68 P06733 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
32 Splicing factor, proline- and glutamine-rich -0.48 N/A -0.45 -0.39 P23246 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
33 Splicing factor, proline- and glutamine-rich -0.21 -0.52 -0.44 -0.76 P23246 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
34 Tubulin alpha-ubiquitous chain -1.00 -0.65 -0.65 -1.00 P68363 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
35 Stress-70 protein, mitochondrial precursor -0.53 N/A -0.54 -0.47 P38646 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
36 Stress-70 protein, mitochondrial precursor -0.51 -0.55 -0.20 -0.47 P38646 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
37 Ubiquitin-conjugating enzyme E2 N -0.36 -0.09 -0.37 N/A P61088 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
38 Peroxiredoxin-5, mitochondrial precursor -0.18 N/A -0.46 -0.66 P30044 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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‘Table IV, continued’ 
39 Ras-related protein Rab-11B -0.21 -0.17 N/A N/A Q15907 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
40 Myosin-9 -1.00 -0.36 -0.11 -1.00 P35579 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
41 Protein disulfide-isomerase A3 precursor -0.21 -0.23 -0.18 -1.00 P30101 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
42 Aldose reductase -1.00 -0.82 -0.77 -0.96 P15121 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
43 Pyruvate kinase isozymes M1/M2 -0.50 -0.09 -0.24 N/A P14618 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
44 Tubulin alpha-ubiquitous chain -0.19 -0.11 -0.13 -0.26 P68363 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
45 Protein disulfide-isomerase A6 precursor N/A N/A -0.13 -0.48 Q15084 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
46 Pyruvate kinase isozymes M1/M2 -0.22 -0.49 -0.51 N/A P14618 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
47 Phosphoglycerate mutase 1 -0.29 -0.09 -0.21 -0.24 P18669 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
48 Heterogeneous nuclear ribonucleoprotein H3 -1.00 N/A -0.39 -1.00 P31942 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
49 Filamin-A -0.53 -0.61 -0.54 -0.86 P21333 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
50 Elongation factor 2 -0.36 N/A -0.31 -0.21 P13639 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
51 Macrophage capping protein -0.23 -0.22 -0.34 -0.42 P40121 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
52 Phosphoglycerate kinase 1 -0.85 -0.50 -0.86 -0.87 P00558 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
53 Triosephosphate isomerase -0.26 N/A -0.12 -0.34 P60174 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
54 Glyceraldehyde-3-phosphate dehydrogenase -0.48 -0.69 -0.65 -0.78 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
55 Glyceraldehyde-3-phosphate dehydrogenase -0.87 -0.51 -0.22 -0.47 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
56 Glyceraldehyde-3-phosphate dehydrogenase -0.55 N/A -0.67 -0.82 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
57 60 kDa heat shock protein, mitochondrial  -0.09 N/A -0.14 -0.21 P10809 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
58 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
-0.81 -0.83 -0.81 -0.57 P22626 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
59 Heterogeneous nuclear ribonucleoproteins A2 -0.59 N/A -0.24 -0.60 P22626 MASCOT;UNIPROT KB/SWISS-PROT;COGS 
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APPENDIX 4: ADDITIONAL OUTPUTS OF THE PHD PROJECT 
1. PUBLICATIONS 
i. Lee SH, Jaganath IB, Wang SM, Sekaran SD (2011) Antimetastatic Effects 
of Phyllanthus on Human Lung (A549) and Breast (MCF-7) Cancer Cell 
Lines. PLoS ONE 6(6): e20994. doi:10.1371/journal.pone.0020994 
ii. Lee SH, Tang YQ, Rathkrishnan A, Wang SM, Ong KC, Manikam R, 
Payne BJ, Jaganath IB, Sekaran SD (2013) Effects of Cocktail of Four 
Local Malaysian Medicinal Plants (Phyllanthus spp.) against Dengue Virus 
2. BMC Complementary and Alternative Medicine 13:192. 
doi:10.1186/1472-6882-13-192. 
iii. Inhibition of Raf-MEK-ERK and Hypoxia pathways by Phyllanthus 
Prevents Metastasis in Human Lung (A549) Cancer Cell Line (Submitted to 
BMC Complementary and Alternative Medicine) 
iv. Phyllanthus Suppresses ERK1/2 and Hypoxia Pathways to Inhibit 
Metastasis in Human Breast (MCF-7) Cancer Cell Line (Submitted to 
Current Cancer Drug Targets) 
2. PATENT APPLICATIONS 
i. Patent application for anticancer properties of Phyllanthus (Under 
processing), Sekaran SD, Lee SH, Tang YQ 
3. ORAL PRESENTATIONS 
i. Induction of apoptosis in A549 and MCF-7 cell lines treated with Phyllantus 
spp. extracts, 17th International Student Congress of Medical Sciences, 8th – 
11th June 2010, University Medical Center Groningen, The Netherlands 
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4. POSTER PRESENTATIONS 
i. Potential anti-proliferative effect of Phyllantus spp. on human cancer cell 
lines, UK-Malaysia Symposium on Cancer Drug Discovery & 
Development, 24th – 25th February 2010, Grand Dorsett Subang Hotel, 
Subang, Malaysia 
ii. Potential anti-proliferative effect and apoptosis induction on human lung 
and breast carcinoma cell lines by Phyllanthus spp., Innovation and 
Creativity Expo, University Malaya, 1st – 3rd April 2010 
iii. Effects of Malaysia medicinal plant (Phyllanthus) against dengue virus type 
2, 9th Asia-pacific congress of Medical Virology, 6th – 8th June 2012, 
Adelaide, Australia 
iv. Inhibitory potential of Malaysian medicinal plant (Phyllanthus) against 
dengue virus type 2 (DENV2), National Postgraduate Seminar, 11th July 
2012, IPS Building, University of Malaya, Malaysia 
5. AWARDS 
i. National Science Fellowship (NSF) from July 2009 to June 2012 
ii. University Malaya research grant (PPP) for the project entitled “Anti-cancer 
effect of Phyllanthus spp. on human cancer cell line’s cellular signalling”, 
Project number: PS180/2010A, PV053/2011B 
iii. ISCOMS Travel Grant to attend the 17th International Student Congress of 
Medical Sciences, 8th – 11th June 2010, University Medical Center 
Groningen, The Netherlands 
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iv. Best Oral Presentation for “Genetics and Molecular Mechanisms” Session, 
17th International Student Congress of Medical Sciences, 8th – 11th June 
2010, University Medical Center Groningen, The Netherlands 
6.WORKSHOPS AND TRAINING 
i. Flow Cytometry Training – BD FacsCanto II, 30th June – 3rd July 2009, 
Department of Medical Microbiology, Faculty of Medicine, University of 
Malaya 
ii. BD FACS Calibur Flow Cytometry Basic Training, 21st – 23rd October 
2009, Blood Bank, University of Malaya Medical Center (UMMC) and 
Department of Medical Microbiology, Faculty of Medicine, University of 
Malaya 
iii. Basic Principle and Application of Real Time PCR - CFX96 Real Time 
PCR System, 10th February 2010, Department of Medical Microbiology, 
Faculty of Medicine, University of Malaya 
iv. 60th Meeting of Nobel Laureates, 27th June – 2nd July 2010, Lindau, 
Germany 
v. Basic Course in Care and Use of Laboratory Animals Research, 17th July 
2010, Laboratory Animal Center, Faculty of Medicine, University of 
Malaya 
vi. Proteomics Seminar Series: Current Trends of 2D Proteomics & Beyond, 
29th September 2010, The Royale Bintang Damansara Hotel, Malaysia 
vii. In-vitro to In-vivo- The Path to Discovery, 2nd December 2010, DKSH, 
Petaling Jaya, Malaysia 
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viii. Confocal Laser Scanning Microscope Workshop Electron Microscopy Unit, 
5th and 6th September 2012, IPS Building, University of Malaya, 50603 
Kuala Lumpur, Malaysia 
ix. Animal Experimental Unit (AEU) Induction Course, 18th October 2012, 
AEU Facility Unit, University of Malaya, 50603 Kuala Lumpur, Malaysia 
x. Basic and Clinical Immunoloy Course, 23rd – 27th July 2013, Faculty of 
Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia 
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